2024-09-10 23:19:57,084 - INFO - Extracted 10 link records.
2024-09-10 23:19:57,086 - INFO - Extracted 5 link records.
2024-09-10 23:19:57,088 - INFO - Extracted 8 link records.
2024-09-10 23:19:57,088 - INFO - Unique links to process: 10
2024-09-10 23:19:57,088 - INFO - Starting to process link: http://r.jina.ai/https://www.cancernetwork.com/view/using-atezolizumab-bevacizumab-in-practice
2024-09-10 23:19:58,614 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://www.cancernetwork.com/view/using-atezolizumab-bevacizumab-in-practice, now generating post.
2024-09-10 23:20:00,010 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 23:20:03,793 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 23:20:04,119 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 23:20:04,119 - INFO - Image query: "advanced liver cancer treatment"
2024-09-10 23:20:04,433 - INFO - Unique image link: https://images.pexels.com/photos/6436249/pexels-photo-6436249.jpeg
2024-09-10 23:20:04,433 - INFO - Post generated successfully for link: http://r.jina.ai/https://www.cancernetwork.com/view/using-atezolizumab-bevacizumab-in-practice
2024-09-10 23:20:04,433 - INFO - Starting to process link: http://r.jina.ai/https://multiplesclerosisnewstoday.com/news-posts/2024/09/09/ms-risk-unvaccinated-people-elevated-rubella-infection-study/
2024-09-10 23:20:07,946 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://multiplesclerosisnewstoday.com/news-posts/2024/09/09/ms-risk-unvaccinated-people-elevated-rubella-infection-study/, now generating post.
2024-09-10 23:20:16,228 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 23:20:20,385 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 23:20:20,725 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 23:20:20,726 - INFO - Image query: "rubella and multiple sclerosis research"
2024-09-10 23:20:21,146 - INFO - Unique image link: https://images.pexels.com/photos/28110799/pexels-photo-28110799.jpeg
2024-09-10 23:20:21,146 - INFO - Post generated successfully for link: http://r.jina.ai/https://multiplesclerosisnewstoday.com/news-posts/2024/09/09/ms-risk-unvaccinated-people-elevated-rubella-infection-study/
2024-09-10 23:20:21,146 - INFO - Starting to process link: http://r.jina.ai/https://pharmaphorum.com/news/regeneron-joins-koneksa-parkinsons-digital-biomarker-study
2024-09-10 23:20:22,413 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://pharmaphorum.com/news/regeneron-joins-koneksa-parkinsons-digital-biomarker-study, now generating post.
2024-09-10 23:20:28,968 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 23:20:31,495 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 23:20:31,784 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 23:20:31,785 - INFO - Image query: ‚Äúdigital biomarkers in Parkinson's disease‚Äù
2024-09-10 23:20:32,072 - INFO - Unique image link: https://images.pexels.com/photos/8376285/pexels-photo-8376285.jpeg
2024-09-10 23:20:32,072 - INFO - Post generated successfully for link: http://r.jina.ai/https://pharmaphorum.com/news/regeneron-joins-koneksa-parkinsons-digital-biomarker-study
2024-09-10 23:20:32,072 - INFO - Starting to process link: http://r.jina.ai/https://www.prnewswire.com/news-releases/diamyd-medical-to-pursue-accelerated-approval-pathway-for-type-1-diabetes-precision-medicine-302241751.html
2024-09-10 23:20:33,540 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://www.prnewswire.com/news-releases/diamyd-medical-to-pursue-accelerated-approval-pathway-for-type-1-diabetes-precision-medicine-302241751.html, now generating post.
2024-09-10 23:20:47,666 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 23:20:53,631 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 23:20:53,927 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 23:20:53,928 - INFO - Image query: Type 1 diabetes treatment research
2024-09-10 23:20:54,208 - INFO - Unique image link: https://images.pexels.com/photos/8965147/pexels-photo-8965147.jpeg
2024-09-10 23:20:54,208 - INFO - Post generated successfully for link: http://r.jina.ai/https://www.prnewswire.com/news-releases/diamyd-medical-to-pursue-accelerated-approval-pathway-for-type-1-diabetes-precision-medicine-302241751.html
2024-09-10 23:20:54,208 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-10 23:20:56,220 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/, now generating post.
2024-09-10 23:20:56,644 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 23:20:56,644 - INFO - No article found for link https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/.
2024-09-10 23:20:56,644 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/. Skipping.
2024-09-10 23:20:56,644 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-10 23:20:56,644 - INFO - Starting to process link: http://r.jina.ai/https://pharmaphorum.com/news/nice-clears-nhs-use-msds-welireg-genetic-disorder
2024-09-10 23:20:58,638 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://pharmaphorum.com/news/nice-clears-nhs-use-msds-welireg-genetic-disorder, now generating post.
2024-09-10 23:21:05,112 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 23:21:07,954 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 23:21:08,250 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 23:21:08,250 - INFO - Image query: "von Hippel-Lindau disease treatment"
2024-09-10 23:21:08,518 - INFO - Unique image link: https://images.pexels.com/photos/7231416/pexels-photo-7231416.jpeg
2024-09-10 23:21:08,518 - INFO - Post generated successfully for link: http://r.jina.ai/https://pharmaphorum.com/news/nice-clears-nhs-use-msds-welireg-genetic-disorder
2024-09-10 23:21:08,518 - INFO - Starting to process link: http://r.jina.ai/https://www.healio.com/news/neurology/20240816/longeviti-neuro-solutions-secures-us-patent-for-neurosurgical-cranial-implant
2024-09-10 23:21:10,658 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://www.healio.com/news/neurology/20240816/longeviti-neuro-solutions-secures-us-patent-for-neurosurgical-cranial-implant, now generating post.
2024-09-10 23:21:12,742 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 23:21:16,025 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 23:21:16,317 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 23:21:16,318 - INFO - Image query: "neurosurgery technology"
2024-09-10 23:21:16,541 - INFO - Unique image link: https://images.pexels.com/photos/28158899/pexels-photo-28158899.jpeg
2024-09-10 23:21:16,541 - INFO - Post generated successfully for link: http://r.jina.ai/https://www.healio.com/news/neurology/20240816/longeviti-neuro-solutions-secures-us-patent-for-neurosurgical-cranial-implant
2024-09-10 23:21:16,541 - INFO - Starting to process link: http://r.jina.ai/https://www.drugtargetreview.com/news/152646/mrna-vaccine-provides-enhanced-protection-against-mpox/
2024-09-10 23:21:17,933 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://www.drugtargetreview.com/news/152646/mrna-vaccine-provides-enhanced-protection-against-mpox/, now generating post.
2024-09-10 23:21:24,507 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 23:21:28,287 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 23:21:28,571 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 23:21:28,571 - INFO - Image query: "mpox vaccine research"
2024-09-10 23:21:28,865 - INFO - Unique image link: https://images.pexels.com/photos/8830484/pexels-photo-8830484.jpeg
2024-09-10 23:21:28,865 - INFO - Post generated successfully for link: http://r.jina.ai/https://www.drugtargetreview.com/news/152646/mrna-vaccine-provides-enhanced-protection-against-mpox/
2024-09-10 23:21:28,865 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-10 23:21:30,651 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/, now generating post.
2024-09-10 23:21:31,109 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 23:21:31,109 - INFO - No article found for link https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/.
2024-09-10 23:21:31,109 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/. Skipping.
2024-09-10 23:21:31,109 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-10 23:21:31,109 - INFO - Starting to process link: http://r.jina.ai/https://pharmaphorum.com/news/gsk-says-nucala-hits-target-new-copd-trial
2024-09-10 23:21:32,794 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://pharmaphorum.com/news/gsk-says-nucala-hits-target-new-copd-trial, now generating post.
2024-09-10 23:21:42,179 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 23:21:44,883 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 23:21:45,142 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-10 23:21:45,142 - INFO - Image query: "COPD treatment progress"
2024-09-10 23:21:45,438 - INFO - Unique image link: https://images.pexels.com/photos/27271454/pexels-photo-27271454.jpeg
2024-09-10 23:21:45,438 - INFO - Post generated successfully for link: http://r.jina.ai/https://pharmaphorum.com/news/gsk-says-nucala-hits-target-new-copd-trial
2024-09-10 23:21:45,438 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/6436249/pexels-photo-6436249.jpeg'}
2024-09-10 23:21:45,438 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-10 23:21:45,438 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/28110799/pexels-photo-28110799.jpeg'}
2024-09-10 23:21:45,438 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-10 23:21:45,438 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/8376285/pexels-photo-8376285.jpeg'}
2024-09-10 23:21:45,438 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-10 23:21:45,438 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/8965147/pexels-photo-8965147.jpeg'}
2024-09-10 23:21:45,438 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-10 23:21:45,438 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/7231416/pexels-photo-7231416.jpeg'}
2024-09-10 23:21:45,438 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-10 23:21:45,438 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/28158899/pexels-photo-28158899.jpeg'}
2024-09-10 23:21:45,438 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-10 23:21:45,438 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/8830484/pexels-photo-8830484.jpeg'}
2024-09-10 23:21:45,438 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-10 23:21:45,438 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/27271454/pexels-photo-27271454.jpeg'}
2024-09-10 23:21:45,438 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-10 23:21:45,438 - INFO - Sending 8 log entries to Firebase.
2024-09-10 23:21:52,878 - INFO - Successfully sent batch data to Firebase: {'message': 'Batch processed successfully. 8 posts added.', 'documentIDs': ['J1zFEYSmFOHHTmGxSvLA', 'pRuzqAYgt3LdrVYEBLmf', 'JCBapsanDOHMVBvofsNE', 'F1vjrtFKDBdbzYEWY5RL', 'jEeJnAOcL0yV3CfCLdzE', 'UridxvEHdIu6pLIAFxQT', 'LANfhyK9OVCPNwtFF4Aq', '4RiH0v4OthWjjKQAg9uu']}
2024-09-10 23:21:52,879 - INFO - Received 8 document IDs from Firebase.
2024-09-10 23:21:52,879 - INFO - 'generated_post' length: 9. Content: ['2024-09-10 09:30:00', '2024-09-10 23:20:03', 'üåü Are you integrating atezolizumab and bevacizumab in your treatment regimens for advanced hepatocellular carcinoma (HCC)? \n\n- The IMBrave150 trial has shown promising results, demonstrating improved overall survival and progression-free survival rates when using this combination therapy. In the trial, notable survival benefit was observed‚Äîthus, many practices are adopting this as a new standard.\n- Real-world data from clinical experiences indicate that patients have tolerated the combination well, with manageable side effects, which is crucial for maintaining quality of life.\n- Additionally, oncologists report that careful monitoring for adverse events is essential, especially in patients with underlying liver conditions, to mitigate risks associated with immunotherapy combined with targeted therapy.\n\nAs we witness this promising shift in clinical applications, how do you see the role of combination therapies evolving in the management of liver cancer? ü§î\n\nFor a deeper dive into clinical experiences and insights, read more here: https://www.cancernetwork.com/view/using-atezolizumab-bevacizumab-in-practice', ['Life Sciences & BioTech', 'Oncology', 'ClinicalTrials', 'PrecisionMedicine', 'PatientSafety'], 'https://images.pexels.com/photos/6436249/pexels-photo-6436249.jpeg', 'https://www.cancernetwork.com/view/using-atezolizumab-bevacizumab-in-practice', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'Using Atezolizumab + Bevacizumab in Practice\n============================================\n\nSeptember 9, 2024\n\nBy Daniel Ahn, DO  \nRahul Gosain, MD  \nRohit Gosain, MD\n\nKey opinion leaders share their impressions of the IMBrave150 trial data and discuss their real-world clinical experiences using atezolizumab plus bevacizumab in practice.\n\n**Video content above is prompted by the following:**\n\n* What are your impressions on the data from the IMBrave150 trial?\n* Please share your experience with using atezo + bev in your practice.', 'gpt-4o-mini']
2024-09-10 23:21:52,880 - INFO - Logged data to databases/llm.csv with DocumentID: J1zFEYSmFOHHTmGxSvLA.
2024-09-10 23:21:52,880 - INFO - 'generated_post' length: 9. Content: ['2024-09-10 09:20:00', '2024-09-10 23:20:20', "üåç Did you know that rubella infection may play a significant role in the risk of developing multiple sclerosis (MS) among unvaccinated individuals?\n\n- A recent Swedish study found an intriguing link between the presence of rubella antibodies and an increased risk of MS in individuals who have not been vaccinated against the virus.\n- Remarkably, nearly 94% of MS patients tested positive for anti-E1 antibodies from rubella compared to 88.5% in healthy controls, spotlighting potential immunity gaps.\n- In unvaccinated individuals, researchers noted that those with MS were four times more likely to have these rubella antibodies than their healthy peers, suggesting a serious connection worth exploring further.\n- This study prompts a crucial reflection on the mechanisms behind MS, particularly the concept of 'molecular mimicry,' where the immune system mistakenly attacks healthy nerve cells following viral infections, like rubella.\n\nAs we look toward improving preventive strategies, how should we approach vaccination and education to mitigate MS risks? ü§î\n\nFor a deeper dive into this emerging research, check out the full study here: https://onlinelibrary.wiley.com/doi/10.1111/ene.16387\n", ['Research & Clinical Trials', 'Neurology', 'PublicHealth', 'EHR', 'PatientSafety'], 'https://images.pexels.com/photos/28110799/pexels-photo-28110799.jpeg', 'https://multiplesclerosisnewstoday.com/news-posts/2024/09/09/ms-risk-unvaccinated-people-elevated-rubella-infection-study/', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'MS risk in unvaccinated people may be elevated by rubella infection: Study\n===============\n\nRubella infection may increase MS risk in unvaccinated people\n=============================================================\n\nHaving antibodies against the rubella virus is associated with an increased risk of developing multiple sclerosis (MS) in unvaccinated people, a Swedish study suggests.\n\nThe findings show a rubella infection may be a risk factor for MS, reinforcing the hypothesis that certain viral infections may trigger the misleading immune response that drives MS.\n\n‚ÄúTo the best of our knowledge, this is the first report of an association between [rubella virus] and MS in pre-\xadMS samples,‚Äù wrote the researchers, who said additional studies will be needed to confirm the association between rubella infection and MS.\n\nThe study, ‚Äú[Rubella virus seropositivity after infection or vaccination as a risk factor for multiple sclerosis](https://onlinelibrary.wiley.com/doi/10.1111/ene.16387),‚Äù was published in the _European Journal of Neurology._\n\n[MS is caused](https://multiplesclerosisnewstoday.com/risk-factors-for-multiple-sclerosis/) by an erroneous immune response that damages healthy parts of the brain and spinal cord. The reason for the immune response isn‚Äôt fully understood, but evidence suggests viral infections may be risk factors. Infection with the [Epstein-Barr virus](https://multiplesclerosisnewstoday.com/epstein-barr-virus-and-ms/) (EBV), in particular, is one of the strongest risk factors for the neurodegenerative condition and some studies have found an association between MS and the human herpesvirus-6A. Also, up to 78% of MS patients have antibodies against measles, varicella zoster, and rubella viruses in their spinal fluid.\n\nIt‚Äôs believed that, due to some similarities between viral and human molecules, the immune system may mistakenly attack nerve cells when trying to fight a viral infection. This ‚Äúmolecular mimicry‚Äù is one proposed mechanism that may explain the association between viruses and a greater risk of MS.\n\nThe rubella virus has several proteins that share similarities with human proteins. One protein from its envelope, called E2, is similar to myelin oligodendrocyte glycoprotein (MOG), an essential protein in [myelin](https://multiplesclerosisnewstoday.com/myelin-sheath/), the fatty coating that covers nerve cells and target of immune responses in MS.\n\nThese similarities raise the possibility of a connection between the rubella virus, the immune response against it, and developing MS.\n\nResearchers in Sweden compared blood samples from MS patients and controls collected before the neurological disease‚Äôs onset to determine if people who developed MS had signs of a previous rubella infection ‚Äî determined through the presence of anti-rubella antibodies ‚Äî before their diagnosis.\n\n‚ÄúWith samples from both the pre-\xadvaccination era and through the different stages of rubella vaccination in Sweden, we explored a unique opportunity to study [the rubella virus] in the field of MS,‚Äù the researchers wrote.\n\nThe study included blood samples from 670 MS patients and 670 matched controls. In both groups, female patients represented the majority (84%) and the median age was 25.\n\nThe researchers tested the samples for the presence of antibodies (seropositivity) that targeted the rubella E1 protein, which the virus uses to infect human cells, and their reactivity. More MS patients (93.7%) had anti-E1 antibodies than healthy controls (88.5%), data showed.\n\nWhen patients and controls were divided based on their rubella vaccination status, seropositivity was only significantly higher in MS patients than controls in unvaccinated people, in whom the presence of antibodies indicates a previous rubella infection. After adjusting for factors such as antibodies against other viruses and vitamin D levels, unvaccinated MS patients were four times more likely to have rubella antibodies than unvaccinated controls. No significant differences were observed in vaccinated patients after accounting for the same factors.\n\nThe presence of antibodies in ‚Äúunvaccinated subjects (i.e., representing rubella infection) was associated with a higher risk of developing MS,‚Äù the researchers wrote. ‚ÄúMolecular mimicry is an attractive hypothesis for a possible mechanism behind these findings.‚Äù\n\nThe researchers advised caution when interpreting their findings, mainly because the test they used to determine seropositivity can have a lot of false negatives. Also, most of the participants received the combined measles, mumps, and rubella vaccine, adding variables that weren‚Äôt evaluated in the study.\n\n‚ÄúFurther serological and epidemiological studies are needed to support our findings,‚Äù they wrote.', 'gpt-4o-mini']
2024-09-10 23:21:52,881 - INFO - Logged data to databases/llm.csv with DocumentID: pRuzqAYgt3LdrVYEBLmf.
2024-09-10 23:21:52,881 - INFO - 'generated_post' length: 9. Content: ['2024-09-10 09:05:00', '2024-09-10 23:20:31', "üåü Have you ever considered how digital biomarkers can transform our understanding of Parkinson's disease?\n\n- Regeneron has recently joined the Koneksa LEARNS trial, which focuses on utilizing smartphone and wearable technologies to track the progression of Parkinson‚Äôs directly from patients‚Äô homes. \n- This pioneering study aims to leverage digital biomarkers to aid in the development of disease-modifying therapies, filling a critical gap in our current understanding. \n- With their partnership, Regeneron gains real-time access to study data alongside MSD/Merck & Co., facilitating comprehensive analyses that can enhance trial design and patient cohort formation. \n- The trial plans to enroll up to 70 patients who will be closely monitored over 12 months, aiming to yield results next year that could change clinical practice forever.\n- Interestingly, advancements in digital assessments are crucial, as traditional subjective measures often fail to capture the fluctuant nature of symptom progression effectively.\n\nThese initiatives underscore a shift towards technology-driven assessments in clinical trials. How do you think the integration of digital biomarkers will alter therapeutic approaches for neurological disorders? ü§î \n\nFor more insights, learn about the trial here: https://pharmaphorum.com/news/regeneron-joins-koneksa-parkinsons-digital-biomarker-study", ['Research & Clinical Trials', 'DigitalHealth', 'Neurology', 'ClinicalTrials', 'PatientEngagement', 'HealthTech'], 'https://images.pexels.com/photos/8376285/pexels-photo-8376285.jpeg', 'https://pharmaphorum.com/news/regeneron-joins-koneksa-parkinsons-digital-biomarker-study', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'Regeneron joins Koneksa Parkinson\'s digital biomarker study\n\nRegeneron is the second pharma group to sign up for access to data from a remote study run by health technology firm Koneksa that is exploring the use of digital biomarkers to track patients with Parkinson\'s disease.\n\nThe LEARNS trial ‚Äì which started earlier this year ‚Äì is using smartphone and wearable technologies to monitor disease progression in Parkinson\'s patients and find ways to use digital biomarkers in the development of disease-modifying therapies.\n\nRegeneron has become a member of the data syndication programme for LEARNS, joining MSD/Merck & Co, which signed up in March, and will have real-time access to data and results from the study. Those can be used for "natural history analysis, trial design, cohort formation, and data analysis," according to the partners.\n\nQuantitative tools for measuring progression are lacking in Parkinson\'s and other neurological disorders, with clinicians relying on subjective measures that make it harder to monitor patients, particularly as the rate of symptom decline fluctuates and varies wildly between individuals with the disease.\n\nLEARNS is set to enrol up to 70 participants with Parkinson\'s who will be followed for 12 months, with first results expected next year. It uses the Koneksa neuroscience toolkit, which combines iPhone-based active assessments and passive monitoring using a wrist-worn wearable.\n\n"Detecting the earliest signs of Parkinson\'s disease and establishing the necessary evidence of validity for new measures are critical needs within the healthcare community," said Chris Benko, Koneksa\'s chief executive.\n\n"Our goal is to bring together biotech and pharma companies with real-time data sharing and analysis to expedite the validation and adoption of digital measures to unlock more data insights in clinical trials," he added.\n\nOther projects looking at digital biomarkers for Parkinson\'s include the crowd-sourced DREAM Challenge, which saw 40 research teams from around the world contribute ways to process accelerometer and gyroscope data from consumer wearable devices that can be used to track muscle tremor, dyskinesia, and bradykinesia - three prominent symptoms of the disease.\n\nRegeneron\'s pipeline doesn\'t currently include a clinical-stage treatment for Parkinson\'s, but it is working on drugs for other neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS).\n\n"At Regeneron, we believe that digital biomarkers have the potential to improve the development of novel therapeutics, and collaboration helps make this a reality," said the company\'s head of clinical development for genetic diseases, Gary Herman.\n\n"Koneksa\'s data syndication community allows us to leverage collective expertise and gain insights that will inform future investigational therapies for Parkinson\'s disease."', 'gpt-4o-mini']
2024-09-10 23:21:52,882 - INFO - Logged data to databases/llm.csv with DocumentID: JCBapsanDOHMVBvofsNE.
2024-09-10 23:21:52,882 - INFO - 'generated_post' length: 9. Content: ['2024-09-10 08:59:00', '2024-09-10 23:20:53', "üí° Aiming for a breakthrough in Type 1 Diabetes treatment, Diamyd Medical is gearing up to utilize the FDA's accelerated approval pathway for their innovative immunotherapy, Diamyd¬Æ.\n\n- This antigen-specific therapy, designed to preserve insulin production for patients at Stage 3 of Type 1 Diabetes, could pave the way for significant advancements in managing the disease.\n- An interim analysis of the ongoing Phase 3 DIAGNODE-3 trial is slated for March 2026, aimed at supporting a Biologics License Application (BLA). This step is predicated on promising findings regarding C-peptide levels, a critical biomarker of insulin production.\n- Notably, the FDA has provided Fast Track designation for Diamyd¬Æ, recognizing its potential to fill a current treatment gap through a surrogate endpoint, thus accelerating its review and potential approval process.\n- The ongoing trial encompasses around 330 patients across Europe and the U.S., emphasizing precision medicine with a focus on a genetically defined cohort that historically responds well to the treatment.\n\nAs we navigate these exciting developments, what implications do you foresee for the future of Type 1 Diabetes management? ü§î \n\nFor in-depth insights, visit: https://www.prnewswire.com/news-releases/diamyd-medical-to-pursue-accelerated-approval-pathway-for-type-1-diabetes-precision-medicine-302241751.html", ['Research & Clinical Trials', 'DigitalHealth', 'Endocrinology', 'ClinicalTrials', 'HealthcareInnovation', 'PrecisionMedicine'], 'https://images.pexels.com/photos/8965147/pexels-photo-8965147.jpeg', 'https://www.prnewswire.com/news-releases/diamyd-medical-to-pursue-accelerated-approval-pathway-for-type-1-diabetes-precision-medicine-302241751.html', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'Diamyd Medical to pursue accelerated approval pathway for Type 1 Diabetes precision medicine\n===============\n\nSTOCKHOLM, Sept. 9, 2024 /PRNewswire/ -- Diamyd Medical will pursue an accelerated approval pathway in the U.S. for its antigen-specific immunotherapy, Diamyd¬Æ (rhGAD65/alum), aimed at preserving endogenous insulin production in patients with Stage 3 Type 1 Diabetes. An earlier interim study readout from the ongoing Phase 3 trial, DIAGNODE-3, is planned to serve as the basis for a Biologics License Application (BLA) under the accelerated approval pathway. Results from the interim readout are expected around March 2026.\n\n"We are committed to working at full speed with our partners and in close dialogue with the FDA to seize this unprecedented opportunity of making Diamyd¬Æ available to patients as quickly as possible," says Ulf Hannelius, CEO of Diamyd Medical. "The earlier readout from the DIAGNODE-3 trial represents a critical step in this process and our confidence in Diamyd¬Æ\'s disease-modifying benefits is boosted by the positive outcome of the recently announced futility analysis. We look forward to working closely with the FDA to ensure that all necessary regulatory requirements are met."\n\nDiamyd Medical recently announced Fast track designation in the U.S. for Diamyd¬Æ, and that the U.S. Food and Drug Administration (FDA) has acknowledged that accelerated approval could be sought based on a demonstration of significant treatment-related benefits on C-peptide levels, a measure of endogenous insulin production, in response to Diamyd¬Æ administration. The FDA\'s Accelerated approval program allows drugs for serious conditions that fills an unmet medical need to be approved based on a surrogate endpoint. Using a surrogate endpoint allows the FDA the potential to approve these drugs faster.\n\nTo prepare the BLA under the FDA\'s Accelerated Approval Program, Diamyd Medical plans to conduct an interim study readout, including efficacy data from approximately 170 participants who have completed their 15-month assessment and safety data from additional individuals enrolled in the DIAGNODE-3 trial. The primary endpoint for this analysis will be C-peptide, a surrogate endpoint now recognized by the FDA as reasonably likely to predict clinical benefit. Following the interim readout, the DIAGNODE-3 trial will continue to follow all enrolled patients until the 24-month end-of-study assessment. To date, 148 patients have been randomized in DIAGNODE-3. The results of the interim study readout are expected around March 2026, the exact time depending on the final number of participants to be included in the readout, followed by submission of a BLA under the accelerated approval pathway.\n\nThe DIAGNODE-3 trial, which is being conducted in eight European countries and the United States, is expected to fully recruit approximately 330 patients by the end of 2025, and all patients are expected to be fully treated before the time the earlier readout is to be performed. The trial focuses on recently diagnosed patients with Stage 3 Type 1 Diabetes carrying the HLA DR3-DQ2 genotype; a subgroup of approximately 40% of Stage 3 Type 1 Diabetes patients that has been shown to respond to Diamyd¬Æ in previous trials.\n\n**About Diamyd Medical**\n\nDiamyd Medical develops precision medicine therapies for the prevention and treatment of Type 1 Diabetes and LADA (Latent Autoimmune Diabetes in Adults). Diamyd¬Æ is an antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production that has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage 1, 2 and 3 Type 1 Diabetes. DIAGNODE-3, a confirmatory Phase III trial is actively recruiting patients with recent-onset (Stage 3) Type 1 Diabetes in eight European countries and in the US. Significant results have previously been shown in a large genetically predefined patient group - in a large-scale meta-analysis as well as in the Company\'s prospective European Phase IIb trial, where Diamyd¬Æ was administered directly into a superficial lymph node in children and young adults with recently diagnosed Type 1 Diabetes. Injections into a superficial lymphnode can be performed in minutes and are intended to optimize the treatment response. A biomanufacturing facility is under development in Ume√•, Sweden, for the manufacture of recombinant GAD65 protein, the active ingredient in the antigen-specific immunotherapy Diamyd¬Æ. Diamyd Medical also develops the GABA-based investigational drug Remygen¬Æ as a component in the treatments of metabolic diseases. Diamyd Medical is a major shareholder in the stem cell company NextCell Pharma AB and in the artificial intelligence company MainlyAI AB.\n\nDiamyd Medical\'s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company\'s Certified Adviser.\n\n**For further information, please contact:  \n**Ulf Hannelius, President and CEO  \nPhone: +46 736 35 42 41  \nE-mail: [ulf.hannelius@diamyd.com](mailto:ulf.hannelius@diamyd.com)', 'gpt-4o-mini']
2024-09-10 23:21:52,883 - INFO - Logged data to databases/llm.csv with DocumentID: F1vjrtFKDBdbzYEWY5RL.
2024-09-10 23:21:52,883 - INFO - 'generated_post' length: 9. Content: ['2024-09-10 08:44:00', '2024-09-10 23:21:07', 'üîç Are we witnessing a breakthrough in the treatment landscape for von Hippel-Lindau disease?  \n\n- The recent draft guidance from NICE marks a turning point for patients in England and Wales, permitting the NHS to provide MSD\'s Welireg (belzutifan) for adults suffering from this rare genetic disorder. This recommendation follows previous approval in Scotland last year.  \n- Welireg is especially indicated for VHL-associated renal cell carcinoma, brain/spinal cord tumours (haemangioblastomas), and pancreatic neuroendocrine tumours (pNETs), addressing scenarios where surgical options are inadequate.  \n- With about 100 eligible patients expected in England and 50 new cases annually, the introduction of Welireg as a non-invasive alternative could transform care for the 600 adults living with VHL. Previously, treatments were often limited to invasive surgeries and radiotherapy, emphasizing the need for better options.  \n- Patient advocates celebrate this as a "game-changing" opportunity. It\'s noteworthy that Welireg has demonstrated promising trial results, leading to tumour stabilization and even eradication in some cases.  \n- This decision by NICE, while conditional pending further evidence, is a beacon of hope for patients and families grappling with debilitating symptoms ranging from pain to severe nausea.  \n\nAs clinicians, how can we better integrate emerging therapies like Welireg into patient care to improve outcomes? ü§î  \n\nFor a detailed overview, check out the full article here: https://pharmaphorum.com/news/nice-clears-nhs-use-msds-welireg-genetic-disorder', ['Healthcare & Policy', 'HealthcareInnovation', 'Oncology', 'PatientSupport', 'HealthEquity'], 'https://images.pexels.com/photos/7231416/pexels-photo-7231416.jpeg', 'https://pharmaphorum.com/news/nice-clears-nhs-use-msds-welireg-genetic-disorder', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'NICE clears NHS use of MSD\'s Welireg for genetic disorder\n\nPatients in England and Wales with a rare genetic disorder will soon be able to access treatment with MSD\'s Welireg via the NHS, nearly a year after their counterparts in Scotland.\n\nIn final draft guidance due to be finalised before the end of the month, Welireg (belzutifan) has been recommended as an option for treating adults with von Hippel-Lindau (VHL) disease, a rare and life-shortening disease that can lead to the development of benign and cancerous tumours and cysts.\n\nSpecifically, Welireg becomes an option for VHL-associated renal cell carcinoma (RCC), brain and spinal cord tumours (haemangioblastomas), or pancreatic neuroendocrine tumours (pNETs) when localised treatment like surgery isn\'t appropriate.\n\nUntil now, the only therapies available to patients with VHL have been invasive surgery or radiotherapy, with patients usually requiring multiple surgeries throughout their lives.\n\nThere are only about 600 adults in England living with the condition, and around 100 of them could be eligible for treatment with Welireg, with another 50 cases per year thereafter.\n\nThe decision comes after NICE withheld a recommendation for the drug last December, saying there were "uncertainties" in the clinical and economic evidence submitted for its appraisal. The SMC in Scotland backed NHS use of the drug in October 2023.\n\nThe new NICE recommendation is conditional, meaning that Welireg can be used while more evidence for its efficacy is collected, according to Helen Knight, director of medicines evaluation at NICE. It comes after NHS England reached a commercial access deal with the manufacturer.\n\nThe appraisal committee heard from patient experts who explained that some people with VHL have a wide variety of debilitating symptoms depending on where the tumours are growing in the body. These include pain, loss of balance and motor skills, loss of vision, breathlessness, coughing, headaches, confusion, severe nausea, and fatigue.\n\nGraham Lovitt, chair of patient advocacy group VHL UK/Ireland, said Welireg has "game-changing potential" and has shown extraordinary results for some patients in trials, including stabilisation of the tumours, reduction in growth, and ‚Äì in some cases ‚Äì the eradication of tumours altogether.\n\n"We are delighted by NICE\'s recommendation of belzutifan [‚Ä¶] a significant milestone in the fight against this rare disease," he added. "This decision brings hope to qualifying patients and their families, offering them an alternative treatment option, when others become too high risk."\n\nWelireg (belzutifan), an oral HIF-2 alpha inhibitor, has been approved by the UK drugs regulator the MHRA for VHL since May 2022. MSD acquired it as part of its $2.2 billion takeover of Peloton Therapeutics in 2019.\n\nDespite the rarity of VHL tumours, MSD has blockbuster aspirations for Welireg, and now has a second regulatory approval for the drug in relapsed or refractory advanced RCC, with clinical trials on the go in glioblastoma multiforme, a hard-to-treat form of brain cancer.', 'gpt-4o-mini']
2024-09-10 23:21:52,884 - INFO - Logged data to databases/llm.csv with DocumentID: jEeJnAOcL0yV3CfCLdzE.
2024-09-10 23:21:52,884 - INFO - 'generated_post' length: 9. Content: ['2024-09-09 06:12:00', '2024-09-10 23:21:16', 'üîç Have you ever wondered how neurosurgery could become even more precise and patient-centered? \n\n- Longeviti Neuro Solutions, based in Maryland, recently secured a U.S. patent for their innovative CLEARFIT CRANIAL IMPLANT. This advanced prosthetic boasts unique features, including:\n  - BRAIN-COMPUTER INTERFACE CAPABILITY: Facilitating direct communication between the brain and external devices.\n  - INTEGRATED BRAIN MAPPING AND NEUROSONOGRAPHY: Offering real-time, detailed anatomical imaging during surgical procedures.\n  - Continuous, non-invasive monitoring of brain activity.\n\n- This combination of technology aims to enhance surgical precision while simultaneously improving patient care, as highlighted by CEO Jesse Christopher. The potential to monitor brain activity anywhere in the world could lead to a remarkable reduction in both costs and time involved in neurosurgical procedures.\n\nAs we witness these advancements, how do you see technology reshaping the landscape of neurosurgery in the coming years? ü§î', ['HealthTech & Startups', 'Neurology', 'HealthTech', 'Neurology', 'HealthcareInnovation'], 'https://images.pexels.com/photos/28158899/pexels-photo-28158899.jpeg', 'https://www.healio.com/news/neurology/20240816/longeviti-neuro-solutions-secures-us-patent-for-neurosurgical-cranial-implant', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'Longeviti Neuro Solutions secures US patent for neurosurgical cranial implant\n=============================================================================\n\nA Maryland-based neurotechnology company has secured a U.S. patent for its novel prosthetic translucent, cranial implant intended for use during neurosurgical procedures.\n\nIn a press release, Longeviti Neuro Solutions said the ClearFit implant combines brain-computer interface capability, brain mapping and neurosonography, which permits direct communication between the brain and external devices, along with the ability for patients to interact with the technology, Longeviti said in the release.\n\nThe implant, when paired with brain-mapping capabilities, allows neurosurgeons to receive real-time, detailed anatomical images, enabling them to enhance their precision during neurological procedures. Further, the company said, integrating neurosonography within the cranial implant enables clinicians to continuously monitor brain activity during surgery in a noninvasive manner.\n\n‚ÄúThis technology represents a significant advancement in the field of neurosurgery,‚Äù Longeviti Neuro Solutions CEO Jesse Christopher said in the release. ‚ÄúTogether, Longeviti and its partners will advance neurosonography and neurosurgical patent care to significantly reduce the cost and time it takes to monitor brains anywhere in the world.‚Äù', 'gpt-4o-mini']
2024-09-10 23:21:52,885 - INFO - Logged data to databases/llm.csv with DocumentID: UridxvEHdIu6pLIAFxQT.
2024-09-10 23:21:52,885 - INFO - 'generated_post' length: 9. Content: ['2024-09-09 06:06:00', '2024-09-10 23:21:28', 'üåü Considering the recent advancements in mpox vaccine technology, have you thought about the implications for your practice?\n\n- In a groundbreaking study, Moderna‚Äôs investigational mRNA mpox vaccine proved more effective than the modified vaccinia Ankara (MVA) vaccine in limiting symptoms and shortening disease duration in non-human primates.\n- Remarkably, animals vaccinated with the mRNA option showed:  \n  - LESS WEIGHT LOSS  \n  - FEWER LESIONS  \n  - REDUCED VIRAL SHEDDING in both blood and respiratory tract \n- Specifically, the mRNA vaccine shortened the disease duration by over 10 DAYS compared to MVA, presenting a substantial advantage in controlling outbreaks.\n\nüíâ This study also revealed enhanced immune responses, with mRNA vaccinations resulting in a greater variety of antibodies that not only neutralized mpox but also other related viruses, paving the way for broader protection.\n\nAs the mRNA-1769 vaccine progresses into Phase I/II trials, how do you envision integrating these findings into your prevention strategies?  \n\nFor in-depth insights, check out the full article here: https://www.drugtargetreview.com/news/152646/mrna-vaccine-provides-enhanced-protection-against-mpox/', ['HealthTech & Startups', 'InfectiousDiseases', 'PublicHealth', 'HealthTech', 'VirtualCare'], 'https://images.pexels.com/photos/8830484/pexels-photo-8830484.jpeg', 'https://www.drugtargetreview.com/news/152646/mrna-vaccine-provides-enhanced-protection-against-mpox/', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'mRNA vaccine provides enhanced protection against mpox\n======================================================\n\nThe mRNA vaccine candidate more effectively limited symptoms and disease duration in non-human primates.\n\nA study, funded by Moderna, the National institute of Allergy and Infectious Diseases (NIAID) and the National Institutes of Health (NIH) compared an investigational mRNA mpox vaccine from Moderna to a currently licensed Modified Vaccinia Ankara (MVA) vaccine. The new mRNA vaccine candidate more effectively limits symptoms and disease duration in non-human primates infected with a lethal strain of mpox.\n\nAlec Freyn, virology researcher at Moderna and co-first author, stated: ‚ÄúThis study is the first in a nonhuman primate model where we compare an investigational mRNA mpox vaccine directly to the current standard of care.‚Äù He continued: ‚ÄúWhen we put those vaccines head-to-head in primates, we saw improved responses from the mRNA vaccine in terms of not just protection from survival but also fewer lesions, shorter duration of disease, and less viral shedding in the blood and respiratory tract.‚Äù\n\nOriginally designed to combat smallpox, MVA vaccines contained weakened whole viruses. Yet, this weakening means that they provide limited protection compared to other vaccines. The use of mRNA technology enables vaccines to be developed to only include parts of the virus that are most likely to induce a lasting, protective immune response without exposing the person to a whole infectious virus. The investigational mpox mRNA vaccine is composed of four viral antigens that are essential for the virus to attach and enter host cells.\n\nPrevious research has demonstrated that mRNA vaccines can prevent lethal mpox infections in nonhuman primates but their ability to lessen disease severity has not been tested. Therefore, to directly compare the investigational mRNA vaccine to MVA vaccines, the team vaccinated six macaques with each vaccine and then exposed them to a lethal strain of mpox virus eight weeks after their initial vaccine dose. Also, they exposed a control group of six unvaccinated animals to mpox. Then, after infection, the researchers monitored the macaque‚Äôs health for four weeks and collected blood samples to study their immune response.\n\nDisease severity\n----------------\n\nFive of the unvaccinated control animals did not survive, whereas all 12 vaccinated animals did, regardless of which vaccine was used. The mRNA-vaccinated animals lost less weight and had fewer lesions than MVA-vaccinated animals, despite both vaccines limiting disease severity compared to the control group.\n\nFurthermore, the mRNA vaccine shortened disease duration, measured by the number of days for which the animals showed lesions, by more than 10 days compared to the MVA vaccine. Lower viral loads were in the blood and throat swabs, indicating that it might be more effective at reducing transmission.\n\nJay Hooper, virologist at the United States Army Medical Research Institute for Infectious Diseases and senior author explained: ‚ÄúWith the mRNA technology, we‚Äôre able to produce a vaccine that gives quite potent responses with a very tolerable safety profile‚Ä¶We‚Äôve been trying to get a vaccine that will prevent spread like ACAM2000¬Æ but without the safety issues. This is showing that mRNA technology might be able to fill that niche.‚Äù\n\nImmune response\n---------------\n\nThe mRNA vaccine resulted in a higher number of antibodies and antibodies with more diverse immune functions. Different classes of antibodies that were associated with enhanced viral control and fewer lesions were identified.\n\nFurthermore, the vaccine demonstrated potential to induce cross-immunity to other Orthopoxviruses, whereas the MVA vaccine results in smaller immune responses that are not as strongly neutralising for more remotely related Orthopoxviruses. Serum from the macaques immunised with the mRNA vaccine ‚Äúneutralised not only mpox but also vaccinia, cowpox, rabbitpox, camelpox, and ectromelia virus,‚Äù Freyn said. ‚ÄúWe believe that this vaccine may protect from other Orthopoxvirus threats that may emerge in the future.‚Äù\n\nNow, Moderna‚Äôs mRNA-1769 vaccine is being assessed in a Phase I/II clinical trial (NCT05995275) to determine the safety, tolerability and immune response of a range of doses of mRNA-1769.\n\nThis study was published in Cell.', 'gpt-4o-mini']
2024-09-10 23:21:52,885 - INFO - Logged data to databases/llm.csv with DocumentID: LANfhyK9OVCPNwtFF4Aq.
2024-09-10 23:21:52,885 - INFO - 'generated_post' length: 9. Content: ['2024-09-09 05:56:00', '2024-09-10 23:21:44', "üå¨Ô∏è Did you know that Nucala (mepolizumab), originally developed for severe asthma, could soon be a game-changer for COPD treatment?  \n\n- In the recent MATINEE trial, adding Nucala to standard inhaled therapies demonstrated a statistically significant reduction in moderate or severe COPD exacerbations compared to a placebo. This is a notable advancement following mixed earlier results from GSK's previous trials.  \n- The implications are profound: not only did this trial show meaningful benefits, but it also paves the way for GSK to seek regulatory approval for COPD indications in the US possibly by mid-2024.  \n- With over 300 million people affected by COPD globally‚Äîapproximately 40% of whom show elevated eosinophil levels‚ÄîNucala could offer significant relief to those struggling with severe exacerbations associated with this condition.  \n- As a healthcare professional, consider how integrating IL-5 inhibitors like Nucala into your COPD management strategies could enhance patient outcomes, especially in those with type 2 inflammation.  \n\nWith new options like Dupixent and Ohtuvayre also entering the market, how do you foresee the future landscape of COPD treatments evolving? ü§î", ['Life Sciences & BioTech', 'ClinicalTrials', 'Pulmonology', 'HealthTech', 'Pharmacovigilance'], 'https://images.pexels.com/photos/27271454/pexels-photo-27271454.jpeg', 'https://pharmaphorum.com/news/gsk-says-nucala-hits-target-new-copd-trial', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'GSK says Nucala hits the target in new COPD trial\n\nGSK\'s severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.\n\nThe headline result from the MATINEE trial of IL-5 inhibitor Nucala (mepolizumab) in adults with COPD was a statistically significant reduction in the annualised rate of moderate or severe exacerbations compared to placebo that GSK said was "clinically meaningful." In the study, Nucala was added to inhaled maintenance therapy for COPD.\n\nGSK has been studying Nucala in COPD for some time, and in 2017 reported mixed results for the drug in two earlier phase 3 trials called METREX and METREO.\n\nMETREX involved patients with a range of eosinophil levels and showed a statistically significant improvement for Nucala versus placebo on exacerbation rates. However, in METREO ‚Äì which focused on patients with higher levels only ‚Äì the difference between the two arms was not significant.\n\nThe company decided to file for approval regardless, but the FDA declined to approve the new indication in 2018, following the advice of an advisory committee, which found that GSK had not proved efficacy. It seems MATINEE will allow GSK to try its luck again.\n\nThe size of the improvement over placebo ‚Äì which reportedly extended for up to two years in the trial ‚Äì won\'t be available until the study is presented at a future medical congress, but is strong enough to warrant discussions with regulators about extending the indications for Nucala, according to the pharma group. It has previously suggested approval for COPD could come in the US in the first half of next year.\n\nNucala has been approved to treat severe eosinophilic asthma for almost a decade, and in the interim has had its label extended to include chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome.\n\nThe drug remains one of GSK\'s top products, with sales of ¬£856 million ($1.1 billion) in the first half of this year, up 15%. COPD could open up a massive new market for the drug, which still has several years of patent life left before it could face biosimilar competition.\n\nThe lung disease affects more than 300 million people globally, with up to 40% of patients exhibiting type 2 inflammation characterised by a raised blood eosinophil count, which would make them suitable for treatment with Nucala.\n\nElevated eosinophil levels are associated with more severe COPD and a higher rate of exacerbations, the sudden flare-ups in symptoms that signal the progression of the disease and can lead to hospitalisation.\n\nThe MATINEE data comes at a time when options for COPD are on the up, after a decade with no new therapies.\n\nIn July, the European Commission became the first regulator worldwide to approve Sanofi and Regeneron\'s big-selling IL-4 and IL-13 inhibitor Dupixent (dupilumab) as a treatment for the progressive lung disease, shortly after Verona Pharma got the go-ahead from the US FDA for its PDE 3/4 inhibitor Ohtuvayre (ensifentrine).\n\nDupixent ‚Äì which is due for a verdict from the FDA as a COPD therapy later this month ‚Äì was cleared for adults with uncontrolled COPD with raised blood eosinophils, while Ohtuvayre can be used in all patients regardless of eosinophil levels.', 'gpt-4o-mini']
2024-09-10 23:21:52,886 - INFO - Logged data to databases/llm.csv with DocumentID: 4RiH0v4OthWjjKQAg9uu.
2024-09-11 00:39:02,855 - INFO - Extracted 8 link records.
2024-09-11 00:39:02,857 - INFO - Extracted 8 image links.
2024-09-11 00:39:02,860 - INFO - Extracted 10 link records.
2024-09-11 00:39:02,862 - INFO - Extracted 5 link records.
2024-09-11 00:39:02,864 - INFO - Extracted 8 link records.
2024-09-11 00:39:02,864 - INFO - Unique links to process: 10
2024-09-11 00:39:02,864 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 00:39:04,370 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/, now generating post.
2024-09-11 00:39:05,046 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 00:39:05,048 - INFO - No article found for link https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/.
2024-09-11 00:39:05,048 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/. Skipping.
2024-09-11 00:39:05,048 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 00:39:05,048 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 00:39:07,254 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/, now generating post.
2024-09-11 00:39:07,564 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 00:39:07,565 - INFO - No article found for link https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/.
2024-09-11 00:39:07,565 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/. Skipping.
2024-09-11 00:39:07,565 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 00:39:07,565 - INFO - Starting to process link: http://r.jina.ai/https://sifted.eu/articles/billionaires-body-scans/
2024-09-11 00:39:09,410 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://sifted.eu/articles/billionaires-body-scans/, now generating post.
2024-09-11 00:39:18,202 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 00:39:23,995 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 00:39:24,280 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 00:39:24,281 - INFO - Image query: preventive healthcare technology
2024-09-11 00:39:24,661 - INFO - Unique image link: https://images.pexels.com/photos/9574543/pexels-photo-9574543.jpeg
2024-09-11 00:39:24,662 - INFO - Post generated successfully for link: http://r.jina.ai/https://sifted.eu/articles/billionaires-body-scans/
2024-09-11 00:39:24,662 - INFO - Starting to process link: http://r.jina.ai/https://sifted.eu/articles/doccla-raises-a-35m-series-b-news/
2024-09-11 00:39:26,168 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://sifted.eu/articles/doccla-raises-a-35m-series-b-news/, now generating post.
2024-09-11 00:39:34,575 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 00:39:38,946 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 00:39:39,230 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 00:39:39,230 - INFO - Image query: "remote patient monitoring"
2024-09-11 00:39:39,567 - INFO - Unique image link: https://images.pexels.com/photos/6823504/pexels-photo-6823504.jpeg
2024-09-11 00:39:39,567 - INFO - Post generated successfully for link: http://r.jina.ai/https://sifted.eu/articles/doccla-raises-a-35m-series-b-news/
2024-09-11 00:39:39,567 - INFO - Starting to process link: http://r.jina.ai/https://sifted.eu/articles/medtech-startup-vc-trends/
2024-09-11 00:39:41,381 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://sifted.eu/articles/medtech-startup-vc-trends/, now generating post.
2024-09-11 00:39:51,768 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 00:39:55,647 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 00:39:56,062 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 00:39:56,063 - INFO - Image query: "medical technology innovations"
2024-09-11 00:39:56,391 - INFO - Unique image link: https://images.pexels.com/photos/7723509/pexels-photo-7723509.jpeg
2024-09-11 00:39:56,392 - INFO - Post generated successfully for link: http://r.jina.ai/https://sifted.eu/articles/medtech-startup-vc-trends/
2024-09-11 00:39:56,392 - INFO - Starting to process link: http://r.jina.ai/https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/
2024-09-11 00:39:57,888 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/, now generating post.
2024-09-11 00:40:15,710 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 00:40:19,600 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 00:40:19,876 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 00:40:19,877 - INFO - Image query: "AI surgical technology"
2024-09-11 00:40:20,218 - INFO - Unique image link: https://images.pexels.com/photos/20897581/pexels-photo-20897581.jpeg
2024-09-11 00:40:20,218 - INFO - Post generated successfully for link: http://r.jina.ai/https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/
2024-09-11 00:40:20,218 - INFO - Starting to process link: http://r.jina.ai/https://sifted.eu/articles/startups-wegovy-ozempic-shift/
2024-09-11 00:40:22,041 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://sifted.eu/articles/startups-wegovy-ozempic-shift/, now generating post.
2024-09-11 00:40:37,158 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 00:40:41,843 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 00:40:42,142 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 00:40:42,143 - INFO - Image query: "obesity treatment options"
2024-09-11 00:40:42,437 - INFO - Unique image link: https://images.pexels.com/photos/7659900/pexels-photo-7659900.jpeg
2024-09-11 00:40:42,437 - INFO - Post generated successfully for link: http://r.jina.ai/https://sifted.eu/articles/startups-wegovy-ozempic-shift/
2024-09-11 00:40:42,438 - INFO - Starting to process link: http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 00:40:45,879 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296, now generating post.
2024-09-11 00:40:46,295 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 00:40:46,296 - INFO - No article found for link https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296.
2024-09-11 00:40:46,296 - ERROR - No valid post generated for http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296. Skipping.
2024-09-11 00:40:46,296 - WARNING - Skipping entry due to missing or invalid log entry for link: https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 00:40:46,296 - INFO - Starting to process link: http://r.jina.ai/http://medscape.co.uk/viewarticle/mastitis-older-women-linked-subsequent-breast-cancer-2024a1000g68
2024-09-11 00:40:49,301 - INFO - Successfully fetched webpage content from http://r.jina.ai/http://medscape.co.uk/viewarticle/mastitis-older-women-linked-subsequent-breast-cancer-2024a1000g68, now generating post.
2024-09-11 00:40:53,937 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 00:40:56,682 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 00:40:56,958 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 00:40:56,959 - INFO - Image query: breast cancer awareness
2024-09-11 00:40:57,253 - INFO - Unique image link: https://images.pexels.com/photos/4611655/pexels-photo-4611655.jpeg
2024-09-11 00:40:57,253 - INFO - Post generated successfully for link: http://r.jina.ai/http://medscape.co.uk/viewarticle/mastitis-older-women-linked-subsequent-breast-cancer-2024a1000g68
2024-09-11 00:40:57,253 - INFO - Starting to process link: http://r.jina.ai/http://medscape.com/viewarticle/abnormal-heart-rate-shifts-tied-risk-death-diabetes-2024a1000g8n
2024-09-11 00:40:59,648 - INFO - Successfully fetched webpage content from http://r.jina.ai/http://medscape.com/viewarticle/abnormal-heart-rate-shifts-tied-risk-death-diabetes-2024a1000g8n, now generating post.
2024-09-11 00:41:05,393 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 00:41:08,121 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 00:41:08,425 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 00:41:08,426 - INFO - Image query: "heart health monitoring in diabetes"
2024-09-11 00:41:08,708 - INFO - Unique image link: https://images.pexels.com/photos/6823491/pexels-photo-6823491.jpeg
2024-09-11 00:41:08,708 - INFO - Post generated successfully for link: http://r.jina.ai/http://medscape.com/viewarticle/abnormal-heart-rate-shifts-tied-risk-death-diabetes-2024a1000g8n
2024-09-11 00:41:08,708 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/9574543/pexels-photo-9574543.jpeg'}
2024-09-11 00:41:08,708 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 00:41:08,708 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/6823504/pexels-photo-6823504.jpeg'}
2024-09-11 00:41:08,708 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 00:41:08,708 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/7723509/pexels-photo-7723509.jpeg'}
2024-09-11 00:41:08,708 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 00:41:08,708 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/20897581/pexels-photo-20897581.jpeg'}
2024-09-11 00:41:08,708 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 00:41:08,708 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/7659900/pexels-photo-7659900.jpeg'}
2024-09-11 00:41:08,708 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 00:41:08,708 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/4611655/pexels-photo-4611655.jpeg'}
2024-09-11 00:41:08,708 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 00:41:08,708 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/6823491/pexels-photo-6823491.jpeg'}
2024-09-11 00:41:08,708 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 00:41:08,708 - INFO - Sending 7 log entries to Firebase.
2024-09-11 00:41:13,420 - INFO - Successfully sent batch data to Firebase: {'message': 'Batch processed successfully. 7 posts added.', 'documentIDs': ['T6jBEutsg4OfnkRcXNWK', '9nj2Jph5BejAt6HcNWLs', 'ZkMGU9qkM9hFZA7ABy02', 'wLCg6WsbiprbrwEI7lHF', 'Mqdn6qI5ixJT096Lckk1', 'Y5hYnfN5H5u0tpelUmi9', 'AY9mxo3hStuYQC4adJvR']}
2024-09-11 00:41:13,420 - INFO - Received 7 document IDs from Firebase.
2024-09-11 00:41:13,420 - INFO - 'generated_post' length: 9. Content: ['2024-09-06 00:00:00', '2024-09-11 00:39:24', 'üåç What do billionaires see in body scans? Could there be a lesson for broader preventive healthcare practices?  \n  \n- Recently, I explored Zoƒ´, a pioneering longevity clinic in Paris, where a three-hour comprehensive check-up taps into over 200 biomarkers. This data is then analyzed through AI to provide tailored lifestyle recommendations aimed at disease prevention.  \n- Interestingly, Zoƒ´‚Äôs approach is about enhancing the quality of life rather than simply extending it. The cofounder emphasizes understanding the body‚Äôs ‚Äòuser manual‚Äô to improve long-term wellness.  \n- While this type of preventive medicine is currently priced around ‚Ç¨3.6k annually, the vision is to democratize access as technology evolves and costs fall. Imagine a future where such services might rival your monthly internet bill!  \n- Other startups like Neko Health are also entering this space, offering similar high-tech scans that have already attracted significant waiting lists, indicating a growing interest in proactive health management among the wealthier demographics.  \n  \nAs we consider the potential of AI in healthcare, could we envision a similar model becoming accessible to all? What strategies could we employ to integrate these insights into mainstream medical practice? ü§î  \n\nFor more details, check out the original article here: https://sifted.eu/articles/billionaires-body-scans/', ['HealthTech & Startups', 'HealthTech', 'DigitalHealth', 'PatientEngagement', 'PrecisionMedicine'], 'https://images.pexels.com/photos/9574543/pexels-photo-9574543.jpeg', 'https://sifted.eu/articles/billionaires-body-scans/', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', "**_This article first appeared in Sifted‚Äôs Daily newsletter, [sign up here](https://sifted.eu/newsletters?utm_medium=onsite&utm_source=article&utm_campaign=daily_big_story&utm_content=flagshipnl)._**\n\nEarlier this week, I visited one of Paris‚Äô few longevity clinics dedicated to preventative medicine ‚Äî and the only one that describes itself as a tech startup.\n\nHidden behind an unassuming Haussmannian door, just a few minutes away from the Paris Opera, the centre has been operating for nine months. The startup behind it, Zoƒ´, promises customers a ‚Äú360-degree check-up‚Äô ‚Äî a three-hour series of tests and exams, ranging from blood tests to eye scans through spirometry and gut microbiome analyses.\n\nThe objective? Collect millions of data points on up to 200 biomarkers that are in turn analysed by an AI model, in order to deliver lifestyle recommendations that, promises Zoƒ´, will prevent disease and improve customers‚Äô long-term wellness.\n\n‚ÄúIt‚Äôs not about adding years of life, but rather life to years,‚Äù says Zoƒ´ cofounder ‚Äî and former special advisor to French president Emmanuel Macron ‚Äî Isma√´l Em√©lien. ‚ÄúThe goal is to learn the body‚Äôs ‚Äòuser manual‚Äô to prevent illnesses and enable people to live in good health for longer.‚Äù\n\nIt‚Äôs not for everyone. Membership to Zoƒ´ is ‚Ç¨3.6k per year, which includes an annual checkup as well as the follow-up recommendations. That‚Äôs roughly the cost of a membership to Soho House, says Zoƒ´'s CFO Antoine Attali ‚Äî and the startup's customers usually belong to the same social circles.\n\nThe clinic caters to premium needs, from snacks elaborated by world-famous chef Alain Ducasse to a balneotherapy section modelled on ‚ÄòJapanese thermal baths‚Äò, featuring a snow cabin (?) and a mineral bath that is, I am told, ‚Äútwice as salty as the Dead Sea‚Äù.\n\nAttali tells me that in the long-term, Zoƒ´ hopes to become accessible to everyone, and that prices will go down to a similar level to your average WiFi subscription.\n\nFor now, though, preventative health remains a hobby of the upper-class. In fact, Zoƒ´'s investors are all private individuals; the company‚Äôs ‚Ç¨20m seed round, which it raised in 2022, included a good number of high-profile billionaires such as Xavier Niel, Rodolphe Saad√© and Moderna CEO St√©phane Bancel.\n\nAnd Zoƒ´ is not the only longevity startup appealing to the ultra-rich. Spotify founder Daniel Ek is behind similar ventures, including [Sand Clinic in Stockholm](https://sifted.eu/articles/daniel-ek-spotify-sand-clinic-longevity-news), where customers can receive full body check-ups and treatments ranging from vacuum therapy to red light saunas ‚Äî with membership expected to cost between ‚Ç¨1,000 and ‚Ç¨10,000 a month.\n\nEk is also the founder of healthtech Neko Health, which has built a full-body scanner for health data collection that it says helps doctors detect potential diseases earlier. The company [has a clinic in Stockholm](https://sifted.eu/articles/ek-neko-body-scanner-test) and has just opened a new spot in London, right in the middle of Marylebone, where it prices a one-hour scan at ¬£299 ‚Äî almost double the price of a visit to the Stockholm clinic when it opened in 2023 (‚Ç¨180).\n\nDespite the cost, the proposition seems appealing enough. Neko Health says it already has a waiting list of 22k people; Zoƒ´ says it has ‚Äúaround 1k members‚Äù to date and is currently carrying out a dozen check-ups per day ‚Äî but the startup is confident that it can ramp up to reach its maximum capacity of 35k annual check-ups in the next five years.\n\nWhether or not the preventative treatments promised by startups like Zoƒ´, Neko Health and Sand Clinic will ever reach the masses remains to be seen; what seems certain for now is that billionaires won‚Äôt get tired of full-body-scanning anytime soon.\n\n![Image 1: A photo of the entrance to Zo√Ø's centre in Paris](https://images.sifted.eu/wp-content/uploads/2024/09/06145636/Zoi%CC%84_WIP6_%C2%A911h45-HD-4.jpg?auto=format&fit=max&w=3840&q=75)\n\nThe entrance to Zo√Ø's centre in Paris. Credit: 11h45", 'gpt-4o-mini']
2024-09-11 00:41:13,422 - INFO - Logged data to databases/llm.csv with DocumentID: T6jBEutsg4OfnkRcXNWK.
2024-09-11 00:41:13,422 - INFO - 'generated_post' length: 9. Content: ['2024-09-03 00:00:00', '2024-09-11 00:39:38', 'üë©\u200d‚öïÔ∏è How can technology redefine patient care while benefiting healthcare providers? \n\n- Doccla, a UK-based healthtech, has just raised ¬£35m in Series B funding to enhance its innovative "virtual ward" services, significantly impacting how we monitor patients remotely. \n- With annual revenue nearly quadrupling in 2023, they are expanding into the DACH region and France, enabling healthcare professionals to monitor patients from home using devices for vital metrics like blood pressure and heart rate. \n- üìâ A recent NHS study highlighted that utilizing Doccla\'s technology led to a remarkable 63% reduction in A&E visits, demonstrating not only improved patient outcomes but also cost savings for healthcare systems.  \n- As they begin discussions with pharmaceutical companies, the potential for improving clinical trial data collection and patient compliance is promising. Their patient compliance sits at an impressive 92-97%‚Äîa testament to their close engagement with patients.  \n- Looking ahead, Doccla aims to onboard 100k new patients monthly, enhancing preventative care, particularly for those frequently hospitalized. \n\nAs healthcare becomes more integrated with technology, how do you see the role of remote monitoring evolving in your practice? ü§î \n\nFor further insights, read more here: https://sifted.eu/articles/doccla-raises-a-35m-series-b-news/', ['HealthTech & Startups', 'DigitalHealth', 'HealthTech', 'Telehealth', 'RemoteMonitoring', 'PatientEngagement'], 'https://images.pexels.com/photos/6823504/pexels-photo-6823504.jpeg', 'https://sifted.eu/articles/doccla-raises-a-35m-series-b-news/', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', "UK-based healthtech Doccla has secured a ¬£35m Series B, led by European VC Lakestar, with new investors French VC Elaia and existing investors General Catalyst, Speedinvest and the investment leg of German media company Bertelsmann also participating.\n\nHaving almost quadrupled its annual revenue in 2023, it's planning its expansion in DACH and France, and says its German and French investors will help its international growth plans.\n\nThe startup, founded in 2019, makes ‚Äúvirtual ward‚Äù technology for healthcare providers. It allows clinicians to monitor patients at home, by providing them with devices to measure health factors like blood pressure and heart rate.\n\nDoccla has become the largest virtual ward provider for the UK‚Äôs National Health Service (NHS). In December 2023, it signed its first contract with a German hospital and, in June, it partnered with Ireland‚Äôs Health Service Executive (HSE).\n\nDoccla‚Äôs founder and chair Martin Ratz tells Sifted that the company has its sights set on France, partly due to a change in the healthcare system that makes it easier to receive compensation for remote monitoring of patients.\n\n‚ÄúWith the new compensation system in France (similar to that in the US), there are specific codes for remote monitoring which will facilitate the financials tremendously, and for us, it‚Äôs a huge opportunity to scale,‚Äù says Ratz.\n\nThe virtual A&E\n\nSweden-founded Doccla entered the UK with a pilot project for a virtual ward in 2020, and the timing of the pandemic meant that the company was off to a flying start. It has since then grown its customer base to 10 countries in Europe. Monitoring patients at home, instead of in an overcrowded emergency department at a hospital, has not only meant that hospitals can better manage the patients they have in-house, but also cut costs.\n\nAccording to a recent study funded by the NHS, by implementing Doccla, regional NHS departments have experienced a 63% reduction in A&E attendance while enjoying a 300% return on investment.\n\nPatients signed over to Doccla from hospitals are monitored around the clock using hardware, software and virtual care, which allow medical staff to access patient data in real-time and pre-emptively flag concerns, triggering in-person appointments before issues escalate.\n\nSo far Doccla has monitored over 4m patient days with over 95% patient compliance. Today the company says it‚Äôs adding 1k new patients every month.\n\n‚ÄúOver time, we want to onboard 100k new patients on a monthly basis,‚Äù Ratz says.\n\nPartnering with pharma\n\nDoccla has also recently started conversations with large pharmaceutical companies to deliver clinical data for use in clinical trials. According to Ratz, what pharma companies often struggle with is recruiting patients, as well as compliance (patients taking their drugs when they should).\n\n‚ÄúWe have a compliance rate of 92-97% for our patients, those are sky-high numbers,‚Äù Ratz says. ‚ÄúThis is because we are in very close contact with our patients.‚Äù\n\nDoccla says it‚Äôs interested in pharma partnerships for two main reasons. The first is that providing clinical data is very close to what Doccla already provides to public health providers. The second is that Ratz says he‚Äôs seen software companies, like UK-based Huma and US-based Biofourmis, run such partnerships this successfully.\n\nWith 180 employees, with around 40 of them clinicians, the company now wants to grow its data science team, which today only consists of a few people. By using the data it collects from patients, and combining it with conversations between patients and the care team, Ratz believes Doccla can improve on the service the patients receive and become more preventative in its care.\n\nIn one region in the UK, Doccla has taken over 500 patients who have been in and out of hospital for a long time, to monitor them in a more preventative way.\n\n‚ÄúWe can in a proactive way decrease the number of hospital visits ‚Äî in this case, we decreased them by 63% which is a huge saving for society,‚Äù Ratz says.\n\nDoccla has raised a total of ¬£52m to date.\n\nIn October of last year, Ratz was the largest shareholder with 35% of the shares, followed by General Catalyst at 26%, Dag Larsson (CEO and cofounder) at 15%, Giant Ventures at 9% and Speedinvest at 11%, according to UK Companies House.", 'gpt-4o-mini']
2024-09-11 00:41:13,423 - INFO - Logged data to databases/llm.csv with DocumentID: 9nj2Jph5BejAt6HcNWLs.
2024-09-11 00:41:13,423 - INFO - 'generated_post' length: 9. Content: ['2024-08-27 00:00:00', '2024-09-11 00:39:55', 'üîç Have you noticed the significant shift in MedTech investments over the past few years?  \n\n- In 2023, MedTech startups raised $2.2bn, a stark contrast to the $4bn in 2021. While the landscape can seem daunting, surgical robotics are on the rise! Notably, CMR Surgical, DistalMotion, and Medical Microinstruments have recently secured substantial funding for their innovative solutions.  \n\n- Attention is also shifting toward next-gen diagnostic devices, with figures like Daniel Ek entering the space to develop body scanning technology that aligns with the growing market for wellness and fitness monitoring devices.  \n\n- Some startups gaining traction include:  \n  - MEDICAL MICROINSTRUMENTS (MMI): Enhancing microsurgery capabilities through advanced robotic technologies.  \n  - GRADIENT DENERVATION TECHNOLOGIES: Aiming to revolutionize treatment for heart failure patients with pulmonary hypertension via minimally invasive ultrasound techniques.  \n  - GANYMED ROBOTICS: Utilizing AI for precision in knee replacement surgeries‚Äîremoving complexities and improving efficiency.  \n  - GLEAMER: Offering AI tools for better bone trauma diagnosis, already making waves in both the US and EU markets.  \n\n- üìâ On the other hand, companies like Vitestro and Bluedrop Medical are addressing essential healthcare challenges with innovative devices that enhance patient care while potentially reducing costs.  \n\nAs we look toward the future, how can healthcare professionals incorporate these technological advancements into their clinical practice? ü§î', ['HealthTech & Startups', 'HealthTech', 'MedicalDevices', 'HealthcareInnovation', 'ClinicalTrials', 'PatientSafety'], 'https://images.pexels.com/photos/7723509/pexels-photo-7723509.jpeg', 'https://sifted.eu/articles/medtech-startup-vc-trends/', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', "Medtech has had a mixed few years. In 2023, startups in the sector raised $2.2bn with 2024 looking similar ‚Äî roughly half of the $4bn picked up in 2021, according to Sifted data.\n\nBut there have still been some sizable rounds in recent times. Since the start of 2023, surgical robotics startups have been the biggest winners. The UK‚Äôs CMR Surgical picked up ¬£165m in September last year, Switzerland‚Äôs DistalMotion $150m in April 2023 and Italy‚Äôs Medical Microinstruments $110m in February this year.\n\nThere‚Äôs also been some buzz around next-gen diagnostic devices, as founders ‚Äî including Spotify‚Äôs Daniel Ek with his body scanning startup Neko Health ‚Äî look to tap into the trend of more people using wellbeing and fitness devices like Apple Watches and Oura rings.\n\nBut which non-portfolio medtech startups are investors keeping a close eye on? To find out, Sifted spoke to VCs at 415 Capital, Sofinnova Partners, MIG Capital and SHS Capital.\n\n### Linus Rieder, principal at 415 Capital\n\n#### Medical Microinstruments (MMI) ‚Äì Italy\n\nMMI is building surgical robots to help with micro-surgery. Its robotics platform can be used in reconstructive surgery, plastic surgery and head-neck surgery. The startup is looking to solve key issues in microsurgery like the effects of surgeon tremor and reduces the need for microsurgery training.\n\n#### Gradient Denervation Technologies ‚Äî France\n\nGradient Denervation Technologies is developing a device for treating heart failure patients with associated pulmonary hypertension. As many as half of heart failure patients around the world have elevated pulmonary vascular resistance, which is shown to lead to an increased risk of mortality and hospitalisation. There are no approved drug or device therapies for this group of pulmonary hypertension patients. By using minimally invasive ultrasound to treat hyperactive nerves in the pulmonary arteries, however, the startup‚Äôs technology has the potential to treat and help tens of thousands of patients each year.\n\n#### CorWave ‚Äî France\n\nCorWave's left ventricular assist device (LVAD) mimics the natural heart's function to treat patients with advanced heart failure. This technology enables the device to replicate the heart pulses, reducing the mechanical damage to blood cells common with current LVADs.\n\n### Anne Osdoit, partner at Sofinnova Partners\n\n#### Ganymed Robotics ‚Äî France\n\nGanymed is working on a robotics platform to assist surgeons with implant placement during knee replacement surgery. The Paris-based company's approach uses computer vision and artificial intelligence to perceive, and extract knowledge from, the surgical environment in a non-invasive manner, removing imaging and registration steps that add time and complexity to knee surgery.\n\n#### Gleamer ‚Äî France\n\nGleamer is developing AI tools to enhance image interpretation for radiologists. The startup‚Äôs main product helps clinicians identify bone trauma at the point of care. Gleamer has achieved multiple regulatory approvals and successfully commercially deployed in both the US and EU.\n\n#### Salvia BioElectronics ‚Äî The Netherlands\n\nSalvia BioElectronics is developing drug-free neuromodulation therapies ‚Äî which refers to a group of medical procedures that look to change brain activity by stimulating nerves ‚Äî for migraines. Salvia's paper-thin implant is designed to be placed under the forehead to reduce the frequency and intensity of migraine attacks by delivering gentle electrical pulses to the nerves associated with the condition. The company is currently in the clinical stage, having received the Breakthrough Device Designation from the United States Food and Drug Administration (FDA), which facilitates expedited market access for devices that treat life-threatening or irreversibly debilitating conditions.\n\n### Fei Tian, principal at MIG Capital\n\n#### Artidis ‚Äî Switzerland\n\nArtidis is developing imaging tools for cancer diagnostics. It combines a nanotechnology device which analyses tissue with a digital data platform to measure the physical characteristics of both tumour cells and the tumour microenvironment. After determining if a tumour is benign or malignant, Artidis‚Äô technology identifies if it will spread to other sites and can help inform chemotherapy and immunotherapy permeability and treatment response.\n\n#### CoreMedic ‚Äî Switzerland\n\nCoreMedic has developed an implant which treats the heart condition mitral valve regurgitation (MR). The CoreMedic implant can replace ruptured mitral ‚Äî a part of the heart ‚Äî in a minimally invasive procedure that is physiological and reproducible, promising long-term clinical benefits.\n\n### Cornelius Maas, partner at SHS Capital\n\n#### Vitestro ‚Äî The Netherlands\n\nVitestro is developing an autonomous blood drawing device. This innovative device combines robotics and AI to perform blood drawing more efficiently and safely. Over the past year, Vitestro has made significant strides in clinical trials and secured an additional ‚Ç¨20m in funding in April. Vitestro‚Äôs tool could mean less burden for patients, less work for the medical staff and consequently reduce costs for the healthcare system.\n\n#### Saphenus ‚Äî Austria\n\nSaphenus is developing sensory feedback systems for prosthetics. Their key product, the Suralis system, provides users of lower-limb prosthetics with the sensation of foot contact, significantly improving balance and gait. Recently, Saphenus received FDA approval with their Suralis systema and received reimbursement status with key German medical insurers.\n\n#### Bluedrop Medical ‚Äî Ireland\n\nBluedrop Medical is developing a medical device to monitor foot health and prevent diabetic foot ulcers. It looks like a weighing scale and aims to enable early detection of foot ulcers, which can lead to amputation. Bluedrop Medical is a good example of how remote monitoring can replace doctor visits while preventing serious disease progression, improving patient outcomes and reducing healthcare costs.", 'gpt-4o-mini']
2024-09-11 00:41:13,424 - INFO - Logged data to databases/llm.csv with DocumentID: ZkMGU9qkM9hFZA7ABy02.
2024-09-11 00:41:13,424 - INFO - 'generated_post' length: 9. Content: ['2024-08-15 00:00:00', '2024-09-11 00:40:19', 'üîç Have you heard about Caresyntax‚Äôs latest funding round? \n\n- üöÄ Berlin-based Caresyntax just raised a whopping $180 million in a Series C extension, comprised of $80 million in equity and $100 million in debt, bringing their total equity funding to $220 million! \n- This influx of capital aims to enhance their AI-driven data platform designed for surgical applications, addressing the global demand for efficiency in operating theaters amidst staff shortages and rising healthcare costs. \n- Their technologies are set to transform surgical practices by analyzing over 1,000 data points per surgical case, enhancing patient outcomes, identifying intraoperative risks, and streamlining workflows. For example, AI algorithms can alert surgeons to concerning drops in heart rate that may go unnoticed! \n- Caresyntax now operates in 3,000 operating rooms worldwide, facilitating over 3 million surgeries each year.\n\nAs we witness significant investments in surgical technology, how do you think AI can further revolutionize surgical practices in your facility? üí≠  \n\nFor more on how Caresyntax is shaping the future of surgery, check out the full article here: https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/', ['HealthTech & Startups', 'HealthTech', 'Surgery', 'AIInHealthcare', 'HealthcareInnovation'], 'https://images.pexels.com/photos/20897581/pexels-photo-20897581.jpeg', 'https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'Berlin-based Caresyntax, which is building an AI-driven data platform for surgery, has raised a $180m Series C extension.\n\nThe round is made up of $80m in equity and $100m in debt ‚Äî and is tied to specific milestones. The fresh funding tops up the startup‚Äôs $130m Series C, raised across two rounds in 2021, and takes its total equity funding to $220m.\n\nIt‚Äôs the latest in a string of big money raises for European startups developing tech for hospital operating theatres as healthcare systems across the globe scramble to increase efficiency amid staff shortages and the rising costs of treating ageing populations.\n\nCaresyntax will use the funds to scale customer adoption in the US and EMEA region, develop AI applications and finance M&A opportunities.\n\n### AI for hospitals\n\nCaresyntax says it wants to build the ‚ÄúAndroid‚Äù platform for surgery. Its tech uses AI algorithms to make sense of data collected before, during and after an operation to help surgeons improve patient outcomes, spot risks during procedures and reduce hospitals‚Äô surgery costs by improving efficiency and reducing readmissions.\n\nThe company‚Äôs platform can pick up on warning signs like drops in heart rate that surgeons might not be aware of during a procedure, for example. It can also streamline operative workflows, inform post-treatment care pathways post-operation and collect 1,000 data points per surgical case.\n\nWhile some surgical robotics solutions in the market only work with certain products, Caresyntax‚Äôs platform can plug into any operating room technology to pull together data, according to a company spokesperson.\n\n‚ÄúEffectively using AI in the operating room requires input from a wide variety of data sources, but today this data exists in silos where it is difficult for clinicians to access and operationalise,‚Äù they add.\n\nIf it does what it sets out to do, it‚Äôs a big opportunity.\n\nCosts associated with operations account for 30% of healthcare expenditure, a huge sum given that Europe spends 11% of GDP on health.\n\nFounded in 2013 in Germany ‚Äî Caresyntax also expanded to San Francisco in 2019 ‚Äî its data platform is currently used in 3k operating rooms globally, in more than 3m surgeries annually, according to the company. 40% of the company‚Äôs revenue comes from the Americas and 60% from the EMEA region.\n\n### The rise of smart surgery\n\nThe round comes on the back of a strong 18 months for startups developing tech for the operating theatre.\n\nSince the start of 2023, three of the four biggest medtech raises have all gone to startups building robots to help surgeons. The UK‚Äôs CMR Surgical picked up ¬£165m in September last year, Switzerland‚Äôs DistalMotion $150m in April 2023 and Italy‚Äôs Medical Microinstruments $110m in February this year.\n\nInvestors in Caresyntax‚Äôs round include Symbiotic Capital, MTIP AG, BIONIQ Capital, PFM Health Sciences, Pictet Alternative Advisors, surgical.ai, BlackRock Innovation Capital, Aescuvest, Optum Ventures, Cure Capital, Relyens Group, Vesalius Biocapital, Lauxera Capital, Plug & Play Growth Fund and ProAssurance Corp.', 'gpt-4o-mini']
2024-09-11 00:41:13,425 - INFO - Logged data to databases/llm.csv with DocumentID: wLCg6WsbiprbrwEI7lHF.
2024-09-11 00:41:13,425 - INFO - 'generated_post' length: 9. Content: ['2024-08-13 00:00:00', '2024-09-11 00:40:41', 'üöÄ Have you noticed the buzz around GLP-1 medications for weight loss? Here are some impactful insights that could influence clinical practice:\n\n- The recent surge in weight loss drugs, particularly GLP-1s like Ozempic and Wegovy, is reshaping the healthcare landscape, with industry projections suggesting up to $150 billion in sales by the early 2030s. üìà \n\n- Startups like Oviva are already integrating GLP-1s into their treatment plans, highlighting a fast-growing demand for effective obesity management options. In fact, Oviva reports double-digit year-on-year growth as a result. \n\n- GLP-1 meds are creating a paradigm shift in treatments for obesity. As a healthcare professional, it‚Äôs essential to evaluate how these medications could enhance your current treatment pathways for patients struggling with weight. \n\n- Notably, the hype surrounding these drugs has had economic implications, even influencing grocery sales in the US. üåç This points to the wider societal impact of effective weight management solutions. \n\n- However, there are challenges ahead, particularly regarding supply chain issues and insurance reimbursements across Europe, affecting startups aiming for growth. üè• \n\n- As the demand for GLP-1 medications continues to rise, how can your practice adapt to these innovations and incorporate best practices in patient care? Let‚Äôs discuss the implications and potential integrations into existing treatment protocols!', ['HealthTech & Startups', 'HealthTech', 'ClinicalTrials', 'DigitalHealth', 'Endocrinology', 'PatientEngagement'], 'https://images.pexels.com/photos/7659900/pexels-photo-7659900.jpeg', 'https://sifted.eu/articles/startups-wegovy-ozempic-shift/', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', "The meteoric rise of a new class of weight loss drugs over the past two years, known as GLP-1s, has seen a new name take the title of Europe‚Äôs most valuable company, helped a country dodge a recession and hit grocery sales in the US.\n\nThe valuations of the companies that make this so-called ‚Äúmiracle‚Äù class of drugs ‚Äî which includes Danish pharma giant Novo Nordisk (maker of Ozempic and Wegovy) and US rival Eli Lilly (maker of Mounjaro and Zepbound) ‚Äî have soared as investors bet big on a medication projected by some to hit $150bn in sales by the early 2030s.\n\nThe potential of the market has not been lost on founders.\n\nIt‚Äôs a ‚Äúhuge‚Äù opportunity, says Kai Eberhardt, the founder and CEO of Oviva, a Swiss weight loss management platform which operates in the UK, France and Germany, alongside its home market. It began offering GLP-1 drugs as part of its treatment options in the second quarter of this year.\n\n‚ÄúFor us [GLP-1 drugs] are already a strong growth driver,‚Äù he says. ‚ÄúThe newer GLP-1 class of medications have created real excitement due to their impressive outcomes in weight loss, transforming the treatment options available for those living with obesity.‚Äù\n\nWhile treatment involving GLP-1 drugs is currently a small part of Oviva‚Äôs overall business ‚Äî Eberhardt says it‚Äôs growing total patient and revenue numbers by ‚Äúdouble digit‚Äù percentage points year-on-year ‚Äî the meds could become the startup‚Äôs ‚Äúlargest‚Äù growth driver in the future, he tells Sifted.\n\n### Riding the wave\n\nOviva‚Äôs not alone. There are a slew of startups in Europe looking to tap into the opportunity ‚Äî many of which have recently shifted operations to focus on selling GLP-1 drugs or provide treatment pathways around the medication, which was first designed to treat diabetes but was later found to be effective at suppressing appetite and helping people lose weight.\n\nIn the last two years GLP-1s have become a go-to weight loss solution popularised by a roster of celebrity users. According to Walmart‚Äôs CEO, food sales have fallen as the one in eight adults in the US who have used the meds slim down their buying habits. The drug class has also seen Novo Nordisk overtake luxury fashion brand LVMH as Europe‚Äôs most valuable company, propping up Denmark‚Äôs GDP in the process.\n\nAll of the attention has got VCs excited, and companies on both sides of the Atlantic have convinced them to get out their chequebook: Danish startup Embla, which prescribes GLP-1 meds alongside ongoing clinical care and lifestyle advice for patients looking to lose weight in its home market and the UK, picked up a ‚Ç¨10m Series A in August 2023 a year on from a ‚Ç¨3.5m seed round. Swedish startup Yazen, which says it too prescribes GLP-1 drugs in combination with clinical care, also raised ‚Ç¨3.1m last summer.\n\nMany startups operating in the GLP-1 space didn‚Äôt start life offering them ‚Äî largely due to launching before the drugs were popularised for weight loss. Ozempic was approved for sale in the US in 2017 and Europe in 2018; Wegovy was approved in the US in 2021 and Europe in 2022.\n\nUK-based Numan, a digital medication and supplements provider founded in 2016, started by selling sexual health treatments; it began prescribing weight loss drugs in 2022. For years the company marketed itself as a ‚Äúmen‚Äôs health‚Äù brand, but has recently changed that. The company‚Äôs website uses images of men and women on its landing page for weight-loss treatments.\n\nYazen, which launched its weight loss service in 2022, initially set out to exclusively target obese men, but broadened its focus before launching to include obesity more generally, after seeing how effective GLP-1 drugs were, says CEO Fredrik Meurling.\n\nMeurling tells Sifted it had hit ‚Ç¨14m annual recurring revenue and treated 15k patients by June this year. It‚Äôs now active in Sweden, Norway, The Netherlands and Spain, and has pilot projects in England and Germany.\n\nOther startups like UK-based Manual, which like Numan started out offering men‚Äôs sexual health treatments, also started prescribing weight loss medications in 2022.\n\n‚Äú[GLP-1 meds] are a game changer,‚Äù says Michael Treskow, partner at Eight Roads Ventures, adding it would be ‚Äústrange‚Äù if a startup working in the weight loss space wasn‚Äôt looking into how they could add the drugs into their offering.\n\nWhile GLP-1 meds have been part of some treatment courses at Embla since it launched in 2021, the ‚Äúhype‚Äù surrounding the drug class has ‚Äúopened doors‚Äù for the startup, says co-CEO and cofounder Nicholas Syhler ‚Äî adding that the startup managed to raise its ‚Ç¨400k pre-seed round in 2021 just three weeks after incorporation. It‚Äôs now gearing up for a fundraise in 2025 and expanding to the US, where it‚Äôll look to target US employers ‚Äî who pay for the majority of healthcare in the country.\n\n### Kinks in the supply chain\n\nThere are still big questions hanging over European startups in the sector ‚Äî not least around whether a European GLP-1 startup can raise the kinds of funds needed to hit real scale.\n\nSome of the biggest rounds for startups vending GLP-1 drugs have been in the US, including Calibrate‚Äôs $100m in 2021 and Form Health‚Äôs $38m in June this year. In Europe, no company selling the drug or treatment pathways around it has raised more than ‚Ç¨10m in a single round.\n\nInvestors and founders tell Sifted supply chain issues are part of that problem. Manufacturers have struggled to keep up with demand for the drug, and last year, startups in the UK were told by the government to remove Ozempic from sale due to shortages of the drug for diabetics ‚Äî Manual was still selling past the deadline.\n\nIf a startup's revenues are closely tied to the availability of those drugs, they could be at the mercy of manufacturing capability. But as pharma bolsters production capabilities those issues could diminish, says Christoph Ruedig, partner at Albion VC.\n\n‚ÄúAs there are severe shortages of GLP-1 drugs in Europe (Eli Lilly and Novo Nordisk are prioritising the US as pricing is higher) the opportunity to date in Europe has been limited but growing.‚Äù\n\n### Who‚Äôll stump up the cash?\n\nThere‚Äôs also a challenge finding the right people to pay, and in Europe, national healthcare providers need to open up to reimbursing startups providing weight loss care, investors say.\n\nWhile Numan‚Äôs head of medical Luke Pratsides says that the ‚Äúsuccess of private sector companies offering GLP-1 [drugs] shows that the public are willing to pay to meet a significant need that is being underserved by the NHS‚Äù, many in the sector think that only serving consumers paying out of their own pocket won‚Äôt be enough to hit real scale.\n\n‚ÄúUS investors have told us that they will only invest in companies that get on enterprise contracts [selling to whole organisations like health insurers],‚Äù says Syhler. ‚ÄúThis means proving that they can deliver high-quality and sustainable care ‚Äî where the economics and outcomes make sense long-term for both patients and payors.‚Äù\n\nIn Europe, where the majority of people have their healthcare paid for by the state, hitting scale will likely come down to whether or not companies can get their services reimbursed by national healthcare providers, say some investors.\n\nIn the UK Wegovy is approved for use to manage obesity in the NHS, but it is currently only available through specialist weight management clinics, limiting availability.\n\nOviva is one the few startups that has had its supply of GLP-1 drugs alongside its weight loss platform reimbursed by the NHS ‚Äî but it had a head start on others, being reimbursed by the organisation long before the rise of weight loss meds, in 2016. Embla co-CEO and cofounder Laust Axelsen tells Sifted that it‚Äôs in ‚Äúmature dialogues with several health systems‚Äù.\n\n‚ÄúIt is still a struggle with reimbursement, in every country,‚Äù says Hekla Arnardottir, partner at Crowberry Capital, which has backed Embla, pointing to difficult regulation and healthcare systems that don‚Äôt always want to work with startups. Without reimbursement in Europe, she adds, it will be hard for companies to reach the sort of revenue figures needed to raise growth capital and hit unicorn status.\n\nWhether a European startup will be able to do that remains to be seen ‚Äî but what is clear is that the hype surrounding GLP-1 meds is unlikely to die down anytime soon. ‚ÄúI've never been an investor in a company that‚Äôs got so much attention ‚Äî in a space that‚Äôs got so much attention,‚Äù says Arnardottir.", 'gpt-4o-mini']
2024-09-11 00:41:13,426 - INFO - Logged data to databases/llm.csv with DocumentID: Mqdn6qI5ixJT096Lckk1.
2024-09-11 00:41:13,426 - INFO - 'generated_post' length: 9. Content: ['2024-09-10 09:00:00', '2024-09-11 00:40:56', 'üîç Did you know that mastitis could indicate a higher risk of breast cancer in women over 50?  \n\n- A recent large-scale study involving 2.4 MILLION GERMAN WOMEN suggests a significant association between mastitis and breast cancer, especially in females aged 50 and above.  \n- Out of nearly 15,000 WOMEN WITH MASTITIS, 2.9% were diagnosed with breast cancer compared to 2.4% of the matched control group.  \n- The hazard ratio of 1.73 indicates a 73% INCREASE in cancer risk for those over 50 with mastitis, highlighting the importance of vigilant monitoring in this demographic.  \n- Conversely, women aged 50 and younger showed no significant increase in risk, suggesting that age plays a critical role here.  \n\nAs healthcare professionals, are we doing enough to inform our patients about the potential implications of mastitis beyond immediate treatment? ü§î  \n\nFor a deeper dive into this study, check out the full findings in Cancer Causes & Control: http://medscape.co.uk/viewarticle/mastitis-older-women-linked-subsequent-breast-cancer-2024a1000g68', ['Research & Clinical Trials', 'Oncology', 'ClinicalTrials', 'MedicalEducation', 'PatientEducation', 'Geriatrics'], 'https://images.pexels.com/photos/4611655/pexels-photo-4611655.jpeg', 'http://medscape.co.uk/viewarticle/mastitis-older-women-linked-subsequent-breast-cancer-2024a1000g68', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'Mastitis in Older Women Linked to Subsequent Breast Cancer\n===============\n\nThis site is intended for UK healthcare professionals\n\nTOPLINE:\n--------\n\nMastitis in women over 50 years of age is a risk factor for development of breast cancer, according to a large retrospective cohort study of 2.4 million German women. Mastitis is an inflammation of breast tissue typically caused by a Staph infection.\n\nMETHODOLOGY:\n------------\n\n*   This study was a retrospective cohort of 2,381,594 women in 315 office-based gynaecology practices in Germany (2005-2021).\n*   Women with mastitis (n = 14,892) were compared with women without mastitis (n = 14,892) and followed from 7 months to 10 years.\n*   The control group without mastitis was propensity score-matched on age, index year, average yearly consultation frequency during the follow-up period, and coexisting conditions.\n*   The primary outcome was an initial diagnosis of breast cancer.\n\nTAKEAWAY:\n---------\n\n*   Over the follow-up period, 2.9% of the mastitis cohort and 2.4% of the matched non-mastitis cohort developed breast cancer.\n*   While Cox regression analysis uncovered a significant association between mastitis and breast cancer (hazard ratio, 1.37; 95% CI, 1.11-1.70), the age-stratified analysis revealed a significant association only among women aged > 50 years. They had a 73% increase in the risk compared with women without mastitis (hazard ratio, 1.73; 95% CI, 1.25-2.40).\n*   Women aged ‚â§ 50 years had no significant increase in the risk for breast cancer.\n\nIN PRACTICE:\n------------\n\nThe authors concluded that "The findings of our retrospective cohort study support an association between mastitis and subsequent breast cancer diagnoses in women aged > 50 years. The pathophysiological basis and possibility of confounders however requires further investigation."\n\nSOURCE:\n-------\n\nThe corresponding author is Karel Kostev, University Hospital Marburg, Philipps-University, Marburg, Germany. The study appeared in *Cancer Causes & Control*.\n\nLIMITATIONS:\n------------\n\nLimitations included a retrospective observational design and possibility of unmeasured confounding factors.\n\nDISCLOSURES:\n------------\n\nThe authors reported no conflicts of interest. The study received no funding.', 'gpt-4o-mini']
2024-09-11 00:41:13,426 - INFO - Logged data to databases/llm.csv with DocumentID: Y5hYnfN5H5u0tpelUmi9.
2024-09-11 00:41:13,427 - INFO - 'generated_post' length: 9. Content: ['2024-09-09 18:00:00', '2024-09-11 00:41:08', 'ü´Ä Did you know that impaired heart rate fluctuations can significantly impact mortality risk in diabetic patients? \n\n- A recent study presented at the EASD Annual Meeting revealed that patients with diabetes displaying low daily heart rate variability (HR SD) face nearly double the risk of cardiovascular death compared to those with healthier fluctuations. \n- Among the 349 participants (predominantly Type 2 diabetes), 39% died over a 21-year follow-up, with a staggering 68% of these deaths being cardiovascular-related.  \n- The study suggests that patients who experience a blunted nocturnal heart rate dip are associated with a 39% higher risk for mortality‚Äîall highlighting the critical need for monitoring heart health. \n- By implementing 24-hour ambulatory blood pressure monitoring (ABPM), healthcare professionals can better stratify risk in this vulnerable population, potentially leading to earlier interventions. \n\nAs we advance in diabetes management, how can we incorporate these heart rate metrics into routine clinical evaluation? ü§î \n\nFor full details, check it out here: http://medscape.com/viewarticle/abnormal-heart-rate-shifts-tied-risk-death-diabetes-2024a1000g8n', ['Research & Clinical Trials', 'Cardiology', 'DigitalHealth', 'DigitalHealth', 'Endocrinology', 'HealthOutcomes'], 'https://images.pexels.com/photos/6823491/pexels-photo-6823491.jpeg', 'http://medscape.com/viewarticle/abnormal-heart-rate-shifts-tied-risk-death-diabetes-2024a1000g8n', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'Abnormal Heart Rate Shifts Tied to Risk for Death in Diabetes\n=============================================================\n\nMarilynn Larkin\n\nSeptember 09, 2024\n\n**TOPLINE:**\n------------\n\nMADRID ‚Äî Impaired circadian heart rate (HR) fluctuations are linked to increased cardiovascular and all-cause mortality in patients with long-standing diabetes.\n\n**METHODOLOGY:**\n----------------\n\n*   Researchers analyzed data from 349 patients with type 2 (81%) or type 1 diabetes; about half were women, with a mean age of 57 years, body mass index (BMI) of 29.4, and A1c of 8.6%.\n*   Participants underwent 24-hour ambulatory blood pressure monitoring (APBM) and HR monitoring, as well as assessment of diabetic microvascular complications.\n*   The median SD value of ABPM-derived HR measurements was used to define patients with low daily HR fluctuations (low 24h-HR SD); a < 10% decline in average nighttime vs daytime HR identified patients (31%) with a blunted nocturnal HR dip.\n\n**TAKEAWAY:**\n-------------\n\n*   Low 24h-HR SD and blunted nocturnal HR dip were associated with an adverse cardiometabolic risk profile and a high prevalence of cardiac autonomic neuropathy and nephropathy.\n*   After a mean 21 years of follow-up, 136 (39%) deaths occurred, of which 100 (68%) had a cardiovascular cause.\n*   After adjustment for potential confounders ‚Äî including age, sex, BMI, glycemic control, diabetes type, and hypertension ‚Äî the low 24h-HR SD group had double the risk (hazard ratio [HR], 1.99) for cardiovascular mortality and a 50% higher risk (HR, 1.50) for all-cause mortality than the high 24h-HR SD group.\n*   Patients with a blunted nocturnal HR dip consistently had a 39% higher adjusted risk for cardiovascular and all-cause mortality (HR, 1.61 for both) than those with a preserved nocturnal HR dip.\n\n**IN PRACTICE:**\n----------------\n\nImpaired circadian HR fluctuations are associated with microvascular disease and increased long-term cardiovascular and all-cause mortality in patients with diabetes, the authors wrote. "Identifying these conditions via 24h-ABPM may provide a cost-effective risk stratification tool in this high-risk population."\n\n**SOURCE:**\n-----------\n\nThe study was presented by lead author Lorenzo Nesti, PhD, of the University of Pisa, Pisa, Italy, in a poster presentation 983 at the European Association for the Study of Diabetes (EASD) 2024 Annual Meeting in Madrid, Spain.\n\n**LIMITATIONS:**\n----------------\n\nThe CHAMPION study is a retrospective, observational, single-center study with mostly White patients.\n\n**DISCLOSURES:**\n----------------\n\nNesti disclosed no conflicts of interest.\n\nMedscape Medical News ¬© 2024 WebMD, LLC  \nSend comments and news tips to news@medscape.net.\n\nCite this: Abnormal Heart Rate Shifts Tied to Risk for Death in Diabetes - Medscape - September 09, 2024.', 'gpt-4o-mini']
2024-09-11 00:41:13,427 - INFO - Logged data to databases/llm.csv with DocumentID: AY9mxo3hStuYQC4adJvR.
2024-09-11 01:40:56,324 - INFO - Extracted 10 link records.
2024-09-11 01:40:56,326 - INFO - Extracted 5 link records.
2024-09-11 01:40:56,329 - INFO - Extracted 8 link records.
2024-09-11 01:40:56,329 - INFO - Unique links to process: 23
2024-09-11 01:40:56,329 - INFO - Starting to process link: http://r.jina.ai/https://www.cancernetwork.com/view/using-atezolizumab-bevacizumab-in-practice
2024-09-11 01:40:58,292 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://www.cancernetwork.com/view/using-atezolizumab-bevacizumab-in-practice, now generating post.
2024-09-11 01:40:59,717 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:41:03,922 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:41:04,285 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:41:04,286 - INFO - Image query: ‚Äúhepatocellular carcinoma treatment‚Äù
2024-09-11 01:41:04,663 - INFO - Unique image link: https://images.pexels.com/photos/27271454/pexels-photo-27271454.jpeg
2024-09-11 01:41:04,663 - INFO - Post generated successfully for link: http://r.jina.ai/https://www.cancernetwork.com/view/using-atezolizumab-bevacizumab-in-practice
2024-09-11 01:41:04,663 - INFO - Starting to process link: http://r.jina.ai/https://multiplesclerosisnewstoday.com/news-posts/2024/09/09/ms-risk-unvaccinated-people-elevated-rubella-infection-study/
2024-09-11 01:41:06,195 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://multiplesclerosisnewstoday.com/news-posts/2024/09/09/ms-risk-unvaccinated-people-elevated-rubella-infection-study/, now generating post.
2024-09-11 01:41:15,586 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:41:20,029 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:41:20,601 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:41:20,601 - INFO - Image query: "multiple sclerosis risk factors"
2024-09-11 01:41:20,876 - INFO - Unique image link: https://images.pexels.com/photos/27409730/pexels-photo-27409730.jpeg
2024-09-11 01:41:20,876 - INFO - Post generated successfully for link: http://r.jina.ai/https://multiplesclerosisnewstoday.com/news-posts/2024/09/09/ms-risk-unvaccinated-people-elevated-rubella-infection-study/
2024-09-11 01:41:20,876 - INFO - Starting to process link: http://r.jina.ai/https://pharmaphorum.com/news/regeneron-joins-koneksa-parkinsons-digital-biomarker-study
2024-09-11 01:41:23,456 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://pharmaphorum.com/news/regeneron-joins-koneksa-parkinsons-digital-biomarker-study, now generating post.
2024-09-11 01:41:28,750 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:41:31,215 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:41:31,501 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:41:31,502 - INFO - Image query: ‚Äúdigital biomarkers Parkinson's disease‚Äù
2024-09-11 01:41:32,124 - INFO - Unique image link: https://images.pexels.com/photos/8376285/pexels-photo-8376285.jpeg
2024-09-11 01:41:32,124 - INFO - Post generated successfully for link: http://r.jina.ai/https://pharmaphorum.com/news/regeneron-joins-koneksa-parkinsons-digital-biomarker-study
2024-09-11 01:41:32,124 - INFO - Starting to process link: http://r.jina.ai/https://www.prnewswire.com/news-releases/diamyd-medical-to-pursue-accelerated-approval-pathway-for-type-1-diabetes-precision-medicine-302241751.html
2024-09-11 01:41:34,636 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://www.prnewswire.com/news-releases/diamyd-medical-to-pursue-accelerated-approval-pathway-for-type-1-diabetes-precision-medicine-302241751.html, now generating post.
2024-09-11 01:41:49,885 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:41:55,543 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:41:55,932 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:41:55,933 - INFO - Image query: "Type 1 diabetes treatment"
2024-09-11 01:41:56,195 - INFO - Unique image link: https://images.pexels.com/photos/6942030/pexels-photo-6942030.jpeg
2024-09-11 01:41:56,195 - INFO - Post generated successfully for link: http://r.jina.ai/https://www.prnewswire.com/news-releases/diamyd-medical-to-pursue-accelerated-approval-pathway-for-type-1-diabetes-precision-medicine-302241751.html
2024-09-11 01:41:56,195 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 01:41:57,633 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/, now generating post.
2024-09-11 01:41:58,116 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:41:58,117 - INFO - No article found for link https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/.
2024-09-11 01:41:58,117 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/. Skipping.
2024-09-11 01:41:58,117 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 01:41:58,117 - INFO - Starting to process link: http://r.jina.ai/https://pharmaphorum.com/news/nice-clears-nhs-use-msds-welireg-genetic-disorder
2024-09-11 01:42:00,420 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://pharmaphorum.com/news/nice-clears-nhs-use-msds-welireg-genetic-disorder, now generating post.
2024-09-11 01:42:07,151 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:42:13,453 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:42:13,767 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:42:13,768 - INFO - Image query: "genetic disorder treatment"
2024-09-11 01:42:14,013 - INFO - Unique image link: https://images.pexels.com/photos/6436249/pexels-photo-6436249.jpeg
2024-09-11 01:42:14,013 - INFO - Post generated successfully for link: http://r.jina.ai/https://pharmaphorum.com/news/nice-clears-nhs-use-msds-welireg-genetic-disorder
2024-09-11 01:42:14,013 - INFO - Starting to process link: http://r.jina.ai/https://www.healio.com/news/neurology/20240816/longeviti-neuro-solutions-secures-us-patent-for-neurosurgical-cranial-implant
2024-09-11 01:42:16,476 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://www.healio.com/news/neurology/20240816/longeviti-neuro-solutions-secures-us-patent-for-neurosurgical-cranial-implant, now generating post.
2024-09-11 01:42:18,938 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:42:21,399 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:42:21,705 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:42:21,706 - INFO - Image query: "neurosurgery innovation"
2024-09-11 01:42:22,040 - INFO - Unique image link: https://images.pexels.com/photos/27269602/pexels-photo-27269602.jpeg
2024-09-11 01:42:22,040 - INFO - Post generated successfully for link: http://r.jina.ai/https://www.healio.com/news/neurology/20240816/longeviti-neuro-solutions-secures-us-patent-for-neurosurgical-cranial-implant
2024-09-11 01:42:22,040 - INFO - Starting to process link: http://r.jina.ai/https://www.drugtargetreview.com/news/152646/mrna-vaccine-provides-enhanced-protection-against-mpox/
2024-09-11 01:42:23,453 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://www.drugtargetreview.com/news/152646/mrna-vaccine-provides-enhanced-protection-against-mpox/, now generating post.
2024-09-11 01:42:29,694 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:42:32,264 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:42:32,533 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:42:32,534 - INFO - Image query: mRNA vaccine research
2024-09-11 01:42:32,733 - INFO - Unique image link: https://images.pexels.com/photos/8830484/pexels-photo-8830484.jpeg
2024-09-11 01:42:32,733 - INFO - Post generated successfully for link: http://r.jina.ai/https://www.drugtargetreview.com/news/152646/mrna-vaccine-provides-enhanced-protection-against-mpox/
2024-09-11 01:42:32,734 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 01:42:34,342 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/, now generating post.
2024-09-11 01:42:34,840 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:42:34,841 - INFO - No article found for link https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/.
2024-09-11 01:42:34,841 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/. Skipping.
2024-09-11 01:42:34,841 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 01:42:34,841 - INFO - Starting to process link: http://r.jina.ai/https://pharmaphorum.com/news/gsk-says-nucala-hits-target-new-copd-trial
2024-09-11 01:42:37,068 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://pharmaphorum.com/news/gsk-says-nucala-hits-target-new-copd-trial, now generating post.
2024-09-11 01:42:43,810 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:42:47,754 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:42:48,085 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:42:48,101 - INFO - Image query: "COPD treatment research"
2024-09-11 01:42:48,292 - INFO - Unique image link: https://images.pexels.com/photos/7578803/pexels-photo-7578803.jpeg
2024-09-11 01:42:48,293 - INFO - Post generated successfully for link: http://r.jina.ai/https://pharmaphorum.com/news/gsk-says-nucala-hits-target-new-copd-trial
2024-09-11 01:42:48,293 - INFO - Starting to process link: http://r.jina.ai/https://sifted.eu/articles/billionaires-body-scans/
2024-09-11 01:42:50,057 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://sifted.eu/articles/billionaires-body-scans/, now generating post.
2024-09-11 01:42:58,170 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:43:00,698 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:43:00,950 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:43:00,950 - INFO - Image query: preventative healthcare technology
2024-09-11 01:43:01,377 - INFO - Unique image link: https://images.pexels.com/photos/6436256/pexels-photo-6436256.jpeg
2024-09-11 01:43:01,377 - INFO - Post generated successfully for link: http://r.jina.ai/https://sifted.eu/articles/billionaires-body-scans/
2024-09-11 01:43:01,377 - INFO - Starting to process link: http://r.jina.ai/https://sifted.eu/articles/doccla-raises-a-35m-series-b-news/
2024-09-11 01:43:09,812 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://sifted.eu/articles/doccla-raises-a-35m-series-b-news/, now generating post.
2024-09-11 01:43:18,256 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:43:21,762 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:43:22,081 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:43:22,081 - INFO - Image query: "virtual patient monitoring"
2024-09-11 01:43:22,394 - INFO - Unique image link: https://images.pexels.com/photos/6823606/pexels-photo-6823606.jpeg
2024-09-11 01:43:22,394 - INFO - Post generated successfully for link: http://r.jina.ai/https://sifted.eu/articles/doccla-raises-a-35m-series-b-news/
2024-09-11 01:43:22,394 - INFO - Starting to process link: http://r.jina.ai/https://sifted.eu/articles/medtech-startup-vc-trends/
2024-09-11 01:43:24,444 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://sifted.eu/articles/medtech-startup-vc-trends/, now generating post.
2024-09-11 01:43:33,340 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:43:36,588 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:43:37,236 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:43:37,237 - INFO - Image query: "medtech innovations"
2024-09-11 01:43:37,487 - INFO - Unique image link: https://images.pexels.com/photos/27269602/pexels-photo-27269602.jpeg
2024-09-11 01:43:37,487 - INFO - Post generated successfully for link: http://r.jina.ai/https://sifted.eu/articles/medtech-startup-vc-trends/
2024-09-11 01:43:37,487 - INFO - Starting to process link: http://r.jina.ai/https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/
2024-09-11 01:43:39,640 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/, now generating post.
2024-09-11 01:43:51,666 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:43:54,531 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:43:55,433 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:43:55,434 - INFO - Image query: "AI in surgical efficiency"
2024-09-11 01:43:55,717 - INFO - Unique image link: https://images.pexels.com/photos/27307692/pexels-photo-27307692.jpeg
2024-09-11 01:43:55,717 - INFO - Post generated successfully for link: http://r.jina.ai/https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/
2024-09-11 01:43:55,717 - INFO - Starting to process link: http://r.jina.ai/https://sifted.eu/articles/startups-wegovy-ozempic-shift/
2024-09-11 01:43:57,750 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://sifted.eu/articles/startups-wegovy-ozempic-shift/, now generating post.
2024-09-11 01:44:10,772 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:44:14,048 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:44:14,386 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:44:14,391 - INFO - Image query: "weight loss medication"
2024-09-11 01:44:14,666 - INFO - Unique image link: https://images.pexels.com/photos/7659461/pexels-photo-7659461.jpeg
2024-09-11 01:44:14,667 - INFO - Post generated successfully for link: http://r.jina.ai/https://sifted.eu/articles/startups-wegovy-ozempic-shift/
2024-09-11 01:44:14,667 - INFO - Starting to process link: http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 01:44:18,414 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296, now generating post.
2024-09-11 01:44:18,789 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:44:18,790 - INFO - No article found for link https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296.
2024-09-11 01:44:18,790 - ERROR - No valid post generated for http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296. Skipping.
2024-09-11 01:44:18,790 - WARNING - Skipping entry due to missing or invalid log entry for link: https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 01:44:18,790 - INFO - Starting to process link: http://r.jina.ai/http://medscape.co.uk/viewarticle/mastitis-older-women-linked-subsequent-breast-cancer-2024a1000g68
2024-09-11 01:44:21,617 - INFO - Successfully fetched webpage content from http://r.jina.ai/http://medscape.co.uk/viewarticle/mastitis-older-women-linked-subsequent-breast-cancer-2024a1000g68, now generating post.
2024-09-11 01:44:26,698 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:44:29,242 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:44:29,774 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:44:29,775 - INFO - Image query: "breast cancer risk assessment"
2024-09-11 01:44:30,050 - INFO - Unique image link: https://images.pexels.com/photos/5412315/pexels-photo-5412315.jpeg
2024-09-11 01:44:30,050 - INFO - Post generated successfully for link: http://r.jina.ai/http://medscape.co.uk/viewarticle/mastitis-older-women-linked-subsequent-breast-cancer-2024a1000g68
2024-09-11 01:44:30,050 - INFO - Starting to process link: http://r.jina.ai/http://medscape.com/viewarticle/abnormal-heart-rate-shifts-tied-risk-death-diabetes-2024a1000g8n
2024-09-11 01:44:32,880 - INFO - Successfully fetched webpage content from http://r.jina.ai/http://medscape.com/viewarticle/abnormal-heart-rate-shifts-tied-risk-death-diabetes-2024a1000g8n, now generating post.
2024-09-11 01:44:40,262 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:44:44,153 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:44:44,519 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:44:44,520 - INFO - Image query: "heart rate monitoring in diabetes patients"
2024-09-11 01:44:45,930 - INFO - Unique image link: https://images.pexels.com/photos/6823491/pexels-photo-6823491.jpeg
2024-09-11 01:44:45,930 - INFO - Post generated successfully for link: http://r.jina.ai/http://medscape.com/viewarticle/abnormal-heart-rate-shifts-tied-risk-death-diabetes-2024a1000g8n
2024-09-11 01:44:45,930 - INFO - Starting to process link: http://r.jina.ai/https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.31715?guestAccessKey=5fccf768-e956-418c-863e-a26f2d537653&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090524
2024-09-11 01:44:50,482 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.31715?guestAccessKey=5fccf768-e956-418c-863e-a26f2d537653&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090524, now generating post.
2024-09-11 01:46:26,071 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:46:31,235 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:46:31,529 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:46:31,530 - INFO - Image query: AI in breast cancer screening
2024-09-11 01:46:31,924 - INFO - Unique image link: https://images.pexels.com/photos/5701081/pexels-photo-5701081.jpeg
2024-09-11 01:46:31,924 - INFO - Post generated successfully for link: http://r.jina.ai/https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.31715?guestAccessKey=5fccf768-e956-418c-863e-a26f2d537653&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090524
2024-09-11 01:46:31,924 - INFO - Starting to process link: http://r.jina.ai/http://medscape.co.uk/viewarticle/demographics-linked-worse-access-cardiac-surgery-2024a1000g4z
2024-09-11 01:46:34,935 - INFO - Successfully fetched webpage content from http://r.jina.ai/http://medscape.co.uk/viewarticle/demographics-linked-worse-access-cardiac-surgery-2024a1000g4z, now generating post.
2024-09-11 01:46:43,083 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:46:45,571 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:46:45,893 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:46:45,893 - INFO - Image query: "equitable access to cardiac surgery"
2024-09-11 01:46:46,432 - INFO - Unique image link: https://images.pexels.com/photos/27469354/pexels-photo-27469354.jpeg
2024-09-11 01:46:46,432 - INFO - Post generated successfully for link: http://r.jina.ai/http://medscape.co.uk/viewarticle/demographics-linked-worse-access-cardiac-surgery-2024a1000g4z
2024-09-11 01:46:46,432 - INFO - Starting to process link: http://r.jina.ai/http://medscape.com/viewarticle/monthly-semaglutide-goal-end-daily-pills-2024a1000g7u
2024-09-11 01:46:48,288 - INFO - Successfully fetched webpage content from http://r.jina.ai/http://medscape.com/viewarticle/monthly-semaglutide-goal-end-daily-pills-2024a1000g7u, now generating post.
2024-09-11 01:46:54,354 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:46:56,748 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:46:57,006 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:46:57,006 - INFO - Image query: "diabetes management innovation"
2024-09-11 01:46:57,303 - INFO - Unique image link: https://images.pexels.com/photos/6823504/pexels-photo-6823504.jpeg
2024-09-11 01:46:57,303 - INFO - Post generated successfully for link: http://r.jina.ai/http://medscape.com/viewarticle/monthly-semaglutide-goal-end-daily-pills-2024a1000g7u
2024-09-11 01:46:57,303 - INFO - Starting to process link: http://r.jina.ai/http://medscape.co.uk/viewarticle/join-dr-julie-oliver-and-primary-care-womens-health-forum-2024a1000fb0
2024-09-11 01:47:00,383 - INFO - Successfully fetched webpage content from http://r.jina.ai/http://medscape.co.uk/viewarticle/join-dr-julie-oliver-and-primary-care-womens-health-forum-2024a1000fb0, now generating post.
2024-09-11 01:47:24,802 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:47:27,644 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:47:28,148 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:47:28,149 - INFO - Image query: "women's health care"
2024-09-11 01:47:28,824 - INFO - Unique image link: https://images.pexels.com/photos/7581591/pexels-photo-7581591.jpeg
2024-09-11 01:47:28,824 - INFO - Post generated successfully for link: http://r.jina.ai/http://medscape.co.uk/viewarticle/join-dr-julie-oliver-and-primary-care-womens-health-forum-2024a1000fb0
2024-09-11 01:47:28,824 - INFO - Starting to process link: http://r.jina.ai/http://medscape.co.uk/viewarticle/rheumatoid-arthritis-whole-food-diet-may-be-protective-2024a1000g29
2024-09-11 01:47:31,647 - INFO - Successfully fetched webpage content from http://r.jina.ai/http://medscape.co.uk/viewarticle/rheumatoid-arthritis-whole-food-diet-may-be-protective-2024a1000g29, now generating post.
2024-09-11 01:47:37,931 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:47:40,635 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:47:40,905 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 01:47:40,906 - INFO - Image query: diet and rheumatoid arthritis prevention
2024-09-11 01:47:41,188 - INFO - Unique image link: https://images.pexels.com/photos/6823606/pexels-photo-6823606.jpeg
2024-09-11 01:47:41,188 - INFO - Post generated successfully for link: http://r.jina.ai/http://medscape.co.uk/viewarticle/rheumatoid-arthritis-whole-food-diet-may-be-protective-2024a1000g29
2024-09-11 01:47:41,188 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/27271454/pexels-photo-27271454.jpeg'}
2024-09-11 01:47:41,188 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 01:47:41,188 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/27409730/pexels-photo-27409730.jpeg'}
2024-09-11 01:47:41,188 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 01:47:41,188 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/8376285/pexels-photo-8376285.jpeg'}
2024-09-11 01:47:41,188 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 01:47:41,188 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/6942030/pexels-photo-6942030.jpeg'}
2024-09-11 01:47:41,188 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 01:47:41,188 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/6436249/pexels-photo-6436249.jpeg'}
2024-09-11 01:47:41,188 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 01:47:41,188 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/27269602/pexels-photo-27269602.jpeg'}
2024-09-11 01:47:41,188 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 01:47:41,188 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/8830484/pexels-photo-8830484.jpeg'}
2024-09-11 01:47:41,188 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 01:47:41,188 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/7578803/pexels-photo-7578803.jpeg'}
2024-09-11 01:47:41,188 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 01:47:41,188 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/6436256/pexels-photo-6436256.jpeg'}
2024-09-11 01:47:41,188 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 01:47:41,188 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/6823606/pexels-photo-6823606.jpeg'}
2024-09-11 01:47:41,188 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 01:47:41,188 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/27269602/pexels-photo-27269602.jpeg'}
2024-09-11 01:47:41,188 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 01:47:41,188 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/27307692/pexels-photo-27307692.jpeg'}
2024-09-11 01:47:41,188 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 01:47:41,188 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/7659461/pexels-photo-7659461.jpeg'}
2024-09-11 01:47:41,188 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 01:47:41,188 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/5412315/pexels-photo-5412315.jpeg'}
2024-09-11 01:47:41,188 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 01:47:41,189 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/6823491/pexels-photo-6823491.jpeg'}
2024-09-11 01:47:41,189 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 01:47:41,189 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/5701081/pexels-photo-5701081.jpeg'}
2024-09-11 01:47:41,189 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 01:47:41,189 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/27469354/pexels-photo-27469354.jpeg'}
2024-09-11 01:47:41,189 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 01:47:41,189 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/6823504/pexels-photo-6823504.jpeg'}
2024-09-11 01:47:41,189 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 01:47:41,189 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/7581591/pexels-photo-7581591.jpeg'}
2024-09-11 01:47:41,189 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 01:47:41,189 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/6823606/pexels-photo-6823606.jpeg'}
2024-09-11 01:47:41,189 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 01:47:41,189 - INFO - Sending 20 log entries to Firebase.
2024-09-11 01:47:47,512 - INFO - Successfully sent batch data to Firebase: {'message': 'Batch processed successfully. 20 posts added.', 'documentIDs': ['yA6rypq7h5wDqOt5rIuY', 'IDkcoKdjUueJWt2wF5MB', 'xpAn0KFAGOmqMoQ2AnOX', 'GmTrddSrSirMwnVORb2j', 'xHsWqgfq1ua0uwlYo3u8', 'w9gUaubdEq1yNLLrX9FL', 'mjNCnnAavWkLvcK7WzGl', '0zIOYAyGUzOwaCYodEu0', 'Binwer8Adxua9h8wMOer', 'w5bIVyGtofH28rqegF1I', 'hKgXcvNHaJV7HlumntC2', 'jxULA7QmvS02S0gAkDya', 'OfJ8QLEaoTknkhadOIK3', '9uoP8HRQLP9zYlEiv56b', '94CGnEYGGMHII3MG2yHP', 'ej56K9yllI3twdB56MJQ', '25kxZsSBG5aVijR2XoxR', 'z1RxUFDKy5TrrSat9xqh', 'WW8dSmdlw9vohFWncREv', 'T0v1p2i0MzX6hgSWrbuP']}
2024-09-11 01:47:47,512 - INFO - Received 20 document IDs from Firebase.
2024-09-11 01:47:47,512 - INFO - 'generated_post' length: 9. Content: ['2024-09-10 09:30:00', '2024-09-11 01:41:03', 'üåü Are we witnessing a shift in treatment paradigms for hepatocellular carcinoma? üåü  \n  \nKey opinion leaders recently shared their insights from the IMBrave150 trial, focusing on the combination of atezolizumab (a PD-L1 inhibitor) and bevacizumab (an angiogenesis inhibitor). Here are some important takeaways for clinical practice:  \n  \n- üß¨ TRIAL INSIGHTS: The IMBrave150 trial demonstrated that the atezolizumab and bevacizumab pairing significantly improved overall survival rates compared to sorafenib in patients with untreated advanced hepatocellular carcinoma (HCC).  \n- üîç REAL-WORLD APPLICATION: Clinicians reported positive outcomes in patient tolerability and response. Most emphasized the importance of monitoring for immune-related adverse events.  \n- üìà EVOLVING STRATEGIES: This combination therapy is being integrated into first-line treatment protocols, leading to a re-evaluation of traditional approaches to HCC management.  \n  \nAs we uncover the full potential of atezo + bev, what challenges do you foresee in implementing this combination therapy in practice? ü§î  \nFor more detailed insights, check out the full discussion: https://www.cancernetwork.com/view/using-atezolizumab-bevacizumab-in-practice', ['HealthTech & Startups', 'Oncology', 'ClinicalTrials', 'HealthTech', 'PatientSafety'], 'https://images.pexels.com/photos/27271454/pexels-photo-27271454.jpeg', 'https://www.cancernetwork.com/view/using-atezolizumab-bevacizumab-in-practice', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'Using Atezolizumab + Bevacizumab in Practice\n============================================\n\nSeptember 9, 2024\n\nBy Daniel Ahn, DO  \nRahul Gosain, MD  \nRohit Gosain, MD\n\nKey opinion leaders share their impressions of the IMBrave150 trial data and discuss their real-world clinical experiences using atezolizumab plus bevacizumab in practice.\n\n**Video content above is prompted by the following:**\n\n* What are your impressions on the data from the IMBrave150 trial?\n* Please share your experience with using atezo + bev in your practice.', 'gpt-4o-mini']
2024-09-11 01:47:47,514 - INFO - Logged data to databases/llm.csv with DocumentID: yA6rypq7h5wDqOt5rIuY.
2024-09-11 01:47:47,514 - INFO - 'generated_post' length: 9. Content: ['2024-09-10 09:20:00', '2024-09-11 01:41:20', 'ü©∫ Are we overlooking potential viral triggers in MS development? A recent Swedish study suggests an intriguing link between rubella infection and an increased risk of multiple sclerosis (MS) for unvaccinated individuals.\n\n- KEY FINDINGS: The study found that having antibodies against the rubella virus correlated with a higher MS risk among those who were unvaccinated. This could imply that rubella may act as a risk factor for the disease, providing support for the viral trigger hypothesis in MS.\n- STUDY INSIGHTS: Conducted on blood samples from 670 MS patients and matched controls, the research revealed that 93.7% of MS patients had anti-E1 antibodies, compared to 88.5% of healthy controls. Notably, unvaccinated MS patients were found to be four times more likely to have these antibodies compared to their unvaccinated counterparts.\n- MECHANISM AT PLAY: The researchers propose that ‚Äúmolecular mimicry,‚Äù where the immune response against the rubella virus may inadvertently target similar human molecules, could explain this increased risk. The rubella virus shares protein similarities with myelin proteins essential in nerve function.\n\nWhile these findings are promising, the authors urge caution due to possible false negatives in serological testing and the limited variable assessment of past vaccination statuses. As we reconsider MS risk factors, this emphasizes the need for further studies to validate these claims and deepen our understanding of viral implications in neurodegenerative diseases. \n\nWhat does this mean for your clinical practice? Are there additional screenings for viral infections that should be implemented for at-risk populations? ü§î \n\nFor more details, check the study here: https://onlinelibrary.wiley.com/doi/10.1111/ene.16387', ['Research & Clinical Trials', 'Neurology', 'InfectiousDiseases', 'ClinicalTrials', 'PatientSafety'], 'https://images.pexels.com/photos/27409730/pexels-photo-27409730.jpeg', 'https://multiplesclerosisnewstoday.com/news-posts/2024/09/09/ms-risk-unvaccinated-people-elevated-rubella-infection-study/', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'MS risk in unvaccinated people may be elevated by rubella infection: Study\n===============\n\nRubella infection may increase MS risk in unvaccinated people\n=============================================================\n\nHaving antibodies against the rubella virus is associated with an increased risk of developing multiple sclerosis (MS) in unvaccinated people, a Swedish study suggests.\n\nThe findings show a rubella infection may be a risk factor for MS, reinforcing the hypothesis that certain viral infections may trigger the misleading immune response that drives MS.\n\n‚ÄúTo the best of our knowledge, this is the first report of an association between [rubella virus] and MS in pre-\xadMS samples,‚Äù wrote the researchers, who said additional studies will be needed to confirm the association between rubella infection and MS.\n\nThe study, ‚Äú[Rubella virus seropositivity after infection or vaccination as a risk factor for multiple sclerosis](https://onlinelibrary.wiley.com/doi/10.1111/ene.16387),‚Äù was published in the _European Journal of Neurology._\n\n[MS is caused](https://multiplesclerosisnewstoday.com/risk-factors-for-multiple-sclerosis/) by an erroneous immune response that damages healthy parts of the brain and spinal cord. The reason for the immune response isn‚Äôt fully understood, but evidence suggests viral infections may be risk factors. Infection with the [Epstein-Barr virus](https://multiplesclerosisnewstoday.com/epstein-barr-virus-and-ms/) (EBV), in particular, is one of the strongest risk factors for the neurodegenerative condition and some studies have found an association between MS and the human herpesvirus-6A. Also, up to 78% of MS patients have antibodies against measles, varicella zoster, and rubella viruses in their spinal fluid.\n\nIt‚Äôs believed that, due to some similarities between viral and human molecules, the immune system may mistakenly attack nerve cells when trying to fight a viral infection. This ‚Äúmolecular mimicry‚Äù is one proposed mechanism that may explain the association between viruses and a greater risk of MS.\n\nThe rubella virus has several proteins that share similarities with human proteins. One protein from its envelope, called E2, is similar to myelin oligodendrocyte glycoprotein (MOG), an essential protein in [myelin](https://multiplesclerosisnewstoday.com/myelin-sheath/), the fatty coating that covers nerve cells and target of immune responses in MS.\n\nThese similarities raise the possibility of a connection between the rubella virus, the immune response against it, and developing MS.\n\nResearchers in Sweden compared blood samples from MS patients and controls collected before the neurological disease‚Äôs onset to determine if people who developed MS had signs of a previous rubella infection ‚Äî determined through the presence of anti-rubella antibodies ‚Äî before their diagnosis.\n\n‚ÄúWith samples from both the pre-\xadvaccination era and through the different stages of rubella vaccination in Sweden, we explored a unique opportunity to study [the rubella virus] in the field of MS,‚Äù the researchers wrote.\n\nThe study included blood samples from 670 MS patients and 670 matched controls. In both groups, female patients represented the majority (84%) and the median age was 25.\n\nThe researchers tested the samples for the presence of antibodies (seropositivity) that targeted the rubella E1 protein, which the virus uses to infect human cells, and their reactivity. More MS patients (93.7%) had anti-E1 antibodies than healthy controls (88.5%), data showed.\n\nWhen patients and controls were divided based on their rubella vaccination status, seropositivity was only significantly higher in MS patients than controls in unvaccinated people, in whom the presence of antibodies indicates a previous rubella infection. After adjusting for factors such as antibodies against other viruses and vitamin D levels, unvaccinated MS patients were four times more likely to have rubella antibodies than unvaccinated controls. No significant differences were observed in vaccinated patients after accounting for the same factors.\n\nThe presence of antibodies in ‚Äúunvaccinated subjects (i.e., representing rubella infection) was associated with a higher risk of developing MS,‚Äù the researchers wrote. ‚ÄúMolecular mimicry is an attractive hypothesis for a possible mechanism behind these findings.‚Äù\n\nThe researchers advised caution when interpreting their findings, mainly because the test they used to determine seropositivity can have a lot of false negatives. Also, most of the participants received the combined measles, mumps, and rubella vaccine, adding variables that weren‚Äôt evaluated in the study.\n\n‚ÄúFurther serological and epidemiological studies are needed to support our findings,‚Äù they wrote.', 'gpt-4o-mini']
2024-09-11 01:47:47,515 - INFO - Logged data to databases/llm.csv with DocumentID: IDkcoKdjUueJWt2wF5MB.
2024-09-11 01:47:47,515 - INFO - 'generated_post' length: 9. Content: ['2024-09-10 09:05:00', '2024-09-11 01:41:31', "üë• Have you ever considered how digital biomarkers could revolutionize the way we monitor Parkinson's disease progression?  \n\n- Regeneron has recently joined the LEARNS trial, a digital biomarker study by Koneksa, aimed at capturing real-time data on Parkinson's patients through smartphones and wearables.  \n- üì± The initiative will track up to 70 participants over one year, enhancing our understanding of disease progression which is often inconsistently monitored using subjective measures.  \n- With the support of partners like MSD/Merck & Co, this trial opens doors to natural history analysis and data-driven insights that could transform trial design and cohort formation.  \n- üöÄ As highlighted by Koneksa's CEO, the goal is clear‚Äîestablish valid measures early in the disease to streamline therapeutic development and adoption of digital tools in clinical settings.  \n\nAs we increasingly rely on technology for patient care, what potential do you see for digital biomarkers in your practice? ü§î \n\nFor further reading, visit: https://pharmaphorum.com/news/regeneron-joins-koneksa-parkinsons-digital-biomarker-study", ['Research & Clinical Trials', 'DigitalHealth', 'Neurology', 'ClinicalTrials', 'PatientEngagement'], 'https://images.pexels.com/photos/8376285/pexels-photo-8376285.jpeg', 'https://pharmaphorum.com/news/regeneron-joins-koneksa-parkinsons-digital-biomarker-study', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'Regeneron joins Koneksa Parkinson\'s digital biomarker study\n\nRegeneron is the second pharma group to sign up for access to data from a remote study run by health technology firm Koneksa that is exploring the use of digital biomarkers to track patients with Parkinson\'s disease.\n\nThe LEARNS trial ‚Äì which started earlier this year ‚Äì is using smartphone and wearable technologies to monitor disease progression in Parkinson\'s patients and find ways to use digital biomarkers in the development of disease-modifying therapies.\n\nRegeneron has become a member of the data syndication programme for LEARNS, joining MSD/Merck & Co, which signed up in March, and will have real-time access to data and results from the study. Those can be used for "natural history analysis, trial design, cohort formation, and data analysis," according to the partners.\n\nQuantitative tools for measuring progression are lacking in Parkinson\'s and other neurological disorders, with clinicians relying on subjective measures that make it harder to monitor patients, particularly as the rate of symptom decline fluctuates and varies wildly between individuals with the disease.\n\nLEARNS is set to enrol up to 70 participants with Parkinson\'s who will be followed for 12 months, with first results expected next year. It uses the Koneksa neuroscience toolkit, which combines iPhone-based active assessments and passive monitoring using a wrist-worn wearable.\n\n"Detecting the earliest signs of Parkinson\'s disease and establishing the necessary evidence of validity for new measures are critical needs within the healthcare community," said Chris Benko, Koneksa\'s chief executive.\n\n"Our goal is to bring together biotech and pharma companies with real-time data sharing and analysis to expedite the validation and adoption of digital measures to unlock more data insights in clinical trials," he added.\n\nOther projects looking at digital biomarkers for Parkinson\'s include the crowd-sourced DREAM Challenge, which saw 40 research teams from around the world contribute ways to process accelerometer and gyroscope data from consumer wearable devices that can be used to track muscle tremor, dyskinesia, and bradykinesia - three prominent symptoms of the disease.\n\nRegeneron\'s pipeline doesn\'t currently include a clinical-stage treatment for Parkinson\'s, but it is working on drugs for other neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS).\n\n"At Regeneron, we believe that digital biomarkers have the potential to improve the development of novel therapeutics, and collaboration helps make this a reality," said the company\'s head of clinical development for genetic diseases, Gary Herman.\n\n"Koneksa\'s data syndication community allows us to leverage collective expertise and gain insights that will inform future investigational therapies for Parkinson\'s disease."', 'gpt-4o-mini']
2024-09-11 01:47:47,516 - INFO - Logged data to databases/llm.csv with DocumentID: xpAn0KFAGOmqMoQ2AnOX.
2024-09-11 01:47:47,516 - INFO - 'generated_post' length: 9. Content: ['2024-09-10 08:59:00', '2024-09-11 01:41:55', 'üíâ Exciting developments in the realm of Type 1 Diabetes treatment! \n\n- Diamyd Medical is gearing up to seek accelerated approval for its antigen-specific immunotherapy, Diamyd¬Æ (rhGAD65/alum), which targets the preservation of insulin production in Stage 3 Type 1 Diabetes patients. \n- The upcoming interim study results from the Phase 3 trial, DIAGNODE-3, are expected by March 2026 and could lay the groundwork for a Biologics License Application (BLA). \n- The FDA has granted Fast Track designation for Diamyd¬Æ, acknowledging its potential to show significant benefits in C-peptide levels, a key indicator of insulin production. \n- This therapy is particularly relevant for the 40% of recently diagnosed Type 1 Diabetes patients carrying the HLA DR3-DQ2 genotype, who have previously shown positive responses. \n\nAs the clinical landscape shifts towards precision medicine, how do you think this approach could reshape diabetes care? ü§î  \n\nFor more details, visit: https://www.prnewswire.com/news-releases/diamyd-medical-to-pursue-accelerated-approval-pathway-for-type-1-diabetes-precision-medicine-302241751.html', ['Life Sciences & BioTech', 'Endocrinology', 'PrecisionMedicine', 'ClinicalTrials', 'DigitalHealth', 'HealthTech'], 'https://images.pexels.com/photos/6942030/pexels-photo-6942030.jpeg', 'https://www.prnewswire.com/news-releases/diamyd-medical-to-pursue-accelerated-approval-pathway-for-type-1-diabetes-precision-medicine-302241751.html', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'Diamyd Medical to pursue accelerated approval pathway for Type 1 Diabetes precision medicine\n\nSTOCKHOLM, Sept. 9, 2024 /PRNewswire/ -- Diamyd Medical will pursue an accelerated approval pathway in the U.S. for its antigen-specific immunotherapy, Diamyd¬Æ (rhGAD65/alum), aimed at preserving endogenous insulin production in patients with Stage 3 Type 1 Diabetes. An earlier interim study readout from the ongoing Phase 3 trial, DIAGNODE-3, is planned to serve as the basis for a Biologics License Application (BLA) under the accelerated approval pathway. Results from the interim readout are expected around March 2026.\n\n"We are committed to working at full speed with our partners and in close dialogue with the FDA to seize this unprecedented opportunity of making Diamyd¬Æ available to patients as quickly as possible," says Ulf Hannelius, CEO of Diamyd Medical. "The earlier readout from the DIAGNODE-3 trial represents a critical step in this process and our confidence in Diamyd¬Æ\'s disease-modifying benefits is boosted by the positive outcome of the recently announced futility analysis. We look forward to working closely with the FDA to ensure that all necessary regulatory requirements are met."\n\nDiamyd Medical recently announced Fast track designation in the U.S. for Diamyd¬Æ, and that the U.S. Food and Drug Administration (FDA) has acknowledged that accelerated approval could be sought based on a demonstration of significant treatment-related benefits on C-peptide levels, a measure of endogenous insulin production, in response to Diamyd¬Æ administration. The FDA\'s Accelerated approval program allows drugs for serious conditions that fills an unmet medical need to be approved based on a surrogate endpoint. Using a surrogate endpoint allows the FDA the potential to approve these drugs faster.\n\nTo prepare the BLA under the FDA\'s Accelerated Approval Program, Diamyd Medical plans to conduct an interim study readout, including efficacy data from approximately 170 participants who have completed their 15-month assessment and safety data from additional individuals enrolled in the DIAGNODE-3 trial. The primary endpoint for this analysis will be C-peptide, a surrogate endpoint now recognized by the FDA as reasonably likely to predict clinical benefit. Following the interim readout, the DIAGNODE-3 trial will continue to follow all enrolled patients until the 24-month end-of-study assessment. To date, 148 patients have been randomized in DIAGNODE-3. The results of the interim study readout are expected around March 2026, the exact time depending on the final number of participants to be included in the readout, followed by submission of a BLA under the accelerated approval pathway.\n\nThe DIAGNODE-3 trial, which is being conducted in eight European countries and the United States, is expected to fully recruit approximately 330 patients by the end of 2025, and all patients are expected to be fully treated before the time the earlier readout is to be performed. The trial focuses on recently diagnosed patients with Stage 3 Type 1 Diabetes carrying the HLA DR3-DQ2 genotype; a subgroup of approximately 40% of Stage 3 Type 1 Diabetes patients that has been shown to respond to Diamyd¬Æ in previous trials.\n\n**About Diamyd Medical**\n\nDiamyd Medical develops precision medicine therapies for the prevention and treatment of Type 1 Diabetes and LADA (Latent Autoimmune Diabetes in Adults). Diamyd¬Æ is an antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production that has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage 1, 2 and 3 Type 1 Diabetes. DIAGNODE-3, a confirmatory Phase III trial is actively recruiting patients with recent-onset (Stage 3) Type 1 Diabetes in eight European countries and in the US. Significant results have previously been shown in a large genetically predefined patient group - in a large-scale meta-analysis as well as in the Company\'s prospective European Phase IIb trial, where Diamyd¬Æ was administered directly into a superficial lymph node in children and young adults with recently diagnosed Type 1 Diabetes. Injections into a superficial lymphnode can be performed in minutes and are intended to optimize the treatment response. A biomanufacturing facility is under development in Ume√•, Sweden, for the manufacture of recombinant GAD65 protein, the active ingredient in the antigen-specific immunotherapy Diamyd¬Æ. Diamyd Medical also develops the GABA-based investigational drug Remygen¬Æ as a component in the treatments of metabolic diseases. Diamyd Medical is a major shareholder in the stem cell company NextCell Pharma AB and in the artificial intelligence company MainlyAI AB.\n\nDiamyd Medical\'s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company\'s Certified Adviser.\n\n**For further information, please contact:  \n**Ulf Hannelius, President and CEO  \nPhone: +46 736 35 42 41  \nE-mail: [ulf.hannelius@diamyd.com](mailto:ulf.hannelius@diamyd.com)', 'gpt-4o-mini']
2024-09-11 01:47:47,516 - INFO - Logged data to databases/llm.csv with DocumentID: GmTrddSrSirMwnVORb2j.
2024-09-11 01:47:47,517 - INFO - 'generated_post' length: 9. Content: ['2024-09-10 08:44:00', '2024-09-11 01:42:13', "ü©∫ Are we about to shift the treatment paradigm for rare genetic disorders?\n\n- The National Institute for Health and Care Excellence (NICE) has recently recommended MSD's Welireg (belzutifan) for NHS use in England and Wales, targeting adults with von Hippel-Lindau (VHL) disease. This comes nearly a year after Scottish approval.\n- Welireg is now an option specifically for treating VHL-associated renal cell carcinoma (RCC), brain and spinal cord tumours (haemangioblastomas), or pancreatic neuroendocrine tumours (pNETs), especially when surgery isn‚Äôt viable. üéâ\n- Previously, options were limited to invasive surgeries or radiotherapy, often requiring recurrent operations throughout a patient‚Äôs life.\n- With roughly 600 VHL patients in England, about 100 are expected to benefit from Welireg, with an additional 50 cases each year thereafter. This represents a significant improvement in management for these patients.\n- After a previous hesitance from NICE regarding economic evidence, the route is now clearer for healthcare providers following an access agreement with NHS England. The decision is conditional, allowing for continued collection of efficacy data. üìà\n- As highlighted by patient representatives, Welireg shows 'game-changing potential,' with some patients in trials experiencing stabilization, reduced growth, or even eradication of tumours. \n\nHow might the introduction of Welireg alter patient management and expectations for those with VHL? ü§î \n\nFor a deeper dive, check out the details here: https://pharmaphorum.com/news/nice-clears-nhs-use-msds-welireg-genetic-disorder", ['Healthcare & Policy', 'HealthcareInnovation', 'ClinicalTrials', 'HealthTech', 'PatientSupport'], 'https://images.pexels.com/photos/6436249/pexels-photo-6436249.jpeg', 'https://pharmaphorum.com/news/nice-clears-nhs-use-msds-welireg-genetic-disorder', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'NICE clears NHS use of MSD\'s Welireg for genetic disorder\n\nPatients in England and Wales with a rare genetic disorder will soon be able to access treatment with MSD\'s Welireg via the NHS, nearly a year after their counterparts in Scotland.\n\nIn final draft guidance due to be finalised before the end of the month, Welireg (belzutifan) has been recommended as an option for treating adults with von Hippel-Lindau (VHL) disease, a rare and life-shortening disease that can lead to the development of benign and cancerous tumours and cysts.\n\nSpecifically, Welireg becomes an option for VHL-associated renal cell carcinoma (RCC), brain and spinal cord tumours (haemangioblastomas), or pancreatic neuroendocrine tumours (pNETs) when localised treatment like surgery isn\'t appropriate.\n\nUntil now, the only therapies available to patients with VHL have been invasive surgery or radiotherapy, with patients usually requiring multiple surgeries throughout their lives.\n\nThere are only about 600 adults in England living with the condition, and around 100 of them could be eligible for treatment with Welireg, with another 50 cases per year thereafter.\n\nThe decision comes after NICE withheld a recommendation for the drug last December, saying there were "uncertainties" in the clinical and economic evidence submitted for its appraisal. The SMC in Scotland backed NHS use of the drug in October 2023.\n\nThe new NICE recommendation is conditional, meaning that Welireg can be used while more evidence for its efficacy is collected, according to Helen Knight, director of medicines evaluation at NICE. It comes after NHS England reached a commercial access deal with the manufacturer.\n\nThe appraisal committee heard from patient experts who explained that some people with VHL have a wide variety of debilitating symptoms depending on where the tumours are growing in the body. These include pain, loss of balance and motor skills, loss of vision, breathlessness, coughing, headaches, confusion, severe nausea, and fatigue.\n\nGraham Lovitt, chair of patient advocacy group VHL UK/Ireland, said Welireg has "game-changing potential" and has shown extraordinary results for some patients in trials, including stabilisation of the tumours, reduction in growth, and ‚Äì in some cases ‚Äì the eradication of tumours altogether.\n\n"We are delighted by NICE\'s recommendation of belzutifan [‚Ä¶] a significant milestone in the fight against this rare disease," he added. "This decision brings hope to qualifying patients and their families, offering them an alternative treatment option, when others become too high risk."\n\nWelireg (belzutifan), an oral HIF-2 alpha inhibitor, has been approved by the UK drugs regulator the MHRA for VHL since May 2022. MSD acquired it as part of its $2.2 billion takeover of Peloton Therapeutics in 2019.\n\nDespite the rarity of VHL tumours, MSD has blockbuster aspirations for Welireg, and now has a second regulatory approval for the drug in relapsed or refractory advanced RCC, with clinical trials on the go in glioblastoma multiforme, a hard-to-treat form of brain cancer.', 'gpt-4o-mini']
2024-09-11 01:47:47,517 - INFO - Logged data to databases/llm.csv with DocumentID: xHsWqgfq1ua0uwlYo3u8.
2024-09-11 01:47:47,517 - INFO - 'generated_post' length: 9. Content: ['2024-09-09 06:12:00', '2024-09-11 01:42:21', 'üîç Have you heard about the latest breakthrough in neurosurgery? Longeviti Neuro Solutions has just secured a U.S. patent for an innovative cranial implant that could transform surgical practices.  \n\n- The ClearFit implant is notable for its translucent design, incorporating cutting-edge capabilities such as brain-computer interface, brain mapping, and neurosonography, all within one device.  \n- üß† With these features, neurosurgeons can obtain real-time, detailed anatomical images during procedures, significantly improving their precision and overall patient care.  \n- This implant also allows continuous, noninvasive monitoring of brain activity throughout surgery, enhancing safety and responsiveness to patient needs.  \n- According to CEO Jesse Christopher, this technology aims to reduce healthcare costs and procedure time dramatically, making advanced monitoring accessible worldwide.  \n\nAs we witness such advancements in neurotechnology, how do you foresee this impacting future neurosurgical practices? ü§î  \n\nFor more insights, explore the full announcement here: https://www.healio.com/news/neurology/20240816/longeviti-neuro-solutions-secures-us-patent-for-neurosurgical-cranial-implant', ['HealthTech & Startups', 'Neurology', 'Neurology', 'Surgery', 'HealthTech', 'MedicalDevices'], 'https://images.pexels.com/photos/27269602/pexels-photo-27269602.jpeg', 'https://www.healio.com/news/neurology/20240816/longeviti-neuro-solutions-secures-us-patent-for-neurosurgical-cranial-implant', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'Longeviti Neuro Solutions secures US patent for neurosurgical cranial implant\n=============================================================================\n\nA Maryland-based neurotechnology company has secured a U.S. patent for its novel prosthetic translucent, cranial implant intended for use during neurosurgical procedures.\n\nIn a press release, Longeviti Neuro Solutions said the ClearFit implant combines brain-computer interface capability, brain mapping and neurosonography, which permits direct communication between the brain and external devices, along with the ability for patients to interact with the technology, Longeviti said in the release.\n\nThe implant, when paired with brain-mapping capabilities, allows neurosurgeons to receive real-time, detailed anatomical images, enabling them to enhance their precision during neurological procedures. Further, the company said, integrating neurosonography within the cranial implant enables clinicians to continuously monitor brain activity during surgery in a noninvasive manner.\n\n‚ÄúThis technology represents a significant advancement in the field of neurosurgery,‚Äù Longeviti Neuro Solutions CEO Jesse Christopher said in the release. ‚ÄúTogether, Longeviti and its partners will advance neurosonography and neurosurgical patent care to significantly reduce the cost and time it takes to monitor brains anywhere in the world.‚Äù', 'gpt-4o-mini']
2024-09-11 01:47:47,518 - INFO - Logged data to databases/llm.csv with DocumentID: w9gUaubdEq1yNLLrX9FL.
2024-09-11 01:47:47,518 - INFO - 'generated_post' length: 9. Content: ['2024-09-09 06:06:00', '2024-09-11 01:42:32', 'üî¨ Curious about advancements in mpox protection? A recent study reveals promising developments in mRNA vaccine technology!\n\n- Funded by Moderna and key health institutions, this study compared their investigational mRNA mpox vaccine with the licensed Modified Vaccinia Ankara (MVA) vaccine in a non-human primate model. \n- The mRNA vaccine significantly reduced symptoms and disease duration, demonstrating a more effective response: vaccinated macaques showed fewer lesions and lost less weight compared to the MVA group. \n- Remarkably, disease duration was shortened by over 10 days, along with lower viral loads, suggesting improved potential for reducing transmission. ü¶† \n- This technology, initially designed for smallpox, allows for a targeted immune response with a favorable safety profile‚Äîopenly addressing the limitations of traditional vaccines. \n- Notably, the mRNA vaccine showed potential for cross-immunity against other Orthopoxviruses, paving the way for protection against future viral threats. \n\nAs these findings transition into clinical trials, they raise an important question: How can we leverage mRNA technology to safeguard against emerging infectious diseases more effectively in our practice? ü©∫\n\nFor further insights, check out the full study here: https://www.drugtargetreview.com/news/152646/mrna-vaccine-provides-enhanced-protection-against-mpox/', ['Research & Clinical Trials', 'ClinicalTrials', 'InfectiousDiseases', 'HealthTech', 'PublicHealth'], 'https://images.pexels.com/photos/8830484/pexels-photo-8830484.jpeg', 'https://www.drugtargetreview.com/news/152646/mrna-vaccine-provides-enhanced-protection-against-mpox/', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'mRNA vaccine provides enhanced protection against mpox\n======================================================\n\nThe mRNA vaccine candidate more effectively limited symptoms and disease duration in non-human primates.\n\nA study, funded by Moderna, the National institute of Allergy and Infectious Diseases (NIAID) and the National Institutes of Health (NIH) compared an investigational mRNA mpox vaccine from Moderna to a currently licensed Modified Vaccinia Ankara (MVA) vaccine. The new mRNA vaccine candidate more effectively limits symptoms and disease duration in non-human primates infected with a lethal strain of mpox.\n\nAlec Freyn, virology researcher at Moderna and co-first author, stated: ‚ÄúThis study is the first in a nonhuman primate model where we compare an investigational mRNA mpox vaccine directly to the current standard of care.‚Äù He continued: ‚ÄúWhen we put those vaccines head-to-head in primates, we saw improved responses from the mRNA vaccine in terms of not just protection from survival but also fewer lesions, shorter duration of disease, and less viral shedding in the blood and respiratory tract.‚Äù\n\nOriginally designed to combat smallpox, MVA vaccines contained weakened whole viruses. Yet, this weakening means that they provide limited protection compared to other vaccines. The use of mRNA technology enables vaccines to be developed to only include parts of the virus that are most likely to induce a lasting, protective immune response without exposing the person to a whole infectious virus. The investigational mpox mRNA vaccine is composed of four viral antigens that are essential for the virus to attach and enter host cells.\n\nPrevious research has demonstrated that mRNA vaccines can prevent lethal mpox infections in nonhuman primates but their ability to lessen disease severity has not been tested. Therefore, to directly compare the investigational mRNA vaccine to MVA vaccines, the team vaccinated six macaques with each vaccine and then exposed them to a lethal strain of mpox virus eight weeks after their initial vaccine dose. Also, they exposed a control group of six unvaccinated animals to mpox. Then, after infection, the researchers monitored the macaque‚Äôs health for four weeks and collected blood samples to study their immune response.\n\nDisease severity\n----------------\n\nFive of the unvaccinated control animals did not survive, whereas all 12 vaccinated animals did, regardless of which vaccine was used. The mRNA-vaccinated animals lost less weight and had fewer lesions than MVA-vaccinated animals, despite both vaccines limiting disease severity compared to the control group.\n\nFurthermore, the mRNA vaccine shortened disease duration, measured by the number of days for which the animals showed lesions, by more than 10 days compared to the MVA vaccine. Lower viral loads were in the blood and throat swabs, indicating that it might be more effective at reducing transmission.\n\nJay Hooper, virologist at the United States Army Medical Research Institute for Infectious Diseases and senior author explained: ‚ÄúWith the mRNA technology, we‚Äôre able to produce a vaccine that gives quite potent responses with a very tolerable safety profile‚Ä¶We‚Äôve been trying to get a vaccine that will prevent spread like ACAM2000¬Æ but without the safety issues. This is showing that mRNA technology might be able to fill that niche.‚Äù\n\nImmune response\n---------------\n\nThe mRNA vaccine resulted in a higher number of antibodies and antibodies with more diverse immune functions. Different classes of antibodies that were associated with enhanced viral control and fewer lesions were identified.\n\nFurthermore, the vaccine demonstrated potential to induce cross-immunity to other Orthopoxviruses, whereas the MVA vaccine results in smaller immune responses that are not as strongly neutralising for more remotely related Orthopoxviruses. Serum from the macaques immunised with the mRNA vaccine ‚Äúneutralised not only mpox but also vaccinia, cowpox, rabbitpox, camelpox, and ectromelia virus,‚Äù Freyn said. ‚ÄúWe believe that this vaccine may protect from other Orthopoxvirus threats that may emerge in the future.‚Äù\n\nNow, Moderna‚Äôs mRNA-1769 vaccine is being assessed in a Phase I/II clinical trial (NCT05995275) to determine the safety, tolerability and immune response of a range of doses of mRNA-1769.\n\nThis study was published in Cell.', 'gpt-4o-mini']
2024-09-11 01:47:47,519 - INFO - Logged data to databases/llm.csv with DocumentID: mjNCnnAavWkLvcK7WzGl.
2024-09-11 01:47:47,519 - INFO - 'generated_post' length: 9. Content: ['2024-09-09 05:56:00', '2024-09-11 01:42:47', 'üöÄ Could Nucala (mepolizumab) be the game changer for COPD management? Recent insights from GSK reveal that its MATINEE trial results could pave the way for a new indication in treating chronic obstructive pulmonary disease (COPD). \n\n- The trial demonstrated a statistically significant reduction in the annual exacerbation rates among adults treated with Nucala, compared to placebo, reinforcing its potential as an effective adjunct to inhaled maintenance therapy.\n- This follows a mixed history, with earlier trials yielding less promising outcomes, yet MATINEE shows promise, particularly for patients with elevated eosinophil counts. An estimated 40% of COPD patients could qualify for this treatment, highlighting a substantial patient population.\n- GSK is eyeing regulatory discussions for potential approval in the US, projected within the next year, following years of established success for Nucala in treating severe eosinophilic asthma and other related conditions.\n- With COPD affecting over 300 million people globally and the recent trends showing advancements in COPD therapies ‚Äì including the recent approvals of other biologics like Dupixent and Ohtuvayre ‚Äì the landscape is evolving rapidly.\n\nAs we consider the broader implications, how might the introduction of biologics shift the management of COPD and patient outcomes? ü§î  \n\nFor further details, check out the full study here: https://pharmaphorum.com/news/gsk-says-nucala-hits-target-new-copd-trial', ['Life Sciences & BioTech', 'HealthTech', 'LifestyleMedicine', 'Pulmonology'], 'https://images.pexels.com/photos/7578803/pexels-photo-7578803.jpeg', 'https://pharmaphorum.com/news/gsk-says-nucala-hits-target-new-copd-trial', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'GSK says Nucala hits the target in new COPD trial\n\nGSK\'s severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.\n\nThe headline result from the MATINEE trial of IL-5 inhibitor Nucala (mepolizumab) in adults with COPD was a statistically significant reduction in the annualised rate of moderate or severe exacerbations compared to placebo that GSK said was "clinically meaningful." In the study, Nucala was added to inhaled maintenance therapy for COPD.\n\nGSK has been studying Nucala in COPD for some time, and in 2017 reported mixed results for the drug in two earlier phase 3 trials called METREX and METREO.\n\nMETREX involved patients with a range of eosinophil levels and showed a statistically significant improvement for Nucala versus placebo on exacerbation rates. However, in METREO ‚Äì which focused on patients with higher levels only ‚Äì the difference between the two arms was not significant.\n\nThe company decided to file for approval regardless, but the FDA declined to approve the new indication in 2018, following the advice of an advisory committee, which found that GSK had not proved efficacy. It seems MATINEE will allow GSK to try its luck again.\n\nThe size of the improvement over placebo ‚Äì which reportedly extended for up to two years in the trial ‚Äì won\'t be available until the study is presented at a future medical congress, but is strong enough to warrant discussions with regulators about extending the indications for Nucala, according to the pharma group. It has previously suggested approval for COPD could come in the US in the first half of next year.\n\nNucala has been approved to treat severe eosinophilic asthma for almost a decade, and in the interim has had its label extended to include chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome.\n\nThe drug remains one of GSK\'s top products, with sales of ¬£856 million ($1.1 billion) in the first half of this year, up 15%. COPD could open up a massive new market for the drug, which still has several years of patent life left before it could face biosimilar competition.\n\nThe lung disease affects more than 300 million people globally, with up to 40% of patients exhibiting type 2 inflammation characterised by a raised blood eosinophil count, which would make them suitable for treatment with Nucala.\n\nElevated eosinophil levels are associated with more severe COPD and a higher rate of exacerbations, the sudden flare-ups in symptoms that signal the progression of the disease and can lead to hospitalisation.\n\nThe MATINEE data comes at a time when options for COPD are on the up, after a decade with no new therapies.\n\nIn July, the European Commission became the first regulator worldwide to approve Sanofi and Regeneron\'s big-selling IL-4 and IL-13 inhibitor Dupixent (dupilumab) as a treatment for the progressive lung disease, shortly after Verona Pharma got the go-ahead from the US FDA for its PDE 3/4 inhibitor Ohtuvayre (ensifentrine).\n\nDupixent ‚Äì which is due for a verdict from the FDA as a COPD therapy later this month ‚Äì was cleared for adults with uncontrolled COPD with raised blood eosinophils, while Ohtuvayre can be used in all patients regardless of eosinophil levels.', 'gpt-4o-mini']
2024-09-11 01:47:47,520 - INFO - Logged data to databases/llm.csv with DocumentID: 0zIOYAyGUzOwaCYodEu0.
2024-09-11 01:47:47,520 - INFO - 'generated_post' length: 9. Content: ['2024-09-06 00:00:00', '2024-09-11 01:43:00', 'üßê Are we on the brink of a new era in preventative healthcare, driven by technology?  \n  \n- A recent visit to Zoƒ´, a Parisian longevity clinic startup, revealed their unique "360-degree check-up" model. It includes three-hour tests covering everything from bloodwork to gut microbiome analysis, all aimed at gathering millions of data points to guide personalized health recommendations.  \n- With a membership cost of ‚Ç¨3.6k annually, access may currently cater to an affluent clientele, similar to venues like Soho House. Yet, the vision is ambitious: make preventative health accessible to everyone in the future.  \n- The clinic currently provides cutting-edge services, including chef-prepared snacks and unique relaxation experiences, pushing the boundaries of traditional healthcare norms.  \n- Interestingly, these longevity tech ventures‚Äîbacked by billionaires‚Äîare on the rise, with companies like Neko Health developing advanced body scanning technology that claims to aid in early disease detection.  \n  \nWith growing interest and substantial investments, can we expect more healthcare innovations that bridge the gap between elite services and broader populations? ü§î  \nFor more in-depth insights, check out the full article here: https://sifted.eu/articles/billionaires-body-scans/', ['HealthTech & Startups', 'HealthTech', 'PatientEngagement', 'HealthcareInnovation', 'CME'], 'https://images.pexels.com/photos/6436256/pexels-photo-6436256.jpeg', 'https://sifted.eu/articles/billionaires-body-scans/', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', "**_This article first appeared in Sifted‚Äôs Daily newsletter, [sign up here](https://sifted.eu/newsletters?utm_medium=onsite&utm_source=article&utm_campaign=daily_big_story&utm_content=flagshipnl)._**\n\nEarlier this week, I visited one of Paris‚Äô few longevity clinics dedicated to preventative medicine ‚Äî and the only one that describes itself as a tech startup.\n\nHidden behind an unassuming Haussmannian door, just a few minutes away from the Paris Opera, the centre has been operating for nine months. The startup behind it, Zoƒ´, promises customers a ‚Äú360-degree check-up‚Äô ‚Äî a three-hour series of tests and exams, ranging from blood tests to eye scans through spirometry and gut microbiome analyses.\n\nThe objective? Collect millions of data points on up to 200 biomarkers that are in turn analysed by an AI model, in order to deliver lifestyle recommendations that, promises Zoƒ´, will prevent disease and improve customers‚Äô long-term wellness.\n\n‚ÄúIt‚Äôs not about adding years of life, but rather life to years,‚Äù says Zoƒ´ cofounder ‚Äî and former special advisor to French president Emmanuel Macron ‚Äî Isma√´l Em√©lien. ‚ÄúThe goal is to learn the body‚Äôs ‚Äòuser manual‚Äô to prevent illnesses and enable people to live in good health for longer.‚Äù\n\nIt‚Äôs not for everyone. Membership to Zoƒ´ is ‚Ç¨3.6k per year, which includes an annual checkup as well as the follow-up recommendations. That‚Äôs roughly the cost of a membership to Soho House, says Zoƒ´'s CFO Antoine Attali ‚Äî and the startup's customers usually belong to the same social circles.\n\nThe clinic caters to premium needs, from snacks elaborated by world-famous chef Alain Ducasse to a balneotherapy section modelled on ‚ÄòJapanese thermal baths‚Äò, featuring a snow cabin (?) and a mineral bath that is, I am told, ‚Äútwice as salty as the Dead Sea‚Äù.\n\nAttali tells me that in the long-term, Zoƒ´ hopes to become accessible to everyone, and that prices will go down to a similar level to your average WiFi subscription.\n\nFor now, though, preventative health remains a hobby of the upper-class. In fact, Zoƒ´'s investors are all private individuals; the company‚Äôs ‚Ç¨20m seed round, which it raised in 2022, included a good number of high-profile billionaires such as Xavier Niel, Rodolphe Saad√© and Moderna CEO St√©phane Bancel.\n\nAnd Zoƒ´ is not the only longevity startup appealing to the ultra-rich. Spotify founder Daniel Ek is behind similar ventures, including [Sand Clinic in Stockholm](https://sifted.eu/articles/daniel-ek-spotify-sand-clinic-longevity-news), where customers can receive full body check-ups and treatments ranging from vacuum therapy to red light saunas ‚Äî with membership expected to cost between ‚Ç¨1,000 and ‚Ç¨10,000 a month.\n\nEk is also the founder of healthtech Neko Health, which has built a full-body scanner for health data collection that it says helps doctors detect potential diseases earlier. The company [has a clinic in Stockholm](https://sifted.eu/articles/ek-neko-body-scanner-test) and has just opened a new spot in London, right in the middle of Marylebone, where it prices a one-hour scan at ¬£299 ‚Äî almost double the price of a visit to the Stockholm clinic when it opened in 2023 (‚Ç¨180).\n\nDespite the cost, the proposition seems appealing enough. Neko Health says it already has a waiting list of 22k people; Zoƒ´ says it has ‚Äúaround 1k members‚Äù to date and is currently carrying out a dozen check-ups per day ‚Äî but the startup is confident that it can ramp up to reach its maximum capacity of 35k annual check-ups in the next five years.\n\nWhether or not the preventative treatments promised by startups like Zoƒ´, Neko Health and Sand Clinic will ever reach the masses remains to be seen; what seems certain for now is that billionaires won‚Äôt get tired of full-body-scanning anytime soon.\n\n![Image 1: A photo of the entrance to Zo√Ø's centre in Paris](https://images.sifted.eu/wp-content/uploads/2024/09/06145636/Zoi%CC%84_WIP6_%C2%A911h45-HD-4.jpg?auto=format&fit=max&w=3840&q=75)\n\nThe entrance to Zo√Ø's centre in Paris. Credit: 11h45", 'gpt-4o-mini']
2024-09-11 01:47:47,521 - INFO - Logged data to databases/llm.csv with DocumentID: Binwer8Adxua9h8wMOer.
2024-09-11 01:47:47,521 - INFO - 'generated_post' length: 9. Content: ['2024-09-03 00:00:00', '2024-09-11 01:43:21', 'üè• How is digital innovation reshaping patient care? \n\n- UK-based healthtech Doccla has just secured a notable ¬£35 million in a Series B funding round to expand its revolutionary \nvirtual ward technology, which empowers clinicians to monitor patients from the comfort of their homes.\n- With a remarkable 63% reduction in A&E attendance noted in NHS studies, this approach not only enhances patient care but also significantly cuts hospital costs. üìâ\n- The company is rapidly scaling, having monitored over 4 million patient days and maintaining 95% compliance with patients‚Äîa game-changer in the world of healthcare.  \n- Excitingly, with new reimbursement codes emerging in France for remote monitoring, Doccla is poised to expand its international footprint and partner with pharmaceutical companies for clinical data utilization, improving patient outcomes while aiding drug compliance. \n- As healthcare systems shift towards more comprehensive remote care solutions, could virtual wards become the new standard in clinical practice?  \n\nDelve deeper into how innovations like Doccla are transforming patient management: https://sifted.eu/articles/doccla-raises-a-35m-series-b-news/', ['HealthTech & Startups', 'DigitalHealth', 'HealthTech', 'PatientEngagement', 'Telehealth', 'HealthcareInnovation'], 'https://images.pexels.com/photos/6823606/pexels-photo-6823606.jpeg', 'https://sifted.eu/articles/doccla-raises-a-35m-series-b-news/', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', "UK-based healthtech Doccla has secured a ¬£35m Series B, led by European VC Lakestar, with new investors French VC Elaia and existing investors General Catalyst, Speedinvest and the investment leg of German media company Bertelsmann also participating.\n\nHaving almost quadrupled its annual revenue in 2023, it's planning its expansion in DACH and France, and says its German and French investors will help its international growth plans.\n\nThe startup, founded in 2019, makes ‚Äúvirtual ward‚Äù technology for healthcare providers. It allows clinicians to monitor patients at home, by providing them with devices to measure health factors like blood pressure and heart rate.\n\nDoccla has become the largest virtual ward provider for the UK‚Äôs National Health Service (NHS). In December 2023, it signed its first contract with a German hospital and, in June, it partnered with Ireland‚Äôs Health Service Executive (HSE).\n\nDoccla‚Äôs founder and chair Martin Ratz tells Sifted that the company has its sights set on France, partly due to a change in the healthcare system that makes it easier to receive compensation for remote monitoring of patients.\n\n‚ÄúWith the new compensation system in France (similar to that in the US), there are specific codes for remote monitoring which will facilitate the financials tremendously, and for us, it‚Äôs a huge opportunity to scale,‚Äù says Ratz.\n\nThe virtual A&E\n\nSweden-founded Doccla entered the UK with a pilot project for a virtual ward in 2020, and the timing of the pandemic meant that the company was off to a flying start. It has since then grown its customer base to 10 countries in Europe. Monitoring patients at home, instead of in an overcrowded emergency department at a hospital, has not only meant that hospitals can better manage the patients they have in-house, but also cut costs.\n\nAccording to a recent study funded by the NHS, by implementing Doccla, regional NHS departments have experienced a 63% reduction in A&E attendance while enjoying a 300% return on investment.\n\nPatients signed over to Doccla from hospitals are monitored around the clock using hardware, software and virtual care, which allow medical staff to access patient data in real-time and pre-emptively flag concerns, triggering in-person appointments before issues escalate.\n\nSo far Doccla has monitored over 4m patient days with over 95% patient compliance. Today the company says it‚Äôs adding 1k new patients every month.\n\n‚ÄúOver time, we want to onboard 100k new patients on a monthly basis,‚Äù Ratz says.\n\nPartnering with pharma\n\nDoccla has also recently started conversations with large pharmaceutical companies to deliver clinical data for use in clinical trials. According to Ratz, what pharma companies often struggle with is recruiting patients, as well as compliance (patients taking their drugs when they should).\n\n‚ÄúWe have a compliance rate of 92-97% for our patients, those are sky-high numbers,‚Äù Ratz says. ‚ÄúThis is because we are in very close contact with our patients.‚Äù\n\nDoccla says it‚Äôs interested in pharma partnerships for two main reasons. The first is that providing clinical data is very close to what Doccla already provides to public health providers. The second is that Ratz says he‚Äôs seen software companies, like UK-based Huma and US-based Biofourmis, run such partnerships this successfully.\n\nWith 180 employees, with around 40 of them clinicians, the company now wants to grow its data science team, which today only consists of a few people. By using the data it collects from patients, and combining it with conversations between patients and the care team, Ratz believes Doccla can improve on the service the patients receive and become more preventative in its care.\n\nIn one region in the UK, Doccla has taken over 500 patients who have been in and out of hospital for a long time, to monitor them in a more preventative way.\n\n‚ÄúWe can in a proactive way decrease the number of hospital visits ‚Äî in this case, we decreased them by 63% which is a huge saving for society,‚Äù Ratz says.\n\nDoccla has raised a total of ¬£52m to date.\n\nIn October of last year, Ratz was the largest shareholder with 35% of the shares, followed by General Catalyst at 26%, Dag Larsson (CEO and cofounder) at 15%, Giant Ventures at 9% and Speedinvest at 11%, according to UK Companies House.", 'gpt-4o-mini']
2024-09-11 01:47:47,521 - INFO - Logged data to databases/llm.csv with DocumentID: w5bIVyGtofH28rqegF1I.
2024-09-11 01:47:47,522 - INFO - 'generated_post' length: 9. Content: ['2024-08-27 00:00:00', '2024-09-11 01:43:36', "üöÄ Have you noticed the shift in the medtech funding landscape? With startups raising around $2.2 billion in 2023, it's evident that while challenges persist, there are remarkable innovations on the horizon. Here are some gems driving this transformation:\n\n- SURGICAL ROBOTICS SURGE: Surgical robotics has captured significant investment attention. Notable raises include ¬£165M for CMR Surgical and $150M for DistalMotion, showcasing strong growth prospects.\n\n- NEXT-GEN DIAGNOSTICS: The rise of wellness devices signals opportunities. With founders like Spotify's Daniel Ek entering the field, we could see exciting new diagnostic devices emerging, particularly tailored for the health-conscious consumer.\n\n- INNOVATIVE THERAPEUTIC SOLUTIONS:  \n  - GRADIENT DENERVATION TECHNOLOGIES in France is addressing heart failure complications with a non-invasive ultrasound technique that targets pulmonary arteries, offering hope for patients lacking current treatment options. \n  - SALVIA BIOELECTRONICS is innovating neuromodulation approaches for migraines, receiving FDA Breakthrough Device Designation for its thin implant, potentially changing how we manage this debilitating condition.\n\n- AI AND IMAGING ADVANCES:  \n  - GLEAMER is pioneering AI tools for real-time bone trauma diagnostics, a vital step to enhance clinical decision-making.  \n  - ARTIDIS couples nanotech and data analytics to better predict cancer spread, aiming to revolutionize oncology practices.\n\nAs we explore these advancements, consider: How might these innovations transform your practice and patient outcomes in the next few years?  üí° \n\nFor the full article, visit: https://sifted.eu/articles/medtech-startup-vc-trends/", ['HealthTech & Startups', 'HealthTech', 'MedicalDevices', 'ClinicalTrials', 'HealthcareInnovation'], 'https://images.pexels.com/photos/27269602/pexels-photo-27269602.jpeg', 'https://sifted.eu/articles/medtech-startup-vc-trends/', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', "Medtech has had a mixed few years. In 2023, startups in the sector raised $2.2bn with 2024 looking similar ‚Äî roughly half of the $4bn picked up in 2021, according to Sifted data.\n\nBut there have still been some sizable rounds in recent times. Since the start of 2023, surgical robotics startups have been the biggest winners. The UK‚Äôs CMR Surgical picked up ¬£165m in September last year, Switzerland‚Äôs DistalMotion $150m in April 2023 and Italy‚Äôs Medical Microinstruments $110m in February this year.\n\nThere‚Äôs also been some buzz around next-gen diagnostic devices, as founders ‚Äî including Spotify‚Äôs Daniel Ek with his body scanning startup Neko Health ‚Äî look to tap into the trend of more people using wellbeing and fitness devices like Apple Watches and Oura rings.\n\nBut which non-portfolio medtech startups are investors keeping a close eye on? To find out, Sifted spoke to VCs at 415 Capital, Sofinnova Partners, MIG Capital and SHS Capital.\n\n### **Linus Rieder, principal at 415 Capital**\n\n#### **Medical Microinstruments (MMI) ‚Äì Italy**\n\nMMI is building surgical robots to help with micro-surgery. Its robotics platform can be used in reconstructive surgery, plastic surgery and head-neck surgery. The startup is looking to solve key issues in microsurgery like the effects of surgeon tremor and reduces the need for microsurgery training.\n\n#### **Gradient Denervation Technologies ‚Äî France**\n\nGradient Denervation Technologies is developing a device for treating heart failure patients with associated pulmonary hypertension. As many as half of heart failure patients around the world have elevated pulmonary vascular resistance, which is shown to lead to an increased risk of mortality and hospitalisation. There are no approved drug or device therapies for this group of pulmonary hypertension patients. By using minimally invasive ultrasound to treat hyperactive nerves in the pulmonary arteries, however, the startup‚Äôs technology has the potential to treat and help tens of thousands of patients each year.\n\n#### **CorWave ‚Äî France**\n\nCorWave's left ventricular assist device (LVAD) mimics the natural heart's function to treat patients with advanced heart failure. This technology enables the device to replicate the heart pulses, reducing the mechanical damage to blood cells common with current LVADs.\n\n### **Anne Osdoit, partner at Sofinnova Partners**\n\n#### **Ganymed Robotics ‚Äî France** \n\nGanymed is working on a robotics platform to assist surgeons with implant placement during knee replacement surgery. The Paris-based company's approach uses computer vision and artificial intelligence to perceive, and extract knowledge from, the surgical environment in a non-invasive manner, removing imaging and registration steps that add time and complexity to knee surgery.\n\n#### **Gleamer ‚Äî France**\n\nGleamer is developing AI tools to enhance image interpretation for radiologists. The startup‚Äôs main product helps clinicians identify bone trauma at the point of care. Gleamer has achieved multiple regulatory approvals and successfully commercially deployed in both the US and EU.\n\n#### **Salvia BioElectronics ‚Äî The Netherlands** \n\nSalvia BioElectronics is developing drug-free neuromodulation therapies ‚Äî which refers to a group of medical procedures that look to change brain activity by stimulating nerves ‚Äî for migraines. Salvia's paper-thin implant is designed to be placed under the forehead to reduce the frequency and intensity of migraine attacks by delivering gentle electrical pulses to the nerves associated with the condition. The company is currently in the clinical stage, having received the Breakthrough Device Designation from the United States Food and Drug Administration (FDA), which facilitates expedited market access for devices that treat life-threatening or irreversibly debilitating conditions.\n\n### **Fei Tian, principal at MIG Capital**\n\n#### **Artidis ‚Äî Switzerland**\n\nArtidis is developing imaging tools for cancer diagnostics. It combines a nanotechnology device which analyses tissue with a digital data platform to measure the physical characteristics of both tumour cells and the tumour microenvironment. After determining if a tumour is benign or malignant, Artidis‚Äô technology identifies if it will spread to other sites and can help inform chemotherapy and immunotherapy permeability and treatment response.\n\n#### **CoreMedic ‚Äî Switzerland**\n\nCoreMedic has developed an implant which treats the heart condition mitral valve regurgitation (MR). The CoreMedic implant can replace ruptured mitral ‚Äî a part of the heart ‚Äî in a minimally invasive procedure that is physiological and reproducible, promising long-term clinical benefits.\n\n### **Cornelius Maas, partner at SHS Capital**\n\n#### **Vitestro ‚Äî The Netherlands**\n\nVitestro is developing an autonomous blood drawing device. This innovative device combines robotics and AI to perform blood drawing more efficiently and safely. Over the past year, Vitestro has made significant strides in clinical trials and secured an additional ‚Ç¨20m in funding in April. Vitestro‚Äôs tool could mean less burden for patients, less work for the medical staff and consequently reduce costs for the healthcare system.\n\n#### **Saphenus ‚Äî Austria**\n\nSaphenus is developing sensory feedback systems for prosthetics. Their key product, the Suralis system, provides users of lower-limb prosthetics with the sensation of foot contact, significantly improving balance and gait. Recently, Saphenus received FDA approval with their Suralis system and received reimbursement status with key German medical insurers.\n\n#### **Bluedrop Medical ‚Äî Ireland**\n\nBluedrop Medical is developing a medical device to monitor foot health and prevent diabetic foot ulcers. It looks like a weighing scale and aims to enable early detection of foot ulcers, which can lead to amputation. Bluedrop Medical is a good example of how remote monitoring can replace doctor visits while preventing serious disease progression, improving patient outcomes and reducing healthcare costs.", 'gpt-4o-mini']
2024-09-11 01:47:47,522 - INFO - Logged data to databases/llm.csv with DocumentID: hKgXcvNHaJV7HlumntC2.
2024-09-11 01:47:47,522 - INFO - 'generated_post' length: 9. Content: ['2024-08-15 00:00:00', '2024-09-11 01:43:54', 'ü§î How can AI reshape the landscape of surgical efficiency and patient care? \n\n- Caresyntax, a Berlin-based startup, has recently secured a substantial $180 million in Series C funding to further develop its AI-driven surgical data platform, bringing total equity funding to $220 million. This includes $80 million in equity and $100 million in debt, aimed at enhancing their technology that integrates with any operating room setup. \n\n- üöÄ With their goal to become the "Android" of surgical platforms, Caresyntax plans to leverage AI to analyze 1,000 data points per surgery. This capability not only supports surgeons in enhancing patient outcomes but also helps identify risks in real-time, such as unrecognized drops in heart rate during operations. \n\n- The platform streamlines workflows, informs post-operative care, and addresses the significant costs associated with surgeries, which account for 30% of healthcare expenditures in Europe alone. As healthcare systems face increasing pressures from aging populations and staffing shortages, innovations like this can allow for more effective resource management. \n\n- With the tech currently utilized in over 3,000 operating rooms and more than 3 million surgeries each year, Caresyntax‚Äôs expansion into the US and EMEA markets could redefine operational efficiency in surgery. \n\nAs we see these advancements, what implications might this have for surgical practice and patient safety?? \n\nFor further details, read more here: https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/', ['HealthTech & Startups', 'HealthTech', 'Surgery', 'AIInHealthcare', 'ClinicalTrials', 'HealthcareInnovation'], 'https://images.pexels.com/photos/27307692/pexels-photo-27307692.jpeg', 'https://sifted.eu/articles/caresyntax-surgery-tech-raise-news/', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'Berlin-based Caresyntax, which is building an AI-driven data platform for surgery, has raised a $180m Series C extension.\n\nThe round is made up of $80m in equity and $100m in debt ‚Äî and is tied to specific milestones. The fresh funding tops up the startup‚Äôs $130m Series C, raised across two rounds in 2021, and takes its total equity funding to $220m.\n\nIt‚Äôs the latest in a string of big money raises for European startups developing tech for hospital operating theatres as healthcare systems across the globe scramble to increase efficiency amid staff shortages and the rising costs of treating ageing populations.\n\nCaresyntax will use the funds to scale customer adoption in the US and EMEA region, develop AI applications and finance M&A opportunities.\n\n### AI for hospitals\n\nCaresyntax says it wants to build the ‚ÄúAndroid‚Äù platform for surgery. Its tech uses AI algorithms to make sense of data collected before, during and after an operation to help surgeons improve patient outcomes, spot risks during procedures and reduce hospitals‚Äô surgery costs by improving efficiency and reducing readmissions.\n\nThe company‚Äôs platform can pick up on warning signs like drops in heart rate that surgeons might not be aware of during a procedure, for example. It can also streamline operative workflows, inform post-treatment care pathways post-operation and collect 1,000 data points per surgical case.\n\nWhile some surgical robotics solutions in the market only work with certain products, Caresyntax‚Äôs platform can plug into any operating room technology to pull together data, according to a company spokesperson.\n\n‚ÄúEffectively using AI in the operating room requires input from a wide variety of data sources, but today this data exists in silos where it is difficult for clinicians to access and operationalise,‚Äù they add.\n\nIf it does what it sets out to do, it‚Äôs a big opportunity.\n\nCosts associated with operations account for 30% of healthcare expenditure, a huge sum given that Europe spends 11% of GDP on health.\n\nFounded in 2013 in Germany ‚Äî Caresyntax also expanded to San Francisco in 2019 ‚Äî its data platform is currently used in 3k operating rooms globally, in more than 3m surgeries annually, according to the company. 40% of the company‚Äôs revenue comes from the Americas and 60% from the EMEA region.\n\n### The rise of smart surgery\n\nThe round comes on the back of a strong 18 months for startups developing tech for the operating theatre.\n\nSince the start of 2023, three of the four biggest medtech raises have all gone to startups building robots to help surgeons. The UK‚Äôs CMR Surgical picked up ¬£165m in September last year, Switzerland‚Äôs DistalMotion $150m in April 2023 and Italy‚Äôs Medical Microinstruments $110m in February this year.\n\nInvestors in Caresyntax‚Äôs round include Symbiotic Capital, MTIP AG, BIONIQ Capital, PFM Health Sciences, Pictet Alternative Advisors, surgical.ai, BlackRock Innovation Capital, Aescuvest, Optum Ventures, Cure Capital, Relyens Group, Vesalius Biocapital, Lauxera Capital, Plug & Play Growth Fund and ProAssurance Corp.', 'gpt-4o-mini']
2024-09-11 01:47:47,523 - INFO - Logged data to databases/llm.csv with DocumentID: jxULA7QmvS02S0gAkDya.
2024-09-11 01:47:47,523 - INFO - 'generated_post' length: 9. Content: ['2024-08-13 00:00:00', '2024-09-11 01:44:14', "ü§î Have you noticed the buzz around GLP-1 medications for weight loss? This class of drugs is changing the landscape not just for obesity treatment, but also for healthcare startups navigating a growing market.\n\n- GLP-1s, including popular drugs like Ozempic and Wegovy from Novo Nordisk, have seen skyrocketing valuations, with projections suggesting they could generate a staggering $150 billion in sales by the early 2030s.\n- Startup founders are quickly recognizing the potential of these medications. For instance, Oviva, a Swiss weight loss management platform, has begun incorporating GLP-1s into their treatment regimens this year, noting double-digit growth in revenue and patient numbers.\n- The excitement isn‚Äôt limited to established firms; new entrants are pivoting their business models to focus on GLP-1s, showcasing a remarkable shift in treatment paradigms for obesity.\n- Despite the strong interest, challenges remain. With supply chain issues and reimbursement hurdles from national healthcare systems, particularly in Europe, startups may struggle to scale effectively.\n- It's essential for these companies to secure reimbursement from public health systems to ensure broader access and sustainable growth. For example, while Wegovy is available through NHS clinics, it‚Äôs currently restrictive and not widely accessible.\n\nAs we assess the implications of this groundbreaking class of drugs on healthcare economics and treatment protocols, how do you think we can better facilitate access for patients seeking effective weight loss solutions?  \n\nFor deeper insights on this evolving landscape, check out the full article here: https://sifted.eu/articles/startups-wegovy-ozempic-shift/  \n\n#HealthTech #HealthcareInnovation #MarketTrends", ['HealthTech & Startups', 'HealthTech', 'HealthcareInnovation', 'MarketTrends'], 'https://images.pexels.com/photos/7659461/pexels-photo-7659461.jpeg', 'https://sifted.eu/articles/startups-wegovy-ozempic-shift/', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', "The meteoric rise of a new class of weight loss drugs over the past two years, known as GLP-1s, has seen a new name take the title of Europe‚Äôs most valuable company, helped a country dodge a recession and hit grocery sales in the US.\n\nThe valuations of the companies that make this so-called ‚Äúmiracle‚Äù class of drugs ‚Äî which includes Danish pharma giant Novo Nordisk (maker of Ozempic and Wegovy) and US rival Eli Lilly (maker of Mounjaro and Zepbound) ‚Äî have soared as investors bet big on a medication projected by some to hit $150bn in sales by the early 2030s.\n\nThe potential of the market has not been lost on founders.\n\nIt‚Äôs a ‚Äúhuge‚Äù opportunity, says Kai Eberhardt, the founder and CEO of Oviva, a Swiss weight loss management platform which operates in the UK, France and Germany, alongside its home market. It began offering GLP-1 drugs as part of its treatment options in the second quarter of this year.\n\n‚ÄúFor us [GLP-1 drugs] are already a strong growth driver,‚Äù he says. ‚ÄúThe newer GLP-1 class of medications have created real excitement due to their impressive outcomes in weight loss, transforming the treatment options available for those living with obesity.‚Äù\n\nWhile treatment involving GLP-1 drugs is currently a small part of Oviva‚Äôs overall business ‚Äî Eberhardt says it‚Äôs growing total patient and revenue numbers by ‚Äúdouble digit‚Äù percentage points year-on-year ‚Äî the meds could become the startup‚Äôs ‚Äúlargest‚Äù growth driver in the future, he tells Sifted.\n\n### Riding the wave\n\nOviva‚Äôs not alone. There are a slew of startups in Europe looking to tap into the opportunity ‚Äî many of which have recently shifted operations to focus on selling GLP-1 drugs or provide treatment pathways around the medication, which was first designed to treat diabetes but was later found to be effective at suppressing appetite and helping people lose weight.\n\nIn the last two years GLP-1s have become a go-to weight loss solution popularised by a roster of celebrity users. According to Walmart‚Äôs CEO, food sales have fallen as the one in eight adults in the US who have used the meds slim down their buying habits. The drug class has also seen Novo Nordisk overtake luxury fashion brand LVMH as Europe‚Äôs most valuable company, propping up Denmark‚Äôs GDP in the process.\n\nAll of the attention has got VCs excited, and companies on both sides of the Atlantic have convinced them to get out their chequebook: Danish startup Embla, which prescribes GLP-1 meds alongside ongoing clinical care and lifestyle advice for patients looking to lose weight in its home market and the UK, picked up a ‚Ç¨10m Series A in August 2023 a year on from a ‚Ç¨3.5m seed round. Swedish startup Yazen, which says it too prescribes GLP-1 drugs in combination with clinical care, also raised ‚Ç¨3.1m last summer.\n\nMany startups operating in the GLP-1 space didn‚Äôt start life offering them ‚Äî largely due to launching before the drugs were popularised for weight loss. Ozempic was approved for sale in the US in 2017 and Europe in 2018; Wegovy was approved in the US in 2021 and Europe in 2022.\n\nUK-based Numan, a digital medication and supplements provider founded in 2016, started by selling sexual health treatments; it began prescribing weight loss drugs in 2022. For years the company marketed itself as a ‚Äúmen‚Äôs health‚Äù brand, but has recently changed that. The company‚Äôs website uses images of men and women on its landing page for weight-loss treatments.\n\nYazen, which launched its weight loss service in 2022, initially set out to exclusively target obese men, but broadened its focus before launching to include obesity more generally, after seeing how effective GLP-1 drugs were, says CEO Fredrik Meurling.\n\nMeurling tells Sifted it had hit ‚Ç¨14m annual recurring revenue and treated 15k patients by June this year. It‚Äôs now active in Sweden, Norway, The Netherlands and Spain, and has pilot projects in England and Germany.\n\nOther startups like UK-based Manual, which like Numan started out offering men‚Äôs sexual health treatments, also started prescribing weight loss medications in 2022.\n\n‚Äú[GLP-1 meds] are a game changer,‚Äù says Michael Treskow, partner at Eight Roads Ventures, adding it would be ‚Äústrange‚Äù if a startup working in the weight loss space wasn‚Äôt looking into how they could add the drugs into their offering.\n\nWhile GLP-1 meds have been part of some treatment courses at Embla since it launched in 2021, the ‚Äúhype‚Äù surrounding the drug class has ‚Äúopened doors‚Äù for the startup, says co-CEO and cofounder Nicholas Syhler ‚Äî adding that the startup managed to raise its ‚Ç¨400k pre-seed round in 2021 just three weeks after incorporation. It‚Äôs now gearing up for a fundraise in 2025 and expanding to the US, where it‚Äôll look to target US employers ‚Äî who pay for the majority of healthcare in the country.\n\n### Kinks in the supply chain\n\nThere are still big questions hanging over European startups in the sector ‚Äî not least around whether a European GLP-1 startup can raise the kinds of funds needed to hit real scale.\n\nSome of the biggest rounds for startups vending GLP-1 drugs have been in the US, including Calibrate‚Äôs $100m in 2021 and Form Health‚Äôs $38m in June this year. In Europe, no company selling the drug or treatment pathways around it has raised more than ‚Ç¨10m in a single round.\n\nInvestors and founders tell Sifted supply chain issues are part of that problem. Manufacturers have struggled to keep up with demand for the drug, and last year, startups in the UK were told by the government to remove Ozempic from sale due to shortages of the drug for diabetics ‚Äî Manual was still selling past the deadline.\n\nIf a startup's revenues are closely tied to the availability of those drugs, they could be at the mercy of manufacturing capability. But as pharma bolsters production capabilities those issues could diminish, says Christoph Ruedig, partner at Albion VC.\n\n‚ÄúAs there are severe shortages of GLP-1 drugs in Europe (Eli Lilly and Novo Nordisk are prioritising the US as pricing is higher) the opportunity to date in Europe has been limited but growing.‚Äù\n\n### Who‚Äôll stump up the cash?\n\nThere‚Äôs also a challenge finding the right people to pay, and in Europe, national healthcare providers need to open up to reimbursing startups providing weight loss care, investors say.\n\nWhile Numan‚Äôs head of medical Luke Pratsides says that the ‚Äúsuccess of private sector companies offering GLP-1 [drugs] shows that the public are willing to pay to meet a significant need that is being underserved by the NHS‚Äù, many in the sector think that only serving consumers paying out of their own pocket won‚Äôt be enough to hit real scale.\n\n‚ÄúUS investors have told us that they will only invest in companies that get on enterprise contracts [selling to whole organisations like health insurers],‚Äù says Syhler. ‚ÄúThis means proving that they can deliver high-quality and sustainable care ‚Äî where the economics and outcomes make sense long-term for both patients and payors.‚Äù\n\nIn Europe, where the majority of people have their healthcare paid for by the state, hitting scale will likely come down to whether or not companies can get their services reimbursed by national healthcare providers, say some investors.\n\nIn the UK Wegovy is approved for use to manage obesity in the NHS, but it is currently only available through specialist weight management clinics, limiting availability.\n\nOviva is one the few startups that has had its supply of GLP-1 drugs alongside its weight loss platform reimbursed by the NHS ‚Äî but it had a head start on others, being reimbursed by the organisation long before the rise of weight loss meds, in 2016. Embla co-CEO and cofounder Laust Axelsen tells Sifted that it‚Äôs in ‚Äúmature dialogues with several health systems‚Äù.\n\n‚ÄúIt is still a struggle with reimbursement, in every country,‚Äù says Hekla Arnardottir, partner at Crowberry Capital, which has backed Embla, pointing to difficult regulation and healthcare systems that don‚Äôt always want to work with startups. Without reimbursement in Europe, she adds, it will be hard for companies to reach the sort of revenue figures needed to raise growth capital and hit unicorn status.\n\nWhether a European startup will be able to do that remains to be seen ‚Äî but what is clear is that the hype surrounding GLP-1 meds is unlikely to die down anytime soon. ‚ÄúI've never been an investor in a company that‚Äôs got so much attention ‚Äî in a space that‚Äôs got so much attention,‚Äù says Arnardottir.", 'gpt-4o-mini']
2024-09-11 01:47:47,524 - INFO - Logged data to databases/llm.csv with DocumentID: OfJ8QLEaoTknkhadOIK3.
2024-09-11 01:47:47,524 - INFO - 'generated_post' length: 9. Content: ['2024-09-10 09:00:00', '2024-09-11 01:44:29', 'üë©\u200d‚öïÔ∏è Did you know that mastitis in older women could signal a heightened risk of breast cancer?  \n\n- A comprehensive study involving over 2.3 million women in Germany has spotlighted an intriguing link between mastitis and breast cancer, particularly in those aged 50 and above.  \n- Amongst the cohort of women with mastitis (approximately 14,892), 2.9% were diagnosed with breast cancer compared to 2.4% in the matched control group without mastitis. üìä  \n- Notably, the risk escalated for women over 50, who exhibited a remarkable 73% increase in breast cancer likelihood (hazard ratio 1.73). In contrast, there was no significant risk found for younger women (‚â§50 years).  \n- These findings beckon us as healthcare professionals to rethink our vigilance in monitoring breast health in patients with a history of mastitis, particularly for those in older demographics.  \n\nAs we process this data, how should our approach to patient consultations evolve regarding mastitis, especially in women over 50? ü§î  \n\nFor further insights, read the full study here: http://medscape.co.uk/viewarticle/mastitis-older-women-linked-subsequent-breast-cancer-2024a1000g68', ['Research & Clinical Trials', 'Oncology', 'PublicHealth', 'Geriatrics', 'PatientSafety', 'ClinicalTrials'], 'https://images.pexels.com/photos/5412315/pexels-photo-5412315.jpeg', 'http://medscape.co.uk/viewarticle/mastitis-older-women-linked-subsequent-breast-cancer-2024a1000g68', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'Mastitis in Older Women Linked to Subsequent Breast Cancer\n===============\n\nThis site is intended for UK healthcare professionals\n\nTOPLINE:\n--------\n\nMastitis in women over 50 years of age is a risk factor for development of breast cancer, according to a large retrospective cohort study of 2.4 million German women. Mastitis is an inflammation of breast tissue typically caused by a Staph infection.\n\nMETHODOLOGY:\n------------\n\n*   This study was a retrospective cohort of 2,381,594 women in 315 office-based gynaecology practices in Germany (2005-2021).\n*   Women with mastitis (n = 14,892) were compared with women without mastitis (n = 14,892) and followed from 7 months to 10 years.\n*   The control group without mastitis was propensity score-matched on age, index year, average yearly consultation frequency during the follow-up period, and coexisting conditions.\n*   The primary outcome was an initial diagnosis of breast cancer.\n\nTAKEAWAY:\n---------\n\n*   Over the follow-up period, 2.9% of the mastitis cohort and 2.4% of the matched non-mastitis cohort developed breast cancer.\n*   While Cox regression analysis uncovered a significant association between mastitis and breast cancer (hazard ratio, 1.37; 95% CI, 1.11-1.70), the age-stratified analysis revealed a significant association only among women aged > 50 years. They had a 73% increase in the risk compared with women without mastitis (hazard ratio, 1.73; 95% CI, 1.25-2.40).\n*   Women aged ‚â§ 50 years had no significant increase in the risk for breast cancer.\n\nIN PRACTICE:\n------------\n\nThe authors concluded that "The findings of our retrospective cohort study support an association between mastitis and subsequent breast cancer diagnoses in women aged > 50 years. The pathophysiological basis and possibility of confounders however requires further investigation."\n\nSOURCE:\n-------\n\nThe corresponding author is Karel Kostev, University Hospital Marburg, Philipps-University, Marburg, Germany. The study appeared in _Cancer Causes & Control_.\n\nLIMITATIONS:\n------------\n\nLimitations included a retrospective observational design and possibility of unmeasured confounding factors.\n\nDISCLOSURES:\n------------\n\nThe authors reported no conflicts of interest. The study received no funding.', 'gpt-4o-mini']
2024-09-11 01:47:47,525 - INFO - Logged data to databases/llm.csv with DocumentID: 9uoP8HRQLP9zYlEiv56b.
2024-09-11 01:47:47,525 - INFO - 'generated_post' length: 9. Content: ['2024-09-09 18:00:00', '2024-09-11 01:44:44', 'Did you know that abnormal heart rate fluctuations can signal increased mortality risk in patients with diabetes? üíî \n\n- A recent study involving 349 patients highlights the significance of circadian heart rate (HR) patterns. Researchers noted a strong correlation between impaired HR variability and both cardiovascular and all-cause mortality, particularly in those with long-standing diabetes. \n\n- Key findings revealed that patients with low 24-hour heart rate standard deviation (SD) had nearly double the risk (hazard ratio: 1.99) of cardiovascular mortality and a 50% increase (hazard ratio: 1.50) in all-cause mortality compared to those with higher variability. \n\n- Further emphasizing this, the presence of a blunted nocturnal heart rate dip was linked to a 39% greater risk in both categories of mortality, suggesting that regular monitoring of heart rate is essential.  \n\nWith these findings, the potential for 24-hour ambulatory blood pressure monitoring (ABPM) as a practical risk stratification tool emerges for this vulnerable population. \n\nAre we doing enough to monitor circadian HR trends in our diabetic patients? ü©∫  \n\nFor more insights, explore the detailed study presentation here: http://medscape.com/viewarticle/abnormal-heart-rate-shifts-tied-risk-death-diabetes-2024a1000g8n', ['Research & Clinical Trials', 'DigitalHealth', 'Cardiology', 'DigitalHealth', 'PrimaryCare', 'PatientSafety'], 'https://images.pexels.com/photos/6823491/pexels-photo-6823491.jpeg', 'http://medscape.com/viewarticle/abnormal-heart-rate-shifts-tied-risk-death-diabetes-2024a1000g8n', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'Abnormal Heart Rate Shifts Tied to Risk for Death in Diabetes\n=============================================================\n\nMarilynn Larkin\n\nSeptember 09, 2024\n\n**TOPLINE:**\n------------\n\nMADRID ‚Äî Impaired circadian heart rate (HR) fluctuations are linked to increased cardiovascular and all-cause mortality in patients with long-standing diabetes.\n\n**METHODOLOGY:**\n----------------\n\n*   Researchers analyzed data from 349 patients with type 2 (81%) or type 1 diabetes; about half were women, with a mean age of 57 years, body mass index (BMI) of 29.4, and A1c of 8.6%.\n*   Participants underwent 24-hour ambulatory blood pressure monitoring (APBM) and HR monitoring, as well as assessment of diabetic microvascular complications.\n*   The median SD value of ABPM-derived HR measurements was used to define patients with low daily HR fluctuations (low 24h-HR SD); a < 10% decline in average nighttime vs daytime HR identified patients (31%) with a blunted nocturnal HR dip.\n\n**TAKEAWAY:**\n-------------\n\n*   Low 24h-HR SD and blunted nocturnal HR dip were associated with an adverse cardiometabolic risk profile and a high prevalence of cardiac autonomic neuropathy and nephropathy.\n*   After a mean 21 years of follow-up, 136 (39%) deaths occurred, of which 100 (68%) had a cardiovascular cause.\n*   After adjustment for potential confounders ‚Äî including age, sex, BMI, glycemic control, diabetes type, and hypertension ‚Äî the low 24h-HR SD group had double the risk (hazard ratio [HR], 1.99) for cardiovascular mortality and a 50% higher risk (HR, 1.50) for all-cause mortality than the high 24h-HR SD group.\n*   Patients with a blunted nocturnal HR dip consistently had a 39% higher adjusted risk for cardiovascular and all-cause mortality (HR, 1.61 for both) than those with a preserved nocturnal HR dip.\n\n**IN PRACTICE:**\n----------------\n\nImpaired circadian HR fluctuations are associated with microvascular disease and increased long-term cardiovascular and all-cause mortality in patients with diabetes, the authors wrote. "Identifying these conditions via 24h-ABPM may provide a cost-effective risk stratification tool in this high-risk population."\n\n**SOURCE:**\n-----------\n\nThe study was presented by lead author Lorenzo Nesti, PhD, of the University of Pisa, Pisa, Italy, in a poster presentation 983 at the European Association for the Study of Diabetes (EASD) 2024 Annual Meeting in Madrid, Spain.\n\n**LIMITATIONS:**\n----------------\n\nThe CHAMPION study is a retrospective, observational, single-center study with mostly White patients.\n\n**DISCLOSURES:**\n----------------\n\nNesti disclosed no conflicts of interest.\n\n0\n\nCredit  \n\nLead image: Supparsorn Wantarnagon/Dreamstime\n\nMedscape Medical News ¬© 2024 WebMD, LLC  \nSend comments and news tips to news@medscape.net.\n\nCite this: Abnormal Heart Rate Shifts Tied to Risk for Death in Diabetes - Medscape - September 09, 2024.', 'gpt-4o-mini']
2024-09-11 01:47:47,526 - INFO - Logged data to databases/llm.csv with DocumentID: 94CGnEYGGMHII3MG2yHP.
2024-09-11 01:47:47,526 - INFO - 'generated_post' length: 9. Content: ['2024-09-09 09:00:00', '2024-09-11 01:46:31', 'üåü Could artificial intelligence be the key to optimizing breast cancer screenings? A recent study evaluated the cost-effectiveness of AI-guided, risk-stratified mammography screening in the UK National Breast Cancer Screening Program. Here‚Äôs what you should know:\n\n- A decision analytical model assessed 4 AI-based screening intervals, producing estimated net benefits ranging from ¬£60.4 million ($77.3 million) to ¬£85.3 million ($109.2 million) if implemented.\n- These AI programs demonstrated greater cost-effectiveness than the current universal screening approach, yielding more health benefits while utilizing fewer resources.\n- Risk stratification could allow women to be screened every 6 years (for low risk), biannually (for average risk), and annually (for high risk), enhancing screening frequency in those who need it most.\n- Notably, the analysis suggests that even minimal allocation of resources for screening could generate substantial benefits‚Äîaround ¬£10.6 million ($13.6 million) annually, highlighting the strong economic potential of AI in this field.\n\nAs we consider integrating AI into routine practice, it raises a crucial question: How can we balance cost savings with the goal of highest-risk individuals receiving optimal care? ü§î \n\nFor a deeper dive, check out the full study here: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.31715?guestAccessKey=5fccf768-e956-418c-863e-a26f2d537653&utmsource=forthemedia&utmmedium=referral&utmcampaign=ftmlinks&utmcontent=tfl&utmterm=090524', ['Research & Clinical Trials', 'HealthcareInnovation', 'AIInHealthcare', 'Oncology', 'PopulationHealth'], 'https://images.pexels.com/photos/5701081/pexels-photo-5701081.jpeg', 'https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.31715?guestAccessKey=5fccf768-e956-418c-863e-a26f2d537653&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090524', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'Cost-Effectiveness of AI for Risk-Stratified Breast Cancer Screening\n\nKey Points\n\n**Question** What is the cost-effectiveness of artificial intelligence (AI)‚Äìguided risk-stratified mammography screening intervals in the United Kingdom National Breast Cancer Screening Program?\n\n**Findings** This decision analytical model evaluated 4 AI-based risk-stratified screening interval regimens in comparison with the current United Kingdom screening program. The net monetary benefit of introducing the optimal regimen ranged from approximately ¬£60.4 million (US $77.3 million) to ¬£85.3 million (US $109.2 million).\n\n**Meaning** These results suggest that AI-based risk stratified breast cancer screening programs may be more cost-effective screening programs, providing additional health benefits with fewer resources than universal screening intervals for all.\n\n**Importance** Previous research has shown good discrimination of short-term risk using an artificial intelligence (AI) risk prediction model (Mirai). However, no studies have been undertaken to evaluate whether this might translate into economic gains.\n\n**Objective** To assess the cost-effectiveness of incorporating risk-stratified screening using a breast cancer AI model into the United Kingdom (UK) National Breast Cancer Screening Program.\n\n**Design, Setting, and Participants** This study, conducted from January 1, 2023, to January 31, 2024, involved the development of a decision analytical model to estimate health-related quality of life, cancer survival rates, and costs over the lifetime of the female population eligible for screening. The analysis took a UK payer perspective, and the simulated cohort consisted of women aged 50 to 70 years at screening.\n\n**Exposures** Mammography screening at 1 to 6 yearly screening intervals based on breast cancer risk and standard care (screening every 3 years).\n\n**Main Outcomes and Measures** Incremental net monetary benefit based on quality-adjusted life-years (QALYs) and National Health Service (NHS) costs (given in pounds sterling; to convert to US dollars, multiply by 1.28).\n\n**Results** Artificial intelligence‚Äìbased risk-stratified programs were estimated to be cost-saving and increase QALYs compared with the current screening program. A screening schedule of every 6 years for lowest-risk individuals, biannually and triennially for those below and above average risk, respectively, and annually for those at highest risk was estimated to give yearly net monetary benefits within the NHS of approximately ¬£60.4 (US $77.3) million and ¬£85.3 (US $109.2) million, with QALY values set at ¬£20\u202f000 (US $25\u202f600) and ¬£30\u202f000 (US $38\u202f400), respectively. Even in scenarios where decision-makers hesitate to allocate additional NHS resources toward screening, implementing the proposed strategies at a QALY value of ¬£1 (US $1.28) was estimated to generate a yearly monetary benefit of approximately ¬£10.6 (US $13.6) million.\n\n**Conclusions and Relevance** In this decision analytical model study of integrating risk-stratified screening with a breast cancer AI model into the UK National Breast Cancer Screening Program, risk-stratified screening was likely to be cost-effective, yielding added health benefits at reduced costs. These results are particularly relevant for health care settings where resources are under pressure. New studies to prospectively evaluate AI-guided screening appear warranted.\n\nEarly detection of breast cancer is a top priority for the United Kingdom (UK) National Health Service (NHS). The NHS largely uses an age-based screening strategy, inviting women aged 50 to 70 years for mammography screening triennially; most other countries with a breast screening program adopt a biennial program. This one-size-fits-all approach might be improved by tailoring screening so that those at highest risk receive the greatest intensity of screening (risk-based screening).\n\nThe NHS is considering the integration of artificial intelligence (AI) and machine learning into mammogram interpretation for breast screening in the future. AI is currently not used in NHS breast screening appointments in the UK due to a lack of high-quality prospective studies, but emerging prospective data are promising.\n\nIn parallel with AI for cancer detection, AI for risk prediction has been proposed. One such model (Mirai) interprets data automatically generated from mammogram screenings, without the need for data collection through questionnaires. The AI model offers an immediate estimation of an individual‚Äôs short-term risk of cancer incidence following a mammogram with negative findings. The AI model is open source and freely available for research and is arguably the best (retrospectively) validated AI model for short-term breast cancer risk assessment. One analysis included an external validation across 7 hospitals spanning 3 continents, and overall, evidence suggests that in the short term, it attains a higher area under the receiving operating characteristics curve than classical risk models or breast density.\n\nWhile the performance of the AI model for risk assessment is highly promising, one area that has not been rigorously evaluated is whether using the model to guide screening could offer value for money. Our aim was therefore to assess the potential cost-effectiveness of integrating risk-stratified screening using the model into the UK National Breast Cancer Screening Program, through a health economic model. We considered risk-based screening strategies that would be expected to require the same number of screens as the current triennial program, assuming perfect adherence. In practice, strategies that involve extended screening intervals for a larger proportion of the population than those who receive more frequent screening might require fewer screens overall.\n\nSpecific risk-stratified breast cancer screening regimens (RSBCRs), determined by risk thresholds, were based on recent work that used a simplified deterministic model to evaluate potential effectiveness. These RSBCRs involve screening intervals aligned with corresponding risk thresholds tailored for the AI model chosen for this research. In this report, we developed an economic model to assess the cost-effectiveness of 4 AI-based screening strategies in comparison with the current screening program. The economic model was then used to estimate health-related quality of life, survival, and NHS costs over the lifetime of the female population eligible for screening in the UK. Results from our analysis might inform future prospective evaluations of AI-guided screening.\n\nThis study was conducted from January 1, 2023, to January 31, 2024. We followed the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) reporting guideline and the National Institute for Health and Care Excellence methods of technology appraisal manual. We developed a discrete event simulation model in R, version 4.2.2, using the simmer‚Äô package (R Project for Statistical Computing) to accommodate individual attributes that evolve over time within the simulation such as breast cancer risk. The work was funded by Cancer Research UK and the policy research unit in Economic Evaluation of Health and Care Interventions. Because the data are drawn from publicly available sources, ethics approval is not required for decision modeling in the UK.\n\nThe following 4 strategies were distinguished by screening intervals in years for groups categorized by a 3-year risk score (RS):\n\n1. One year (RS, ‚â•2.57%), 2 years (RS, 1.32%-2.57%), 3 years (RS, 1.22%-1.32%), or 6 years (RS, ‚â§1.22%)\n2. One year (RS, ‚â•2.72%), 3 years (RS, 1.23%-2.72%), or 6 years (RS, ‚â§1.23%)\n3. Two years (RS, ‚â•2.79%), 3 years (RS, 1.35%-2.79%), or 6 years (RS, ‚â§1.35%)\n4. One year (RS, ‚â•2.20%), 3 years (RS, 1.23%-2.20%), or 4 years (RS, ‚â§1.23%).\n\nThe model focused on 5 dynamic processes: (1) Women transition between risk groups based on screen attendance and AI-model‚Äìassessed risk scores. (2) Mammogram accuracy is based on breast density, which changes as women age. (3) Attendance patterns to screening appointments are influenced by age and attendance history. (4) Attendance history and time intervals between screenings impact cancer stage. (5) Cancer prognosis is influenced by age, where it was identified (at regular screening or not), and attendance history, with worse outcomes for women who have not attended breast screenings.\n\nStructure and Model Events\n\n[Figure 1](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.31715?guestAccessKey=5fccf768-e956-418c-863e-a26f2d537653#zoi240951f1) depicts the model structure, illustrating the sequence of clinical events and potential pathways from initiation to screening, cancer detection, and mortality. Women enter the model at the first screening invitation at 50 years of age, with subsequent invitations occurring at regular intervals until 70 years of age. Each screening appointment includes an updated AI risk assessment, determining the timing of the next screen invitation. If a woman misses her initial screening, invitations are sent every 3 years thereafter. The model ends when individuals reach cancer-related mortality or mortality from all other causes.\n\nAt entry, women are assigned predetermined ages of noncancer mortality and have a chance of developing breast cancer up to 74 years of age, sourced from Office for National Statistics life expectancy tables (2018-2020) and NHS breast cancer registry data. The age at which symptomatic cancer is detected in a primary care setting is sampled from 2020 incidence data, adjusted for age-related lead time in the UK screening program using overdiagnosis estimates. Screening may identify cancer at an earlier age than this determined age of symptomatic cancer. Data on attendance from 2018 to 2019, stratified by age and screening history, were used to calculate attendance probability to a screening invitation. The NHS incurs a cost of ¬£14.52 (US $18.59) for each screening invitation (details of screening costs are in eTable 2 in [Supplement 1](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.31715?guestAccessKey=5fccf768-e956-418c-863e-a26f2d537653#note-ZOI240951-1)). Screening invitations end at 70 years of age or the nearest subsequent year if screening is not scheduled at 70 years of age. For instance, in simulating the current program with screenings every 3 years, a woman attending screening at 68 years of age would receive her last invitation at 71 years of age, after which any developing cancers would be detected symptomatically.\n\nModel Event: Screening Appointment\n\nAttending women undergo a mammogram; if cancer is detected, further assessments are conducted. Breast density and AI model scores are from UK women aged 46 to 74 years and applied based on age and cancer presence. Details are available in eMethods 1 in [Supplement 1](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.31715?guestAccessKey=5fccf768-e956-418c-863e-a26f2d537653#note-ZOI240951-1).\n\nIn the model, a woman‚Äôs age for potential tumor detection is set before her first screening and remains constant throughout her life. Screening detection ages are calculated by subtracting the tumor presence period from the age at which symptomatic cancer is detected. The tumor presence period is derived from national breast screening program data and is based on age, with mean durations ranging from approximately 6 years at 35 years of age to 8 years at 85 years of age.\n\nEach mammography session has a cost of ¬£54.32 (US $69.53) and results in a quality-adjusted life-year (QALY) loss of 0.0014 due to associated discomfort. A summary table of the diagnostic accuracy of mammography is presented in eTable 1 in [Supplement 1](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.31715?guestAccessKey=5fccf768-e956-418c-863e-a26f2d537653#note-ZOI240951-1). Sensitivity estimates are sourced from recent estimates in a population-based screening program and vary based on breast density, ranging from 62% (dense) to 90% (not dense). False-positive results occur when no underlying tumor is present during a screening, with chances ranging from 1.5% (not dense) to 2.9% (dense), and they cause a QALY loss of 0.0771. Mammographic results indicating cancer leads to further assessments, which verify whether the cancer is present, and involve mammography, ultrasonography, and biopsy totaling ¬£484.90 (US $620.67). Detailed breakdowns of mammography‚Äôs diagnostic accuracy, screening and further assessment costs, and screen-related QALY losses are found in eTables 2 and 3 in [Supplement 1](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.31715?guestAccessKey=5fccf768-e956-418c-863e-a26f2d537653#note-ZOI240951-1).\n\nModel Event: Interval Between Screening Appointments\n\nBetween screening appointments, cancers are detected immediately in primary care on reaching the age of symptomatic detection, with the primary care appointment costing ¬£37.00 (US $47.36), and further assessment totaling ¬£484.90 (US $620.67) NHS cost. Mortality due to other causes than breast cancer can occur and aging results in a health utility loss based on a published formula.\n\nModel Event: Cancer Treatment and Survival\n\nAfter cancer detection, cancer is classified as ductal carcinoma in situ (DCIS) or invasive tumor TNM stages I to IV, determined by age and mode of detection (at a screening appointment or symptomatically in primary care) using UK population screening data. The stage distribution is adjusted based on the time since the last screen, using US data comparing stage distribution by screening frequency. Detailed methodology and sources can be found in Hill et al.\n\nTreatment-related health losses and NHS costs vary by age, stage, mode of detection (screen or symptomatic), and time since detection (for follow-up costs and health recovery). Health utility losses after cancer are taken from multivariate regression, using the utility decrements on age, stage, and mode of detection. Recovery times are 11 years for screen-detected and interval cancers and 12 years for symptomatic cancers, based on peak health-related quality of life values post cancer detection. Stage 4 cancers are assumed to show no improvement in quality of life.\n\nCancer survival estimates come from Office for National Statistics mortality statistics and multivariable regressions. Mortality hazard ratios by stage and detection mode are applied to age-based mortality to determine life expectancy. Cancer treatment-related utility losses, costs, and survival estimates are available in eTables 4 to 6 in [Supplement 1](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.31715?guestAccessKey=5fccf768-e956-418c-863e-a26f2d537653#note-ZOI240951-1).\n\nEconomic and Clinical Outcomes\n\nCosts were assessed from a UK payer perspective and reported in 2022 pounds sterling. Quality-adjusted life-years and costs were discounted at 3.5%. The main economic outcome is incremental net monetary benefit (INMB) per woman, which quantifies in monetary terms the net benefit of interventions by reflecting the potential alternative use of intervention resources for other health care treatments. Incremental net monetary benefit is established from differences in patient costs, and from assigning a monetary value to the difference in QALYs, which we assume to be ¬£20 000 (US $25 600), ¬£30 000 (US $38 400), and ¬£1 (US $1.28) per QALY. The latter represents a scenario where a decision-maker is reluctant to spend additional NHS resources to increase population health. Population-wide INMB is derived by multiplying the per-woman INMB by the population size of women at 50 years of age eligible for screening invitations, which is 174\u202f523, sourced from the 2022 national breast screening program data. Clinical outcomes include tumor stage at detection, cancers detected during screening, breast cancer deaths prevented by RSBCRs in the population (174\u202f523 women), and the number of screens conducted.\n\nAll analyses were performed using R, version 4.2.2 (R Program for Statistical Computing). We conducted external validation of the model against targets derived from the 2022 national breast screening program data. To identify where savings occur, cost results are divided into screening-related costs and those for treating DCIS and invasive cancers. Cancer treatment costs are broken down by stage (DCIS, stages I-II, and stages III-IV) and mode of detection (screen-detected and interval cancers). Deterministic sensitivity analysis is conducted by adjusting the cancer treatment and screening costs, health-related quality of life losses from cancer and screening, and mammography sensitivity. Probabilistic sensitivity analysis is performed using 250 Monte Carlo simulations using probabilistic sensitivity analysis parameter distributions reported in eTable 8 in [Supplement 1](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.31715?guestAccessKey=5fccf768-e956-418c-863e-a26f2d537653#note-ZOI240951-1). The probability that each RSBCR is cost-effective is illustrated on a cost-effectiveness acceptability curve. Population-wide INMB estimates from the 250 Monte Carlo simulations are calculated across cost per QALY values ranging from ¬£1 (US $1.28) to ¬£100 000 (US $128 000).\n\n[Table 1](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.31715?guestAccessKey=5fccf768-e956-418c-863e-a26f2d537653#zoi240951t1) shows base-case economic results and the annual impact of the economic results in the entire population. All the AI-based regimens were associated with reduced NHS costs and increased QALYs compared with the current screening program. The strategy of conducting screening every 6 years for low risk, every 2 to 3 years for medium risk, and annually for high risk had the highest additional net monetary gain per woman invited for screening. This amounts to ¬£346 (US $442.88) and ¬£489 (US $625.92) under the assumption of QALY values being ¬£20\u202f000 (US $25 600) and ¬£30 000 (US $38 400), respectively. Consequently, this leads to an annual net monetary benefit within the NHS screening program totaling ¬£10.6 million (US $13.6 million) for QALY values of ¬£1, ¬£60.4 million (US $77.3 million) for QALY values of ¬£20 000, and ¬£85.3 million (US $109.2 million) for QALY values of ¬£30 000. The 3 alternative approaches had comparable figures for the net monetary benefit gained. For instance, the screening strategy of 6 yearly, triannual, and biannual screening has the smallest incremental net monetary benefit, amounting to ¬£188 (US $240.64) and ¬£236 (US $302.08) per person, assuming QALY values of ¬£20 000 and ¬£30 000, respectively. This resulted in an annual population incremental net benefit of ¬£32.7 million (US $41.9 million), assuming ¬£20 000 per QALY and ¬£41.2 million (US $52.7 million), assuming ¬£30 000 per QALY.\n\n[Table 2](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.31715?guestAccessKey=5fccf768-e956-418c-863e-a26f2d537653#zoi240951t2) shows the clinical and screening program results. The clinical outcomes of all regimens showed an improvement compared with the current screening program. Compared with the current screening program, conducting screening every 6 years for low risk, every 2 to 3 years for medium risk, and annually for high risk resulted in a higher number of screen-detected cancers (10\u202f549 vs 8943), a greater percentage of DCIS cancers at detection (17.1% vs 13.6%), a reduction in the number of screens (mean [SD], 3.22 [0.02] vs 4.68 [0.05]), and prevention of 834 deaths due to breast cancer.\n\nDeterministic Sensitivity Analysis Results\n\nThe deterministic sensitivity analysis results align with the cost-effectiveness of screening regimens found in the base-case model. Screening every 6 years for low risk, every 2 to 3 years for medium risk, and annually for high risk was likely to be most beneficial. Risk-stratified breast cancer screening regimens maintained their cost-effectiveness compared with the current program and each other. The breakdown of NHS costs incurred by women shows screening costs are lower in the RSBCR than in the current program. Cancer treatment costs incurred are larger for RSBCRs due to life extension for patients with cancer from increased screen detection of cancers and early cancer detection.\n\nProbabilistic Sensitivity Analysis Results\n\nThe probabilistic sensitivity analysis results demonstrate an improvement in the cost-effectiveness of screening regimens compared with the base-case model, without a shift in the ranking of programs from most to least cost-effective. The regimen with screening intervals of 1, 2, 3, or 6 years had the highest probability of being cost-effective (59% at ¬£20\u202f000 [US $25 600] per QALY) and had the largest net monetary benefit for all cost per QALY thresholds. The cost-effectiveness acceptability curve shows the regimen of 2, 3, or 6 years was likely to be the least cost-effective alternative option for RSBCRs, and the current screening program has a negligible probability of being cost-effective across all cost per QALY thresholds.\n\nUnder our analytic model, AI-based risk-stratified screening is likely to be cost-effective compared with the current one-size-fits-all screening program. Our findings are consistent with previous modeling studies demonstrating the cost-effectiveness of risk-stratified screening, whether based on traditional risk factors like family history or newer methods such as polygenic risk scores. However, our model is the first to suggest that health care resources might be reduced with RSBCRs, while attaining at least the same effectiveness for the population. This study is also the first to assess the cost-effectiveness of AI interpretation of breast images for risk assessment during routine screening. This might be more feasible at scale than the other risk assessment methods.\n\nWhile the estimated incremental economic benefits per individual invited to breast screening may seem modest in the base-case model, ranging from ¬£188 (US $240.64) to ¬£346 (US $442.88), the annual monetary gains for the NHS might be substantial, estimated to range from ¬£32.7 million (US $ 41.9 million) to ¬£60.4 million (US $77.3 million). In the probabilistic model, these savings are around 3 times larger. The health economic model suggests that RSBCRs can reduce screening utilization, NHS costs, and invasive cancer in the population and increase QALYs. The reduction in the number of screenings with an RSBCR could free up resources to address screening backlogs and reduce wait times where those problems exist in the UK, potentially further improving breast cancer outcomes.\n\nAnnual screening RSBCRs lead to higher percentages of screen-detected cancers and greater percentages of DCIS cancers at detection, along with higher QALYs. However, biennial screening for the highest-risk group, with corresponding 3 and 6 yearly screening for other risk groups, incurs lower costs due to fewer screenings. Screen utilization is not the only explanation of the difference in cost-effectiveness among the regimens. Other contributing factors are the proportion of individuals at medium and high risk within the population undergoing intensified screening surveillance, their uptake to screening appointments, and the accuracy of mammography in women with denser breast tissue that makes cancers harder to detect. Although cost-effectiveness is important, it is not the only factor to consider when comparing the benefits of the regimen. For example, a population accustomed to the UK‚Äôs triennial screening program may view a 6-year gap between screenings as unacceptable, favoring a 4-year interval instead. This change to an RSBCR screening program with a 4-year screening interval for patients at low risk would generate an annual monetary benefit of ¬£50 million (US $64 million), assuming a QALY is valued at ¬£20 000 (US $25 600). Significant variations in screening frequency within programs can be accepted by patients. In the UK, colonoscopy surveillance guidelines for cancer vary by risk level, with no surveillance for patients at low risk, every 3 years for patients at intermediate risk, and annually for patients at high risk.\n\nThis study has some limitations. First, the model is parametrized for the UK. Findings may not be directly generalizable to alternative geographical populations, such as the US or elsewhere in Europe. Clinical guidelines in these regions often recommend universal annual or biennial screening, while a triennial screening program is in place in the UK, and typically screening also begins at earlier ages in these regions. Therefore, the comparator screen detection rates based on triennial screening, on which the model depends, are likely to differ across populations with varied screening frequencies and onset ages. For example, in a setting where annual screening is the norm, all the regimens considered would reduce costs but also effectiveness. Further analysis using the model could usefully contribute to decisions on the economic value of decreasing intensity of screening based on breast cancer AI in such settings.\n\nIn this decision analytical model study of risk-based screening with AI-based risk assessment, risk-based screening delivered health benefits while using fewer NHS resources compared with the current UK breast screening program. New studies to prospectively evaluate AI-guided screening appear warranted.\n\nArticle Information\n\n**Accepted for Publication:** July 10, 2024.\n\n**Published:** September 5, 2024. doi:10.1001/jamanetworkopen.2024.31715\n\n**Open Access:** This is an open access article distributed under the terms of the CC-BY License. ¬© 2024 Hill H et al. _JAMA Network Open_.\n\n**Corresponding Author:** Harry Hill, PhD, School of Medicine and Population Health, Regent Court, University of Sheffield, Sheffield S1 4 DA, United Kingdom (harry.hill@sheffield.ac.uk).\n\n**Author Contributions:** Dr Hill had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.\n\n_Concept and design:_ Hill, Roadevin, Duffy, Brentnall.\n\n_Acquisition, analysis, or interpretation of data:_ All authors.\n\n_Drafting of the manuscript:_ Hill, Roadevin.\n\n_Critical review of the manuscript for important intellectual content:_ Hill, Duffy, Mandrik, Brentnall.\n\n_Statistical analysis:_ All authors.\n\n_Obtained funding:_ Hill, Brentnall.\n\n_Administrative, technical, or material support:_ Hill, Roadevin.\n\n_Supervision:_ Hill, Duffy.\n\n**Conflict of Interest Disclosures:** Dr Brentnall reported receiving royalties from Cancer Research UK arising from commercial use of the Tyrer-Cuzick breast cancer risk evaluation tool (IBIS) outside the submitted work. No other disclosures were reported.\n\n**Funding/Support:** This research was funded by grant 2019DecPR1395 from Breast Cancer Now (Dr Brentnall); grant C49757/A28689 from Cancer Research UK (Dr Brentnall); grant PR-PRU-1217-20401 from the National Institute of Health Research (NIHR) Policy Research Programme, conducted through the Policy Research Unit in Economic Methods of Evaluation in Health and Social Care Interventions (Dr Hill); and grant PR-PRU-1217-21601 from the NIHR Policy Research Programme, conducted through the Policy Research Unit in Cancer Awareness, Screening and Early Diagnosis (Dr Duffy).\n\n**Role of the Funder/Sponsor:** The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.\n\n**Disclaimer:** The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.\n\n**Data Sharing Statement:** See [Supplement 2](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.31715?guestAccessKey=5fccf768-e956-418c-863e-a26f2d537653#note-ZOI240951-1).', 'gpt-4o-mini']
2024-09-11 01:47:47,527 - INFO - Logged data to databases/llm.csv with DocumentID: ej56K9yllI3twdB56MJQ.
2024-09-11 01:47:47,527 - INFO - 'generated_post' length: 9. Content: ['2024-09-09 09:00:00', '2024-09-11 01:46:45', "ü©∫ Are we doing enough to ensure equitable access to cardiac surgery? \n\nA recent study sheds light on a concerning disparity in the UK healthcare system:\n- A retrospective analysis of nearly 300,000 heart disease patients reveals that women, Black individuals, and residents of deprived areas are significantly less likely to receive cardiac surgeries like CABG and valve procedures.\n- üö® Key findings indicate that these demographics have:\n  - 59% (women), 32% (Black patients), and 35% (deprived communities) lower access to CABG.\n  - 24% (women), 85% (Black patients), and 18% (deprived communities) higher likelihood of dying within one year post-CABG.\n\nIn practical terms, this highlights a critical need for targeted healthcare strategies.\n- It's imperative for healthcare providers to regularly analyze data and assess whether their outreach is effectively reaching these underserved populations. \n\nHow can we, as healthcare professionals, contribute to bridging this gap for vulnerable patients? ü§î  \n\nFor further insights, dive into the full study here: http://medscape.co.uk/viewarticle/demographics-linked-worse-access-cardiac-surgery-2024a1000g4z", ['Healthcare & Policy', 'HealthcareInnovation', 'HealthEquity', 'Cardiology'], 'https://images.pexels.com/photos/27469354/pexels-photo-27469354.jpeg', 'http://medscape.co.uk/viewarticle/demographics-linked-worse-access-cardiac-surgery-2024a1000g4z', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'Demographics Linked to Worse Access to Cardiac Surgery\n===============\n\nThis site is intended for UK healthcare professionals\n\nTOPLINE:\n--------\n\nIn the United Kingdom, women, Black people, and those living in deprived areas are less likely to be offered heart surgery and have higher postoperative mortality rates.\n\nMETHODOLOGY:\n------------\n\n*   Retrospective cohort study of the UK National Health Service and national mortality data.\n*   Among adults admitted to the hospital with heart disease from 2010 to 2019, authors examined demographics of 292,140 who had coronary artery bypass graft (CABG) and/or valve surgery.\n*   Outcomes of interest were access to surgery, in-hospital mortality, 1-year mortality, and hospital readmission.\n\nTAKEAWAY:\n---------\n\n*   Worse outcomes occurred in women vs men, Black vs White people, and people living in the lowest vs highest socioeconomic quintile.\n*   These groups were 59%, 32%, and 35% less likely to get CABG and 31%, 33%, and 39% less likely to get valve surgery, respectively, than comparator groups.\n*   They were 24%, 85%, and 18%, respectively, more likely to die within a year after CABG.\n*   After valve surgery, women were 19% more likely to die, and people from the most deprived areas were 10% more likely to die within a year.\n\nIN PRACTICE:\n------------\n\n"Healthcare providers must also undertake surveillance using routinely collected data to ensure that their interventions are reaching underserved groups," the authors wrote.\n\nSOURCE:\n-------\n\nThe study was conducted by a team in the United Kingdom and was published in _Heart_.\n\nLIMITATIONS:\n------------\n\nThe authors looked at only one measure of access to care. Ethnicity data were lacking in 1 in 10 patients.\n\nDISCLOSURES:\n------------\n\nThe study was funded by the National Institute for Health Research, and the authors declared no conflicts of interest.', 'gpt-4o-mini']
2024-09-11 01:47:47,528 - INFO - Logged data to databases/llm.csv with DocumentID: 25kxZsSBG5aVijR2XoxR.
2024-09-11 01:47:47,528 - INFO - 'generated_post' length: 9. Content: ['2024-09-09 03:26:09', '2024-09-11 01:46:56', "üíâ Have we finally found a way to simplify diabetes management? \n\n- Recent research presented in Madrid introduces a promising approach: a monthly injectable semaglutide, delivered via a unique hydrogel formulation. \n- This innovation aims to replace daily pills or weekly injections with just one monthly dose, potentially increasing patient adherence and enhancing quality of life for those managing type 2 diabetes or obesity. \n- The study demonstrated initial successful trials in rats, showcasing sustained release of drug over a month without significant side effects‚Äîan important consideration for long-term user experience. \n- The hydrogel demonstrated good biocompatibility, making it a strong candidate for future applications in human trials.\n\nImagine a world where managing chronic conditions like diabetes no longer feels burdensome. Could this be the breakthrough we've been waiting for? ü§î \n\nFor a detailed look at the research, check out the full abstract here: https://www.easd.org/media-centre/home.html#!resources/b-development-of-a-once-a-month-formulation-of-semaglutide-from-an-innovative-injectable-and-biodegradable-hydrogel-b-3a26d010-e0a3-4d7f-99a3-eff96220f163", ['Life Sciences & BioTech', 'DigitalHealth', 'Endocrinology', 'ClinicalTrials', 'PatientEngagement'], 'https://images.pexels.com/photos/6823504/pexels-photo-6823504.jpeg', 'http://medscape.com/viewarticle/monthly-semaglutide-goal-end-daily-pills-2024a1000g7u', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'Monthly Semaglutide Goal: The End of Daily Pills?\n=================================================\n\nEdited by Shrabasti Bhattacharya\n\nSeptember 09, 2024\n\n0\n\n0\n\n**TOPLINE:**\n------------\n\nMADRID ‚Äî In a rat study, two versions of an experimental monthly injectable semaglutide-loaded hydrogel show extended release over 1 month and good tolerance. If found to be safe and effective in people, a once-monthly formulation could improve patient adherence and quality of life of those with type 2 diabetes or obesity.\n\n**METHODOLOGY:**\n----------------\n\n*   About half or more patients taking semaglutide, a glucagon-like peptide 1 receptor agonist approved for treating obesity with or without type 2 diabetes, may discontinue treatment with their once-weekly subcutaneous injections or daily oral pills at 12 months, but longer-acting formulations may increase drug efficacy and patient adherence.\n*   Researchers have developed two versions of an injectable semaglutide-loaded hydrogel mixed with a pair of degradable polymers that chemically bond together.\n*   After injection, the formulations form either a gel disk or microgel suspension that enables a gradual and prolonged drug release.\n*   To identify the optimal formulation, researchers analyzed the hydrogel compositions in vitro to study drug release kinetics, duration of effectiveness, and semaglutide loading content.\n*   The experimental semaglutide-loaded hydrogel disk or microgel particles were injected subcutaneously in six wild-type Wistar Han male rats of normal weight (250-300 g) to characterize semaglutide pharmacokinetics and hydrogel biocompatibility.\n\n**TAKEAWAY:**\n-------------\n\n*   The formulation could be easily injected using a 25G needle, with gelation starting within minutes of mixing.\n*   In both versions, a single injection of the hydrogel-based formulations in rats demonstrated a minimal initial early release, followed by a consistent release over the course of 1 month.\n*   The product was well tolerated with no edema or inflammatory reaction during the treatment period.\n*   The hydrogel could be easily degraded by enzymes in in vitro studies.\n\n**IN PRACTICE:**\n----------------\n\n"A small dollop of gel, known as a \'depot,\' of the semaglutide-laden hydrogel is injected under the skin," said Claire M√©gret, PhD, lead author of the poster presentation, in a news release. "Our pre-clinical results demonstrate that the regular, slow release of semaglutide over one month after administering a single dose, with limited early release, is achievable," she added.\n\n**SOURCE:**\n-----------\n\nThis study was led by Audrey Marechal, Adocia, Lyon, France, and was published online on September 8, 2024, as a poster [abstract](https://www.easd.org/media-centre/home.html#!resources/b-development-of-a-once-a-month-formulation-of-semaglutide-from-an-innovative-injectable-and-biodegradable-hydrogel-b-3a26d010-e0a3-4d7f-99a3-eff96220f163) 746 at the annual meeting of the European Association for the Study of Diabetes in Madrid, Spain.\n\n**LIMITATIONS:**\n----------------\n\nNo limitations were discussed.\n\n**DISCLOSURES:**\n----------------\n\nThis study was funded by Adocia. No conflicts of interests by the authors were reported.\n\n_This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication._\n\n0\n\nCredit  \n\nLead image: Jakub Gojda/Dreamstime\n\nMedscape Medical News ¬© 2024 WebMD, LLC  \nSend comments and news tips to [news@medscape.net](mailto:news@medscape.net).\n\nCite this: Edited by Shrabasti Bhattacharya. Monthly Semaglutide Goal: The End of Daily Pills? - Medscape \\- September 09, 2024.', 'gpt-4o-mini']
2024-09-11 01:47:47,529 - INFO - Logged data to databases/llm.csv with DocumentID: z1RxUFDKy5TrrSat9xqh.
2024-09-11 01:47:47,529 - INFO - 'generated_post' length: 9. Content: ['2024-09-09 02:59:00', '2024-09-11 01:47:27', "üåü Have you considered the unique challenges women face in primary care?\n\nAs we gear up for Guidelines Live 2024, the Primary Care Women's Health Forum (PCWHF) is set to delve into pressing women's health issues, especially surrounding menopause and hormone replacement therapy (HRT).\n\n- KEY SESSIONS: \n   - DR. JULIE OLIVER will introduce new British Menopause Society guidelines on managing unscheduled bleeding with HRT, providing a practical flowchart to aid decision-making and risk stratification.\n   - DR. CAROLINE COOPER will present updated contraceptive options tailored for women over 40, emphasizing an individualised approach to care.\n   - DR. ANGELA WRIGHT will broaden the discussion to younger women, addressing the role of testosterone in managing libido alongside menopause issues.\n\nIt's crucial to stay informed on these critical updates in women's health. With the ongoing debates about access to HRT and the importance of women's perspectives in healthcare policies, such sessions are vital for enhancing our clinical practices.\n\nü§î How are you currently addressing women‚Äôs health issues in your practice? Let's share strategies for improvement!\n\nDiscover more about these initiatives and register for Guidelines Live 2024 here: https://www.guidelineslive.co.uk/ \n\n#WomenHealth #HRT #GuidelinesLive #PrimaryCare", ['Healthcare & Policy', 'HealthcareInnovation', 'WearableTech', 'HealthPolicy', 'PatientEngagement', 'WearableTech'], 'https://images.pexels.com/photos/7581591/pexels-photo-7581591.jpeg', 'http://medscape.co.uk/viewarticle/join-dr-julie-oliver-and-primary-care-womens-health-forum-2024a1000fb0', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'Join Dr Julie Oliver and the Primary Care Women‚Äôs Health Forum at Guidelines Live 2024\n===============\n\nThis site is intended for UK healthcare professionals\n\nWelcome to the new home of Guidelines in Practice\n\nBrowse our expert articles to support best practice for UK healthcare professionals.\n\nFor Primary Care | Hot topic\n\nJoin Dr Julie Oliver and the Primary Care Women‚Äôs Health Forum at _Guidelines Live_ 2024\n========================================================================================\n\nPrimary Care Women\'s Health Forum\n\n**In Anticipation of** _**Guidelines Live**_ **2024, the PCWHF Provides a Taster of its Sessions in the Women‚Äôs Health Stream, Which Will Address Key Issues Around Menopause and HRT**\n\nA PCWHF session at _Guidelines Live_ 2023\n\nThe Primary Care Women‚Äôs Health Forum (PCWHF) is excited to return to _Guidelines Live_ in 2024, following its success delivering presentations to full lecture theatres in 2023. This year, PCWHF speaker sessions will have a primary-care relevant, practical focus, underpinned by realistic case studies to illustrate the application of guidelines in the real world.\n\nPublished in 2022, the _Women‚Äôs Health Strategy for England_ notes that there is not enough focus on women-specific issues such as menopause. Over the past few years, healthcare professionals have faced challenges such as shortages of hormone-replacement therapy (HRT), a lack of licensed options for testosterone as part of HRT, and funding for the fitting of intrauterine devices and implants that may not cover the costs of the procedure.\n\nIn the first of the PCWHF speaker sessions on Day 1, **Dr Julie Oliver**, PCWHF Chair, will discuss the recent British Menopause Society guideline on the management of unscheduled bleeding in women taking HRT. The guideline provides a new approach to risk stratification, and includes a helpful one-page summary flowchart to guide management. It also answers the perennial question ‚Äò_How high is too high?_‚Äô‚Äîthat is, what is the oestrogen dose needed to increase the amount of progestogen in an HRT regime? Dr Oliver is an NHS GP in County Durham, with an extended role in women‚Äôs health and a long history of speaking at conferences such as _Guidelines Live_.\n\nOn the Day 2 of _Guidelines Live_ 2024, **Dr Caroline Cooper** will give a contraception update, with a focus on new guidance. Dr Cooper will explore contraceptive options for women over 40 years of age, emphasising safety, efficacy, and individualised care approaches. Dr Cooper is an experienced GP with an extended role in women‚Äôs health. She is also a faculty-registered trainer, and has served on the Faculty of Sexual & Reproductive Healthcare committees, as well as being a current director of the PCWHF.\n\nNext, **Dr Angela Wright** will continue the HRT theme, but adding relevance to younger women, by discussing testosterone and libido. Informed by her experience of primary and secondary care NHS work, Dr Wright‚Äôs speaker session will explain how those in primary care can support women who have complex menopause issues, sexual dysfunction, and premenstrual disorders. Dr Wright is a fellow of the European Committee of Sexual Medicine, and an active committee member of the British Society of Sexual Medicine.\n\n### The Primary Care Women‚Äôs Health Forum\n\nThese _Guidelines Live_ sessions are supported by the Primary Care Women‚Äôs Health Forum (PCWHF), a group of 10,000 healthcare professionals with a special interest in women‚Äôs health. The PCWHF aims to promote and progress standards in women‚Äôs health in primary care through education, resources, and events, and lobbies on behalf of its members to determine future strategic direction and policymaking for women‚Äôs health. [Find out more about the PCWHF](https://pcwhf.co.uk/).\n\nFor more information on _Guidelines Live_ 2024, click [here](https://www.guidelineslive.co.uk/).  \n\nIn 2024, _Guidelines Live_ will take place on Tuesday 19 and Wednesday 20 November at ExCeL London‚Äîto dedicate 2 days to your learning and development, [book now](https://eventdata.uk/Forms/Form.aspx?FormRef=GuiB4Visitor) at the summer offer rate of only ¬£49.  \n\n_Guidelines Live_ is an educational event made possible by sponsorship from organisations including pharmaceutical companies. Sponsors have had no input into the agenda of the meeting unless through sponsored session(s) as indicated on the main programme.\n\nNote: Some of the issues discussed in this article only affect those of the female sex and so the terms woman/women and the pronouns she/her have been used throughout this article. Sensitivity should be used when your patient‚Äôs gender does not match their biological sex, including using the patient‚Äôs preferred pronouns.\n\nNote: At the time of publication (September 2024), some of the treatments discussed in this article did not have UK marketing authorisation for the indications discussed. Prescribers should refer to the individual summaries of product characteristics for further information and recommendations regarding the use of pharmacological therapies. For off-licence use of medicines, the prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council‚Äôs [_Good practice in prescribing and managing medicines and devices_](https://www.gmc-uk.org/ethical-guidance/ethical-guidance-for-doctors/good-practice-in-prescribing-and-managing-medicines-and-devices) for further information. \n\nCreate an account Today\n\nAlready a member? Log in\n\nEDITOR\'S RECOMMENDATIONS\n------------------------\n\n*   [Decipher Lipid Management Guidance at Guidelines Live](https://www.medscape.co.uk/viewarticle/decipher-lipid-management-guidance-guidelines-live-2024a1000dvg)\n    \n    In advance of the Diabetes Stream at Guidelines Live 2024, Dr Kevin Fernando outlines key Issues for cardiovascular risk management in primary care\n    \n    Hot topic | Dr Kevin Fernando | 12 August 2024\n    \n*   [Get Up to Speed on Practice Management With Guidelines Live](https://www.medscape.co.uk/viewarticle/get-speed-practice-management-guidelines-live-2024a1000bwx)\n    \n    Valerie Benfield, Head of Events, answers the Guidelines in Practice Team\'s questions about the Management Stream at Guidelines Live‚Äîa brand new stream for the 2024 event\n    \n    Hot topic | Guidelines in Practice Team | 15 July 2024\n    \n*   [Take Advantage of the Educational Resources on Offer at Guidelines Live](https://www.medscape.co.uk/viewarticle/take-advantage-educational-resources-offer-guidelines-live-2024a1000997)\n    \n    The Guidelines in Practice Team reviews the opportunities for continuing professional development offered by Guidelines Live\n    \n    Hot topic | Guidelines in Practice Team | 17 May 2024\n\nYOU MAY ALSO LIKE\n-----------------\n\n[Epilepsy Drug Offers Hope for Patients With Sleep Apnoea](https://www.medscape.co.uk/s/viewarticle/epilepsy-drug-offers-hope-patients-sleep-apnoea-2024a1000gdz "Epilepsy Drug Offers Hope for Patients With Sleep Apnoea")\n\n[Chronic PPI Use Weakens Bones, but Only in Men](https://www.medscape.co.uk/viewarticle/chronic-ppi-use-weakens-bones-only-men-2024a1000fsl "Chronic PPI Use Weakens Bones, but Only in Men")\n\n[Mastitis in Older Women Linked to Subsequent Breast Cancer](https://www.medscape.co.uk/viewarticle/mastitis-older-women-linked-subsequent-breast-cancer-2024a1000g68 "Mastitis in Older Women Linked to Subsequent Breast Cancer")\n\n[Night Owls May Be at Greater Risk for T2D, Beyond Lifestyle](https://www.medscape.co.uk/s/viewarticle/night-owls-may-be-greater-risk-t2d-beyond-lifestyle-2024a1000gcj "Night Owls May Be at Greater Risk for T2D, Beyond Lifestyle")\n\n[Large Trials Support Mitral Valve Repair in Heart Failure](https://www.medscape.co.uk/s/viewarticle/large-trials-support-mitral-valve-repair-heart-failure-2024a1000gcs "Large Trials Support Mitral Valve Repair in Heart Failure")\n\n[Chemical Submission Remains an Overlooked Crisis in Healthcare](https://www.medscape.co.uk/s/viewarticle/chemical-submission-remains-overlooked-crisis-healthcare-2024a1000gca "Chemical Submission Remains an Overlooked Crisis in Healthcare")\n\n[Nonhormonal Treatment May Ease Menopausal Symptoms](https://www.medscape.co.uk/s/viewarticle/nonhormonal-treatment-may-ease-menopausal-symptoms-2024a1000gc4 "Nonhormonal Treatment May Ease Menopausal Symptoms")\n\n[Abnormal HR Shifts Tied to Risk for Death in Diabetes](https://www.medscape.co.uk/s/viewarticle/abnormal-heart-rate-shifts-tied-risk-death-diabetes-2024a1000g8n "Abnormal HR Shifts Tied to Risk for Death in Diabetes")\n\n[NHS Staff Share Emotional Stories from the Covid-19 Pandemic](https://www.medscape.co.uk/s/viewarticle/nhs-staff-share-emotional-stories-covid-19-pandemic-2024a1000g9v "NHS Staff Share Emotional Stories from the Covid-19 Pandemic")\n\n[What Do We Know About Postoperative Cognitive Dysfunction?](https://www.medscape.co.uk/s/viewarticle/what-do-we-know-about-postoperative-cognitive-dysfunction-2024a1000g9b "What Do We Know About Postoperative Cognitive Dysfunction?")\n\n[Vascular and Cardiac Collaboration Essential‚Ä¶So Is AI](https://www.medscape.co.uk/s/viewarticle/vascular-and-cardiac-collaboration-essential-so-ai-2024a1000g99 "Vascular and Cardiac Collaboration Essential‚Ä¶So Is AI")\n\n[AI-Based Breast Cancer Screening Will Save Lives & Money](https://www.medscape.co.uk/s/viewarticle/ai-based-breast-cancer-screening-found-cost-effective-nhs-2024a1000g49 "AI-Based Breast Cancer Screening Will Save Lives & Money")\n\n[Demographics Linked to Worse Access to Cardiac Surgery](https://www.medscape.co.uk/s/viewarticle/demographics-linked-worse-access-cardiac-surgery-2024a1000g4z "Demographics Linked to Worse Access to Cardiac Surgery")\n\n[Will Tirzepatide Vials Help Patients? Endos Weigh in](https://www.medscape.co.uk/s/viewarticle/will-tirzepatide-vials-help-patients-endos-weigh-2024a1000g8q "Will Tirzepatide Vials Help Patients? Endos Weigh in")\n\n[Key Clinical Updates on Mastocytosis](https://www.medscape.co.uk/viewarticle/key-clinical-updates-mastocytosis-2024a1000g7x "Key Clinical Updates on Mastocytosis")\n\n[Monthly Semaglutide Goal: The End of Daily Pills?](https://www.medscape.co.uk/s/viewarticle/monthly-semaglutide-goal-end-daily-pills-2024a1000g7u "Monthly Semaglutide Goal: The End of Daily Pills?")\n\n[UK\'s Poor Blood Cancer Survival Cost a Million Life Years](https://www.medscape.co.uk/s/viewarticle/uks-poor-blood-cancer-survival-cost-million-life-years-2024a1000g6o "UK\'s Poor Blood Cancer Survival Cost a Million Life Years")\n\n[Temporary NHS Staff Fear Speaking Up About Patient Safety](https://www.medscape.co.uk/s/viewarticle/temporary-nhs-staff-fear-speaking-about-patient-safety-2024a1000g6h "Temporary NHS Staff Fear Speaking Up About Patient Safety")\n\n[Rheumatoid Arthritis: Whole-Food Diet May Be Protective](https://www.medscape.co.uk/s/viewarticle/rheumatoid-arthritis-whole-food-diet-may-be-protective-2024a1000g29 "Rheumatoid Arthritis: Whole-Food Diet May Be Protective")', 'gpt-4o-mini']
2024-09-11 01:47:47,530 - INFO - Logged data to databases/llm.csv with DocumentID: WW8dSmdlw9vohFWncREv.
2024-09-11 01:47:47,530 - INFO - 'generated_post' length: 9. Content: ['2024-09-06 10:00:00', '2024-09-11 01:47:40', 'üåø Have you considered the impact of diet on rheumatoid arthritis (RA) risk?\n\n- A recent study involving over 207,000 middle-aged adults from the UK Biobank found compelling evidence linking ultra-processed food consumption to increased RA risk. \n- Participants consuming the highest amounts of ultra-processed foods faced a 17% GREATER risk of developing RA compared to those in the lowest consumption group. üìä  \n- Notably, this risk heightened with each incremental increase in ultra-processed food intake, suggesting a direct correlation worth considering in dietary advice. \n- Inflammatory markers, lipids, and liver enzymes accounted for up to 14.8% of this association, emphasizing the biological pathway connecting diet with autoimmune conditions. \n\nAs we continue to explore dietary influences in clinical practice, it‚Äôs critical to advocate for reduced ultra-processed food consumption. With nearly HALF of food intake in the UK classified as ultra-processed, integrating these findings into guidelines could be pivotal in RA prevention strategies. \n\nWhat changes can we implement in dietary counseling to prioritize whole foods over ultra-processed options for our patients?  ü§î \n\nFor further insights, check out the full study here: http://medscape.co.uk/viewarticle/rheumatoid-arthritis-whole-food-diet-may-be-protective-2024a1000g29', ['Healthcare & Policy', 'Nutrition', 'Rheumatology', 'PublicHealth', 'HealthPolicy'], 'https://images.pexels.com/photos/6823606/pexels-photo-6823606.jpeg', 'http://medscape.co.uk/viewarticle/rheumatoid-arthritis-whole-food-diet-may-be-protective-2024a1000g29', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'Rheumatoid Arthritis: Whole-Food Diet May Be Protective\n===============\n                                      \n\nThis site is intended for UK healthcare professionals\n\n*   Recent Searches [Clear](http://medscape.co.uk/viewarticle/rheumatoid-arthritis-whole-food-diet-may-be-protective-2024a1000g29#)\n\nClinical Summary\n\nRheumatoid Arthritis: Whole-Food Diet May Be Protective\n=======================================================\n\nSusan London\n\nTOPLINE:\n--------\n\nMiddle-aged adults who consume more ultra-processed foods have an elevated risk for rheumatoid arthritis (RA) that is mediated in part through circulating biomarkers.\n\nMETHODOLOGY:\xa0\n-------------\n\n*   Investigators conducted a retrospective cohort study of 207,012 middle-aged adults without RA from the UK Biobank who completed 24-hour dietary recalls.\n*   Foods and beverages were classified as (1) unprocessed or minimally processed foods, (2) processed culinary ingredients, (3) processed foods, or (4) ultra-processed foods (eg, soft drinks, sweet or savoury packaged snacks, reconstituted meat products, pre-prepared frozen dishes).\n*   The main outcome was the incident RA based on hospital diagnoses.\n\nTAKEAWAY:\n---------\n\n*   Overall, 0.9% of participants received an RA diagnosis during a median follow-up of about 12 years.\n*   Relative to peers in the lowest quintile of ultra-processed food consumption, participants in the highest quintile had a 17% greater adjusted risk for RA.\n*   The risk rose across quintile (P < .05) and increased by 6% with each standard deviation increase in ultra-processed food intake.\n*   Mediation analyses suggested that inflammatory, lipid, and liver enzyme biomarkers explained 3.1%-14.8% of the association between ultra-processed food intake and RA risk.\n*   Findings were similar regardless of participants\' age, sex, body mass index, smoking status, household income, and healthy diet score.\n\nIN PRACTICE:\xa0\n-------------\n\n"Lower [ultra-processed food] consumption is recommended to reduce RA incidence," the authors wrote, noting that up to half of the food consumed in the United Kingdom now falls into the ultra-processed category. "Dietary guidelines should prominently feature the detrimental effects of [ultra-processed foods], and recommendations to curtail their consumption should be integrated into public health initiatives, to mitigate the risk of RA," they added.\n\nSOURCE:\n-------\n\nThe study was led by Haodong Zhao, Soochow University, Suzhou, China, and was published online in the American Journal of Clinical Nutrition.\n\nLIMITATIONS:\n------------\n\nLimitations included possible recall and social desirability biases, potential residual confounding, and uncertain causality of the observed associations.\n\nDISCLOSURES:\n------------\n\nThe study was funded by grants from the National Natural Science Foundation of China and other institutions. The authors reported no conflicts of interest.', 'gpt-4o-mini']
2024-09-11 01:47:47,531 - INFO - Logged data to databases/llm.csv with DocumentID: T0v1p2i0MzX6hgSWrbuP.
2024-09-11 02:37:28,137 - INFO - Extracted 20 link records.
2024-09-11 02:37:28,141 - INFO - Extracted 20 image links.
2024-09-11 02:37:28,143 - INFO - Extracted 10 link records.
2024-09-11 02:37:28,145 - INFO - Extracted 5 link records.
2024-09-11 02:37:28,147 - INFO - Extracted 8 link records.
2024-09-11 02:37:28,147 - INFO - Unique links to process: 3
2024-09-11 02:37:28,147 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 02:37:29,323 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/, now generating post.
2024-09-11 02:37:29,777 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 02:37:29,779 - INFO - No article found for link https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/.
2024-09-11 02:37:29,779 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/. Skipping.
2024-09-11 02:37:29,779 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 02:37:29,779 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 02:37:32,140 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/, now generating post.
2024-09-11 02:37:32,825 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 02:37:32,826 - INFO - No article found for link https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/.
2024-09-11 02:37:32,826 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/. Skipping.
2024-09-11 02:37:32,826 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 02:37:32,826 - INFO - Starting to process link: http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 02:37:33,970 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296, now generating post.
2024-09-11 02:37:34,907 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 02:37:34,908 - INFO - No article found for link https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296.
2024-09-11 02:37:34,908 - ERROR - No valid post generated for http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296. Skipping.
2024-09-11 02:37:34,908 - WARNING - Skipping entry due to missing or invalid log entry for link: https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 04:11:54,697 - INFO - Extracted 20 link records.
2024-09-11 04:11:54,701 - INFO - Extracted 20 image links.
2024-09-11 04:11:54,703 - INFO - Extracted 10 link records.
2024-09-11 04:11:54,705 - INFO - Extracted 5 link records.
2024-09-11 04:11:54,707 - INFO - Extracted 8 link records.
2024-09-11 04:11:54,708 - INFO - Unique links to process: 3
2024-09-11 04:11:54,708 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 04:11:56,146 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/, now generating post.
2024-09-11 04:11:56,642 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 04:11:56,644 - INFO - No article found for link https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/.
2024-09-11 04:11:56,644 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/. Skipping.
2024-09-11 04:11:56,644 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 04:11:56,644 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 04:11:58,287 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/, now generating post.
2024-09-11 04:11:58,946 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 04:11:58,946 - INFO - No article found for link https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/.
2024-09-11 04:11:58,947 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/. Skipping.
2024-09-11 04:11:58,947 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 04:11:58,947 - INFO - Starting to process link: http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 04:12:01,277 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296, now generating post.
2024-09-11 04:12:01,684 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 04:12:01,685 - INFO - No article found for link https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296.
2024-09-11 04:12:01,685 - ERROR - No valid post generated for http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296. Skipping.
2024-09-11 04:12:01,685 - WARNING - Skipping entry due to missing or invalid log entry for link: https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 06:12:58,874 - INFO - Extracted 20 link records.
2024-09-11 06:12:58,879 - INFO - Extracted 20 image links.
2024-09-11 06:12:58,881 - INFO - Extracted 10 link records.
2024-09-11 06:12:58,883 - INFO - Extracted 5 link records.
2024-09-11 06:12:58,885 - INFO - Extracted 8 link records.
2024-09-11 06:12:58,885 - INFO - Unique links to process: 3
2024-09-11 06:12:58,885 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 06:13:00,362 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/, now generating post.
2024-09-11 06:13:00,806 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 06:13:00,808 - INFO - No article found for link https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/.
2024-09-11 06:13:00,808 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/. Skipping.
2024-09-11 06:13:00,808 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 06:13:00,808 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 06:13:02,277 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/, now generating post.
2024-09-11 06:13:02,755 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 06:13:02,756 - INFO - No article found for link https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/.
2024-09-11 06:13:02,756 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/. Skipping.
2024-09-11 06:13:02,756 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 06:13:02,756 - INFO - Starting to process link: http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 06:13:06,234 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296, now generating post.
2024-09-11 06:13:06,666 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 06:13:06,667 - INFO - No article found for link https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296.
2024-09-11 06:13:06,667 - ERROR - No valid post generated for http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296. Skipping.
2024-09-11 06:13:06,667 - WARNING - Skipping entry due to missing or invalid log entry for link: https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 08:11:38,804 - INFO - Extracted 20 link records.
2024-09-11 08:11:38,808 - INFO - Extracted 20 image links.
2024-09-11 08:11:38,810 - INFO - Extracted 15 link records.
2024-09-11 08:11:38,812 - INFO - Extracted 5 link records.
2024-09-11 08:11:38,815 - INFO - Extracted 8 link records.
2024-09-11 08:11:38,815 - INFO - Unique links to process: 8
2024-09-11 08:11:38,815 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 08:11:40,838 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/, now generating post.
2024-09-11 08:11:41,304 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 08:11:41,306 - INFO - No article found for link https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/.
2024-09-11 08:11:41,307 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/. Skipping.
2024-09-11 08:11:41,307 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 08:11:41,307 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 08:11:43,029 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/, now generating post.
2024-09-11 08:11:43,493 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 08:11:43,494 - INFO - No article found for link https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/.
2024-09-11 08:11:43,494 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/. Skipping.
2024-09-11 08:11:43,494 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 08:11:43,494 - INFO - Starting to process link: http://r.jina.ai/https://doi.org/10.1186/s12883-024-03811-z
2024-09-11 08:11:45,111 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://doi.org/10.1186/s12883-024-03811-z, now generating post.
2024-09-11 08:14:25,155 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 08:14:30,875 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 08:14:31,191 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 08:14:31,192 - INFO - Image query: "anti-NMDAR encephalitis treatment"
2024-09-11 08:14:31,551 - INFO - Unique image link: https://images.pexels.com/photos/6619477/pexels-photo-6619477.jpeg
2024-09-11 08:14:31,552 - INFO - Post generated successfully for link: http://r.jina.ai/https://doi.org/10.1186/s12883-024-03811-z
2024-09-11 08:14:31,552 - INFO - Starting to process link: http://r.jina.ai/https://medicalxpress.com/news/2024-09-diabetes-drug-immune-reservoirs-hiv.html
2024-09-11 08:14:32,701 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://medicalxpress.com/news/2024-09-diabetes-drug-immune-reservoirs-hiv.html, now generating post.
2024-09-11 08:14:41,240 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 08:14:45,296 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 08:14:45,669 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 08:14:45,670 - INFO - Image query: "HIV treatment research"
2024-09-11 08:14:45,971 - INFO - Unique image link: https://images.pexels.com/photos/7723389/pexels-photo-7723389.jpeg
2024-09-11 08:14:45,972 - INFO - Post generated successfully for link: http://r.jina.ai/https://medicalxpress.com/news/2024-09-diabetes-drug-immune-reservoirs-hiv.html
2024-09-11 08:14:45,972 - INFO - Starting to process link: http://r.jina.ai/https://www.hcplive.com/view/mirtazapine-fails-to-ease-breathlessness-in-new-study-despite-previous-hopes
2024-09-11 08:14:47,749 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://www.hcplive.com/view/mirtazapine-fails-to-ease-breathlessness-in-new-study-despite-previous-hopes, now generating post.
2024-09-11 08:15:03,057 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 08:15:08,546 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 08:15:08,901 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 08:15:08,903 - INFO - Image query: "antidepressants in respiratory disease"
2024-09-11 08:15:09,287 - INFO - Unique image link: https://images.pexels.com/photos/5858850/pexels-photo-5858850.jpeg
2024-09-11 08:15:09,287 - INFO - Post generated successfully for link: http://r.jina.ai/https://www.hcplive.com/view/mirtazapine-fails-to-ease-breathlessness-in-new-study-despite-previous-hopes
2024-09-11 08:15:09,287 - INFO - Starting to process link: http://r.jina.ai/https://www.targetedonc.com/view/fda-grants-orphan-drug-designation-to-abd-147-in-neuroendocrine-carcinoma
2024-09-11 08:15:10,907 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://www.targetedonc.com/view/fda-grants-orphan-drug-designation-to-abd-147-in-neuroendocrine-carcinoma, now generating post.
2024-09-11 08:15:19,432 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 08:15:22,086 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 08:15:22,791 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 08:15:22,791 - INFO - Image query: "neuroendocrine carcinoma treatments"
2024-09-11 08:15:23,310 - INFO - Unique image link: https://images.pexels.com/photos/6724357/pexels-photo-6724357.jpeg
2024-09-11 08:15:23,310 - INFO - Post generated successfully for link: http://r.jina.ai/https://www.targetedonc.com/view/fda-grants-orphan-drug-designation-to-abd-147-in-neuroendocrine-carcinoma
2024-09-11 08:15:23,311 - INFO - Starting to process link: http://r.jina.ai/https://www.prnewswire.com/news-releases/once-weekly-dose-of-insulin-efsitora-alfa-delivers-a1c-reduction-consistent-with-the-most-advanced-daily-insulin-in-people-with-type-2-diabetes-302243899.html
2024-09-11 08:15:24,673 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://www.prnewswire.com/news-releases/once-weekly-dose-of-insulin-efsitora-alfa-delivers-a1c-reduction-consistent-with-the-most-advanced-daily-insulin-in-people-with-type-2-diabetes-302243899.html, now generating post.
2024-09-11 08:15:25,007 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 08:15:25,008 - INFO - No article found for link https://www.prnewswire.com/news-releases/once-weekly-dose-of-insulin-efsitora-alfa-delivers-a1c-reduction-consistent-with-the-most-advanced-daily-insulin-in-people-with-type-2-diabetes-302243899.html.
2024-09-11 08:15:25,009 - ERROR - No valid post generated for http://r.jina.ai/https://www.prnewswire.com/news-releases/once-weekly-dose-of-insulin-efsitora-alfa-delivers-a1c-reduction-consistent-with-the-most-advanced-daily-insulin-in-people-with-type-2-diabetes-302243899.html. Skipping.
2024-09-11 08:15:25,009 - WARNING - Skipping entry due to missing or invalid log entry for link: https://www.prnewswire.com/news-releases/once-weekly-dose-of-insulin-efsitora-alfa-delivers-a1c-reduction-consistent-with-the-most-advanced-daily-insulin-in-people-with-type-2-diabetes-302243899.html
2024-09-11 08:15:25,009 - INFO - Starting to process link: http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 08:15:29,076 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296, now generating post.
2024-09-11 08:15:29,475 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 08:15:29,476 - INFO - No article found for link https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296.
2024-09-11 08:15:29,476 - ERROR - No valid post generated for http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296. Skipping.
2024-09-11 08:15:29,476 - WARNING - Skipping entry due to missing or invalid log entry for link: https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 08:15:29,476 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/6619477/pexels-photo-6619477.jpeg'}
2024-09-11 08:15:29,476 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 08:15:29,476 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/7723389/pexels-photo-7723389.jpeg'}
2024-09-11 08:15:29,476 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 08:15:29,476 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/5858850/pexels-photo-5858850.jpeg'}
2024-09-11 08:15:29,476 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 08:15:29,476 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/6724357/pexels-photo-6724357.jpeg'}
2024-09-11 08:15:29,476 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 08:15:29,476 - INFO - Sending 4 log entries to Firebase.
2024-09-11 08:15:36,904 - INFO - Successfully sent batch data to Firebase: {'message': 'Batch processed successfully. 4 posts added.', 'documentIDs': ['fEIcd8MvuEf5WfoyM32k', 'W4TMfs0JxyijACiukOeF', 'CqFgQAXBzh42vFImeW4o', 'nCVkmQNqfHfq6243bJkK']}
2024-09-11 08:15:36,904 - INFO - Received 4 document IDs from Firebase.
2024-09-11 08:15:36,904 - INFO - 'generated_post' length: 9. Content: ['2024-09-11 07:50:00', '2024-09-11 08:14:30', "ü§î Have you explored adjunctive treatments for anti-NMDAR encephalitis? A recent study sheds light on the efficacy of olanzapine, magnesium valproate, and lamotrigine as adjunctive therapies.\n\n- A retrospective analysis involving 90 patients revealed that both magnesium valproate and lamotrigine significantly improved neuropsychiatric outcomes compared to olanzapine. After three weeks, both adjunctive treatments led to lower PANSS total scores (P < 0.05).  \n\n- üìä The improvements extended to cognitive function as measured by the Montreal Cognitive Assessment (MoCA), showing higher scores for patients treated with magnesium valproate and lamotrigine when compared to those on olanzapine.\n\n- After three months, the proportion of patients achieving a modified Rankin scale score of 0-1, indicative of good functional outcomes, was significantly higher in the magnesium valproate and lamotrigine groups (P < 0.05).\n\n- EEG abnormalities also improved, highlighting greater normalization in those receiving magnesium valproate and lamotrigine after three months (P < 0.05).\n\n- Notably, both magnesium valproate and lamotrigine treatments contributed to a significant decrease in the Glx/Cr ratio, suggesting a rebalance in excitatory/inhibitory neurotransmission which may underlie the clinical benefits observed.\n\nAs the landscape of treating anti-NMDAR encephalitis evolves, could focusing on neurotransmitter balance promise even better patient outcomes? Let's discuss! \n\nFor more insights, check the full study here: https://doi.org/10.1186/s12883-024-03811-z", ['Research & Clinical Trials', 'Neurology', 'Psychiatry', 'ClinicalTrials', 'PatientEngagement', 'CME'], 'https://images.pexels.com/photos/6619477/pexels-photo-6619477.jpeg', 'https://doi.org/10.1186/s12883-024-03811-z', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'Olanzapine vs. magnesium valproate vs. lamotrigine in anti-N-methyl-D-aspartic acid receptor encephalitis: a retrospective study\n\nAbstract\n--------\n\n### Background\n\nThis study aimed to compare the impact of olanzapine, magnesium valproate, and lamotrigine as adjunctive treatments for anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. And it is expected to add supporting points related to the rebalance of neurotransmitters in the brain through adjuvant therapy in the clinical management of anti-NMDAR encephalitis.\n\n### Methods\n\nThis retrospective study included patients diagnosed with anti-NMDAR encephalitis who received standardized immunotherapy at Hunan Brain Hospital between January 2018 and December 2020.\n\n### Results\n\nCompared to the olanzapine group, both the magnesium valproate and lamotrigine groups showed lower scores on the positive and negative symptom scale (PANSS) total score after 3 weeks of treatment (all _P_\u2009<\u20090.05). The Montreal Cognitive Assessment Scale (MoCA) scores in the magnesium valproate and lamotrigine groups were significantly higher than in the olanzapine group after 3 weeks and 3 months of treatment (all _P_\u2009<\u20090.05). After 3 months of treatment, the proportions of patients with a modified Rankin scale score (mRS) of 0‚Äì1 in the magnesium valproate and lamotrigine groups were significantly higher than in the olanzapine group (all _P_\u2009<\u20090.05). The electroencephalogram (EEG) abnormality ranks at 3 months were significantly lower in the magnesium valproate and lamotrigine groups compared with the olanzapine group (all _P_\u2009<\u20090.05). Furthermore, the Glx/Cr ratio significantly decreased after 3 months of treatment (all _P_\u2009<\u20090.05) in the magnesium valproate and lamotrigine groups, while the Glx/Cr ratio in the olanzapine group showed no significant change (_P_\u2009>\u20090.05).\n\n### Conclusion\n\nCompared with olanzapine, the addition of magnesium valproate or lamotrigine to immunotherapy might be associated with a lower PANSS score, higher MoCA score, and lower mRS score. The improvement of neurological functions and cognitive function may be related to the decreased Glx/Cr ratio.\n\nIntroduction\n------------\n\nAnti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a rare autoimmune encephalitis with acute onset neuropsychiatric symptoms due to an autoimmune reaction to the glutamate N receptor (GluN1) subunit of the neuronal NMDAR. The reported annual incidence is about 1.5 per million persons-year. Currently, the recommended treatment for anti-NMDAR encephalitis is the use of first-line immunotherapy that includes glucocorticoids, Œ≥-globulin, plasma exchange, tumor resection, acyclovir (until a viral etiology is ruled out), and symptomatic support. Still, only about 53% of patients appear to respond well to first-line immunotherapy, with a fairly high recurrence rate. Pathogenically, the autoantibody binds to the extracellular domain of the GluN1 subunit, resulting in NMDAR internalization and glutamatergic hypofunction. The first-line immunotherapies appear to intervene at the antigen/antibody reaction stage, which might underscore the limited effectiveness of this treatment strategy in the context of potentially broader pathophysiological alterations in the brain.\n\nGiven the existence of glutamatergic hypofunction in anti-NMDAR encephalitis, it can be hypothesized that an imbalance of excitatory/inhibitory neurotransmission should be present in the brain, contributing to the pathophysiology of the disease. Accordingly, adjuvant therapies that help mitigate this imbalance could be beneficial in the clinical management of patients with anti-NMDAR encephalitis. A case report suggested using adjuvant memantine to manage catatonia in anti-NMDAR encephalitis. Ketamine can also be used in patients with anti-NMDAR encephalitis and refractory persistent epilepsy. Intrathecal methotrexate has been suggested for refractory anti-NMDAR encephalitis. Still, few data are available regarding adjuvant therapies in anti-NMDAR encephalitis.\n\nTherefore, this retrospective study aimed to compare the cognitive and neurological functions of three adjuvant drugs in treating anti-NMDAR encephalitis, and to establish a relationship between these improvements and the balance in neuronal excitation and inhibition through glutamate (Glu) and Œ≥-aminobutyric acid (GABA). Based on this study, we hypothesized that the effects of three adjunctive therapeutics in the treatment of anti-NMDAR encephalitis were determined by relating their clinical efficacy for the improvement of cognitive and neurological functions to their extent of pharmacological modulation of glutamate (Glu) and Œ≥-aminobutyric acid (GABA) transmission in the cerebrum.\n\nMaterials and methods\n---------------------\n\n### Study design and patients\n\nThis retrospective study collected the clinical data of patients with anti-NMDAR encephalitis admitted to Hunan Brain Hospital between January 2018 and December 2020. All included patients received standard immunotherapy and different adjuvant treatments. The patients were then grouped based on the adjuvant medications they received.\n\nThe study was approved by the Medical Ethics Committee of Hunan Brain Hospital (approval #2018K065). The requirement for informed consent was waived by the committee because of the retrospective nature of the study. All data were anonymized after extraction and before analysis.\n\n### Inclusion and exclusion criteria\n\nClinical cases meeting the diagnostic criteria for anti-NMDAR encephalitis according to clinical guidelines. The exclusion criteria included encephalitis with other causes, tumors found, seizures as the first symptom, and incomplete clinical data.\n\n### Drug administration\n\nAll patients receive standardized first-line immunotherapy after admission, including intravenous immunoglobulin injection (According to the patient‚Äôs weight, a total of 2 g/kg should be administered intravenously for three to five days.), plasma exchange (with a dose of 1.0 to 1.5 times the total plasma volume, performed 3‚Äì6 exchanges within 10‚Äì14 days.), glucocorticoids (methylprednisolone 1000 mg/d for 3 consecutive days, 500 mg/d for 3 consecutive days, followed by a reduction of 40-80 mg/d.). According to the 2017 Consensus of Chinese Experts on the Diagnosis and Treatment of Autoimmune Encephalitis, doctors choose different drugs for adjuvant treatment based on the different clinical symptoms of patients.\n\n### Outcomes and data collection\n\nThe primary outcome was improving the Positive and Negative Syndrome Scale (PANSS), the Montreal Cognitive Assessment Scale (MoCA), and the modified Rankin Scale (mRS). As per routine practice, all patients underwent assessments using the PANSS, the MoCA, and the mRS before initiating any treatment. The PANSS and the MoCA were conducted at 3 weeks and 3 months after the initial treatments. The mRS were assessed at 3 months after the start of treatments. The PANSS quantifies positive symptoms (which refer to excess or distortion of normal functions, e.g., hallucinations and delusions) and negative symptoms (which represent a diminution or loss of normal functions) and is widely used in the study of psychopharmacologic therapy. Each subscale is scored 1‚Äì7 points ranging from absent to extreme. The range for the positive and negative scales is 7‚Äì49, and the range for the general psychopathology scale is 16‚Äì112. The MoCA is a test used to detect mild cognitive decline and early signs of dementia. It contains 11 tests in eight cognitive areas: attention and concentration, executive function, memory, language, visual structure skills, abstract thinking, computation, and orientation. The total score is 30, and _‚â•_\u200926 is considered normal. The mRS is originally developed to evaluate the state of neurological recovery in patients after stroke, and it has been extended used to various neurological conditions, including autoimmune encephalitis. The mRS scores are categorized as follows: 0: no symptoms; 1: no significant disability and able to carry out all usual activities; 2: slight disability; 3: moderate disability; 4: moderately severe disability; 5: severe disability; 6: death. Generally, mRS scores of 0‚Äì1 indicate a good functional prognosis. The above experimental scales were evaluated by two residents of the psychiatric department of this hospital.\n\nThe secondary outcomes were magnetic resonance imaging (MRI), electroencephalogram (EEG), and antibody titer changes. The above experimental scales were evaluated by two Imaging doctors and electroencephalography doctors.\n\nAll patients underwent EEG assessments before initiating any treatment, as well as at 3 weeks and 3 months after the start of the treatments. The EEGs were rated as normal, mild, moderate, or severe. The EEG records from the patients were scored as the frequency (n) of ‚Äúnormal and mild background abnormalities (No\u2009+\u2009Mi)‚Äù or ‚Äúmoderate background and severe background abnormalities (Mo\u2009+\u2009Se)‚Äù. The improvement rate of EEG was defined as (No\u2009+\u2009Mi)/total number of patients √ó100%. The patients underwent magnetic resonance spectroscopy (MRS) before treatment and 3 months after treatment. The powers of the neurotransmitters Glu and GABA were determined by brain fluctuation mapping, with the Glx/Cr index measured at the top of the left frontal lobe in each patient. The reference powers of Glu and GABA in the brain were determined by Shenzhen Kangli High Tech Co., Ltd. after testing 10,000 healthy people nationwide and were 38.36\u2009¬±\u200912.91 for Glu and 31.67\u2009¬±\u200913.93 for GABA. In order to further explore the influence of drug treatment on the excitatory/inhibitory homeostasis of the brain, the resonance peaks of Glx (contributed by glutamate, glutamine, and GABA together) and Cr (contributed largely by GABA) were obtained at the top of the left frontal lobe by MRS, with the Glx/Cr ratio calculated for each patient before treatment and three months after treatment.\n\nDemographic data were collected from the medical records of included patients, including age, sex, disease course, time of drug initiation and clinical symptoms.\n\n### Statistical analysis\n\n### Sample size\n\nthe retrospective nature of the study predetermines the sample size. A priori sample size calculation was not performed.\n\nAll analyses were performed using SPSS 25.0 (IBM, Armonk, NY, USA). The continuous data were tested for normal distribution using the Shapiro-Wilk test. Continuous data with a normal distribution were represented as means\u2009¬±\u2009standard deviations and analyzed using ANOVA and the LSD-t post hoc test. Continuous data with a non-normal distribution were presented as medians (ranges) and analyzed using the Kruskal-Wallis H-test. Paired sample _t_-test signed rank sum test was used to compare before and after treatment. Categorical data were presented using n (%) and analyzed using the chi-squared test or Fisher‚Äôs exact test. Two-sided P-values\u2009<\u20090.05 were considered statistically significant. The graphs were prepared using GraphPad Prism 7.0 (GraphPad Software Inc., San Diego, CA, USA).\n\nResults\n-------\n\nAccording to the inclusion criteria, 97 patients with anti NMDAR encephalitis were included, 2 patients with concomitant tumors were excluded, and 5 patients with incomplete clinical data were excluded. Finally, 90 patients with anti NMDAR encephalitis were enrolled. Patients were grouped according to the adjuvant medications they received: group A (olanzapine group, _n_\u2009=\u200936), group B (magnesium valproate group, _n_\u2009=\u200930) and group C (lamotrigine group, _n_\u2009=\u200924).\n\n### Characteristics of the patients\n\nNinety patients were included in the study. The olanzapine group consisted of 24 males and 12 females. The patients were 28.50\u2009¬±\u20099.29 years old. The median disease course was 9.5 (4.00, 29.05) days. The time to drug initiation was 0 (0, 1) days. The magnesium valproate group included 17 males and 13 females. The patients were 29.97\u2009¬±\u200911.71 years old. The disease course was 10 (5, 20) days. The time to drug initiation was 0 (0, 2) days. The lamotrigine group included 13 males and 11 females. They were 33.88\u2009¬±\u20099.59 years old. The disease course was 10 (6.25, 17.25) days. The time to drug initiation was 0 (1, 3) days. There were no significant differences in the above indicators among the three groups (all _P_\u2009>\u20090.05). There were no significant differences in cognitive impairment, motor impairment, speech impairment, autonomic dysfunction, seizures, and decreased consciousness among the three groups before any treatment (all _P_\u2009>\u20090.05).\n\n### Psychiatric symptoms\n\nBefore treatment, there were no significant differences in total PANSS scores, positive symptom scores, negative symptom scores, and general psychopathological scores among the three groups (all _P_\u2009>\u20090.05). After 3 weeks of treatment, the PANSS total score and positive symptom scores in the magnesium valproate and lamotrigine groups were lower than in the olanzapine group (all _P_\u2009<\u20090.05). The general psychopathological scores in the magnesium valproate group were lower than in the olanzapine and lamotrigine groups after 3 weeks of treatment (_P_\u2009<\u20090.05). After 3 months of treatment, the PANSS total and negative symptom scores in the magnesium valproate and lamotrigine groups were lower than in the olanzapine group (all _P_\u2009<\u20090.05).\n\n### Cognitive functions\n\nAmong the 90 patients, 22 had missing data regarding the MoCA scores, and a total of 68 patients were included in the evaluation of cognitive performance. Among them, 26 patients were in the olanzapine group, 23 were in the magnesium valproate group, and 19 were in the lamotrigine group. Before treatment, the MoCA scores were 21.35\u2009¬±\u20093.76, 22.39\u2009¬±\u20094.30, and 22.26\u2009¬±\u20094.37 in the olanzapine, magnesium valproate, and lamotrigine groups, respectively (_P_\u2009>\u20090.05). After 3 months of treatment, the MoCA scores in the olanzapine, magnesium valproate, and lamotrigine groups were improved compared with baseline (all _P_\u2009<\u20090.05). Notably, after 3 weeks and 3 months of treatment, the scores in the magnesium valproate and lamotrigine groups were higher than in the olanzapine group (all _P_\u2009<\u20090.05).\n\n### Functional status of the patients\n\nThere were no significant differences in the mRS score among the olanzapine group (0/36, mRS score 0‚Äì1/mRS score\u2009‚â•\u20092), the magnesium valproate group (0/30), and the lamotrigine group (0/24) before treatment (all _P_\u2009>\u20090.05). After 3 months of treatment, the proportions of patients with an mRS score 0‚Äì1 in the magnesium valproate and lamotrigine groups were significantly higher than in the olanzapine group (all _P_\u2009<\u20090.05).\n\n### EEG characteristics\n\nBefore treatment, the EEG ranks were 7/29 (No\u2009+\u2009Mi/Mo\u2009+\u2009Se) in the olanzapine group, 7/23 in the magnesium valproate group, and 5/19 in the lamotrigine group. There were no significant differences among the three groups (_P_\u2009>\u20090.05). After 3 weeks and 3 months of treatment, the EEG ranks were as follows: 10/26 after 3 weeks and 18/18 after 3 months in the olanzapine group, 11/19 after 3 weeks, and 24/6 after 3 months in the magnesium valproate group, 12/12 after 3 weeks and 21/3 after 3 months in the olanzapine group. There was a significant improvement in the EEG characteristics after 3 weeks and 3 months of treatment (all _P_\u2009<\u20090.05). The abnormality EEG ranks at 3 months were significantly lower in the magnesium valproate and lamotrigine groups compared with the olanzapine group (all _P_\u2009<\u20090.05).\n\n### Excitatory/inhibitory rebalance\n\nCompared with the reference range for healthy people, the Glu powers (294.41\u2009¬±\u2009160.09, 300.55\u2009¬±\u2009205.34, and 314.46\u2009¬±\u2009224.11 for the olanzapine, magnesium valproate, and lamotrigine groups, respectively) were increased significantly, and the GABA powers (6.31\u2009¬±\u20095.04, 5.92\u2009¬±\u20094.68, and 5.26\u2009¬±\u20094.98 for the olanzapine, magnesium valproate, and lamotrigine groups, respectively) were decreased significantly in all three groups before treatment, while no intergroup difference existed at this point. The olanzapine group showed no significant alterations in Glu and GABA power after 3 months of treatment. Compared with the olanzapine group, the power of Glu was significantly decreased after treatment in the magnesium valproate group, whereas the power of GABA was significantly elevated after treatment. Similarly, compared with the olanzapine group, the power of Glu was decreased, and the power of GABA was increased after treatment in the lamotrigine group.\n\n### Cerebral Glx/Cr ratio measured by MRS\n\nThe Glx/Cr ratios before treatment were 0.35\u2009¬±\u20090.24, 0.30\u2009¬±\u20090.10, and 0.28\u2009¬±\u20090.20 for the olanzapine, magnesium valproate, and lamotrigine groups, respectively (_P_\u2009>\u20090.05). After 3 months of treatment, the Glx/Cr ratio in the olanzapine group remained comparable to the pre-treatment levels. However, in the magnesium valproate group, the Glx/Cr ratio significantly decreased, and in the lamotrigine group, it decreased compared to the pre-treatment levels. Furthermore, the Glx/Cr ratios obtained after 3 months of treatment were significantly lower in the magnesium valproate and lamotrigine groups compared to the olanzapine group.\n\nDiscussion\n----------\n\nThe findings of this study indicate that the addition of magnesium valproate or lamotrigine to immunotherapy might be associated with lower PANSS scores and higher MoCA scores compared to olanzapine. It has been observed that patients with anti-NMDAR encephalitis show an imbalance between glutamatergic and GABAergic neurotransmission in the brain. The beneficial effects of magnesium valproate and lamotrigine appear to be associated with restoring the balance between excitatory and inhibitory neurotransmission in the brain.\n\nIn patients with anti NMDAR encephalitis, the incidence of epileptic seizures is second only to mental disorders, consistent with previous reports. Other clinical symptoms in the present study included cognitive impairment, autonomic nerve dysfunction, decreased level of consciousness, dyskinesia, and speech disorder, also consistent with clinical characteristics reported in previous studies.\n\nImmunotherapy is the gold standard in the clinical management of anti-NMDAR encephalitis. Because the disease often presents with broad and complex neurological and psychiatric symptoms, other central nervous system medicines can be used for anti-NMDAR encephalitis. Along with the mainstay immunotherapy, adjuvant pharmacological intervention to facilitate the homeostasis of neurotransmission in the brain could be beneficial in the clinical management of anti-NMDAR encephalitis by managing specific symptoms related to the imbalance described above.\n\nOlanzapine, magnesium valproate, and lamotrigine are commonly used antipsychotics in the treatment of schizophrenia, epilepsy, bipolar disorder, and other psychiatric diseases. Although their specific use in anti-NMDAR encephalitis carries little evidence, they can be used to manage psychiatric symptoms. Compared with olanzapine, magnesium valproate and lamotrigine led to lower scores on the PANSS total score and positive symptom scores after 3 weeks of treatment. The MoCA scores were significantly higher with magnesium valproate and lamotrigine than with olanzapine. The proportions of patients with good clinical outcomes of mRS scores in the magnesium valproate and lamotrigine groups were greater than in the olanzapine group after 3 months of treatment.\n\nOlanzapine is a second-generation antipsychotic agent and exhibits high affinity to many neuroactive receptors, such as serotonin, dopamine Œ±-adrenaline, and histamine, with limited influence on the glutamatergic pathway. Limited evidence (mostly case reports) supports using olanzapine in anti-NMDAR encephalitis, with some effectiveness. Valproate is approved for manic or mixed episodes associated with bipolar disorder or for the prevention of migraine headaches; it can competitively inhibit GABA transferase and reduce its metabolism to increase the content of GABA in the brain, which may, in turn, inhibit glutamatergic neurons and reduce glutamate release. The evidence for valproate using in anti-NMDAR encephalitis is also limited but appears favorable, but the use of valproate before an anti-NMDAR encephalitis diagnosis could possibly interfere with the diagnosis. Lamotrigine mainly blocks glutamate release from the presynaptic membrane, inhibiting the excitatory action potential mediated by glutamate and managing seizures. Although lamotrigine has been reported to control the seizures associated with anti-NMDAR encephalitis, the evidence is limited. Previous evidence suggested that the dysfunction of the glutamatergic pathway is related to the epileptic symptoms of anti-NMDAR encephalitis.\n\nHowever, the mechanism by which NMDAR down-regulation causes complex clinical symptoms in patients with anti-NMDAR encephalitis remains incompletely understood. Some studies have proposed that besides NMDAR down-regulation and resulting glutamatergic hypofunction, an imbalance of excitatory/inhibitory neurotransmission may be involved in the pathogenesis and clinical manifestations among patients with anti-NMDAR encephalitis. Accordingly, the present study showed that such imbalances exist based on the Glu, GABA, and Glx/Cr ratio obtained by MRS and compared with reference values obtained from 10,000 healthy individuals in China.\n\nBased on their neuropharmacological characteristics, this study evaluated the clinical benefits of adjuvant administration of olanzapine, magnesium valproate, and lamotrigine in anti-NMDAR encephalitis, particularly about their capability of facilitating the rebalance of excitatory/inhibitory neurotransmission in the brain. Olanzapine treatment did not alter the Glu and GABA powers in the brain, nor the cortical Glx/Cr ratio, which is consistent with the notion that this drug does not modulate the glutamate system in the brain. On the contrary, adjuvant magnesium valproate lowered the Glu power and the Glx/Cr ratio and elevated GABA power in the cerebrum. Similarly, lamotrigine treatment reduced the power of Glu and Glx/Cr ratio but increased the power of GABA in the brain. Importantly, these above differential neurochemical modulations by the three drugs are associated with measurable differences regarding neurological recovery. Thus, compared with olanzapine, magnesium valproate, and lamotrigine showed better therapeutical effects, as indicated by the assessments on the extent of mitigation of mental symptoms, improvement of cognitive function, better functional outcome, and normalization of EEG features in patients with anti-NMDAR encephalitis.\n\nThis study had limitations. It was performed at a single hospital and included patients diagnosed over a limited period, resulting in a relatively small sample size. The retrospective nature of the study limited the data that could be analyzed to the ones available in the patient charts. No control group of patients treated with immunotherapy could be included because most patients received adjuvant treatments during the study period. Additional studies with other adjuvant drugs, such as memantine, ketamine, and intrathecal methotrexate, should be carried out to determine the most optimal adjuvant treatments and determine whether specific subgroups of patients could benefit more from a given drug.\n\nConclusion\n----------\n\nThis study shows that based on standard immunotherapy, adjuvant therapeutics aiming to correct the cerebral Glu/GABA or excitatory/inhibitory imbalance, such as valproate and lamotrigine, can improve the clinical outcome among patients with anti-NMDAR encephalitis.\n\nData availability\n-----------------\n\nAll data generated or analysed during this study are included in this published article.\n\nAbbreviations\n-------------\n\n3M: The 3rd month\n\n3W: The 3rd week\n\nBT: Before drug treatment\n\nCr: Creatine, contributed largely by GABA\n\nEEG: Electroencephalogram\n\nGABA: Glutamate (Glu) and Œ≥-aminobutyric acid\n\nGlx: Glutamate, contributed by glutamate, glutamine, and GABA together\n\nMo\u2009+\u2009Se: Moderate background and severe background abnormalities.\n\nMoCA: Montreal Cognitive Assessment Scale\n\nMRS: Magnetic resonance spectroscopy\n\nmRS: Modified Rankin scale score\n\nNMDAR: N-methyl-D-aspartate receptor\n\nNo\u2009+\u2009Mi: Normal and mild background abnormalities\n\nPANSS: Positive and negative symptom scale\n\nReferences\n----------\n\n1. Dalmau J, Armangu√© T, Planagum√† J, Radosevic M, Mannara F, Leypoldt F, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol. 2019;18:1045‚Äì57.\n\n2. Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15:391‚Äì404.\n\n3. Hau L, Cs√°bi G, T√©nyi T. [Anti-N-methyl-D aspartate receptor encephalitis - guideline to the challenges of diagnosis and therapy]. Psychiatr Hung. 2015;30:402‚Äì8.\n\n4. Abboud H, Probasco JC, Irani S, Ances B, Benavides DR, Bradshaw M, et al. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. J Neurol Neurosurg Psychiatry. 2021;92:757‚Äì68.\n\n5. Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L, Tsou R, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci. 2010;30:5866‚Äì75.\n\n6. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7:1091‚Äì8.\n\n7. Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad S, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol. 2009;66:11‚Äì8.\n\n8. Kim K, Caravella R, Deutch A, Gurin L. Adjunctive memantine for Catatonia due to Anti-NMDA receptor encephalitis. J Neuropsychiatry Clin Neurosci. 2023:appineuropsych20220206.\n\n9. Du J, Guo Y, Zhu Q. Use of anti-seizure medications in different types of autoimmune encephalitis: a narrative review. Front Neurol. 2023;14:1111384.\n\n10. Hommady R, Alsohibani A, Alayed R, Alshehri A, AbuMelha A, Aljomah L, et al. Effectiveness of intra-thecal methotrexate in refractory Anti-N-methyl-d-aspartate receptor encephalitis. BMC Neurol. 2023;23:261.\n\n11. Kay SR. Positive-negative symptom assessment in schizophrenia: psychometric issues and scale comparison. Psychiatr Q. 1990;61:163‚Äì78.\n\n12. Islam N, Hashem R, Gad M, Brown A, Levis B, Renoux C, et al. Accuracy of the Montreal Cognitive Assessment tool for detecting mild cognitive impairment: a systematic review and meta-analysis. Alzheimers Dement. 2023;19:3235‚Äì43.\n\n13. Banks JL, Marotta CA. Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke. 2007;38:1091‚Äì6.\n\n14. Broderick JP, Adeoye O, Elm J. Evolution of the Modified Rankin Scale and its use in future stroke trials. Stroke. 2017;48:2007‚Äì12.\n\n15. Zhang Y, Tu E, Yao C, Liu J, Lei Q, Lu W. Validation of the Clinical Assessment Scale in Autoimmune Encephalitis in Chinese patients. Front Immunol. 2021;12:796965.\n\n16. Macher S, Bsteh G, H√∂ftberger R, Berger T, Rommer P, Zrzavy T. Clinical scales in autoimmune encephalitis-A retrospective monocentric cohort study. Ann Clin Transl Neurol. 2023;10:1768‚Äì75.\n\n17. Ebersole JS, Husain AM, Nordli DR. Current Practice of Clinical Electroencephalography, Fourth Edition. Alphen aan den Rijn: Wolters Kluwer; 2014.\n\n18. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10:63‚Äì74.\n\n19. Ito H, Takano H, Takahashi H, Arakawa R, Miyoshi M, Kodaka F, et al. Effects of the antipsychotic risperidone on dopamine synthesis in human brain measured by positron emission tomography with L-[beta-11 C]DOPA: a stabilizing effect for dopaminergic neurotransmission? J Neurosci. 2009;29:13730‚Äì4.\n\n20. Bhat AA, Gupta G, Afzal O, Kazmi I, Al-Abbasi FA, Alfawaz Altamimi AS, et al. Neuropharmacological effect of risperidone: from chemistry to medicine. Chem Biol Interact. 2023;369:110296.\n\n21. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry. 2000;57:270‚Äì6.\n\n22. de Bruijn M, van Sonderen A, van Coevorden-Hameete MH, Bastiaansen AEM, Schreurs MWJ, Rouhl RPW, et al. Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABA(B)R encephalitis. Neurology. 2019;92:e2185‚Äì96.\n\n23. Nagai N, Watanabe K. [Olanzapine]. Nihon Rinsho. 2013;71:666‚Äì72.\n\n24. Del‚Äôguidice T, Beaulieu JM. Messing up with traffic: different effects of antipsychotic agents on glutamate receptor complexes in vivo. Mol Pharmacol. 2008;73:1339‚Äì42.\n\n25. Neerukonda N, Bliss M, Jafroodifar A, Leontieva L. Olanzapine and Lorazepam used in the Symptomatic Management of Excited Catatonia secondary to Anti-N-Methyl-D-Aspartate receptor encephalitis. Cureus. 2020;12:e8689.\n\n26. Gin√© Serv√©n E, Boix Quintana E, Guanyabens Busc√† N, Casado Ruiz V, Torres Rivas C, Niubo Gurgui M, et al. Considerations of psychotic symptomatology in anti-NMDA encephalitis: similarity to cycloid psychosis. Clin Case Rep. 2019;7:2456‚Äì61.\n\n27. Gobbi G, Janiri L. Sodium- and magnesium-valproate in vivo modulate glutamatergic and GABAergic synapses in the medial prefrontal cortex. Psychopharmacology. 2006;185:255‚Äì62.\n\n28. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev. 2010;62:405‚Äì96.\n\n29. Scharko AM, Panzer J, McIntyre CM. Treatment of delirium in the context of anti-N-methyl-D-aspartate receptor antibody encephalitis. J Am Acad Child Adolesc Psychiatry. 2015;54:233‚Äì4.\n\n30. Huang Q, Xie Y, Hu Z, Tang X. Anti-N-methyl-D-aspartate receptor encephalitis: a review of pathogenic mechanisms, treatment, prognosis. Brain Res. 2020;1727:146549.\n\n31. Toral D, Belzeaux R, Dumas R. Valproate delays diagnosis of anti-NMDA-receptor-encephalitis in a patient with psychiatric presentation. Aust N Z J Psychiatry. 2019;53:476‚Äì7.\n\n32. Zhang J, Sun J, Zheng P, Feng S, Yi X, Ren H, et al. Clinical characteristics and Follow-Up of seizures in Children with Anti-NMDAR Encephalitis. Front Neurol. 2021;12:801289.\n\n33. Liu HG, Yang AC, Meng DW, Chen N, Zhang JG. Stimulation of the anterior nucleus of the thalamus induces changes in amino acids in the hippocampi of epileptic rats. Brain Res. 2012;1477:37‚Äì44.\n\n34. Miya K, Takahashi Y, Mori H. Anti-NMDAR autoimmune encephalitis. Brain Dev. 2014;36:645‚Äì52.\n\n35. Liang Z, Yang S, Sun X, Li B, Li W, Liu Z, et al. Teratoma-associated anti-NMDAR encephalitis: two cases report and literature review. Med (Baltim). 2017;96:e9177.\n\n36. Lotfi M, Ghaderian Jahromi M, Firoozabadi A, Razeghian Jahromi L. Effect of adjuvant electroconvulsive therapy compared to antipsychotic medication alone on the brain metabolites of patients with chronic Schizophrenia: a Proton magnetic resonance spectroscopy study. Iran J Psychiatry. 2018;13:215‚Äì21.\n\nAcknowledgements\n----------------\n\nWe thank the physicians and nurses in the Department of Neurology of Hunan Brain Hospital for the care of the patients and Professor Xiao-Xin Yan at Central South University Xiangya School of Medicine for editorial assistance.\n\nFunding\n-------\n\nThis study was supported by the Natural Science Foundation of Hunan Province (#2018JJ6014) and the Department of Science and Technology of Hunan Province (#2020SK2122).\n\nAuthor information\n------------------\n\nAuthor notes\n\n1. Yinhua Yan and Chenxiao Yao contributed equally to this work.\n\n### Authors and Affiliations\n\n1. College of Clinical Medicine, Hunan University of Chinese Medicine, Changsha, 410007, Hunan, China\n\n    Yinhua Yan, Bo Zhang, Zhenyu Yang, Jiahui Xie, Miao Tang, Qiong Long & Ewen Tu\n\n2. Department of Neurology, Brain Hospital of Hunan Province (The Second Hospital of Hunan Province), Changsha, 410007, Hunan, China\n\n    Yinhua Yan, Zhenyu Yang, Jiahui Xie, Miao Tang, Qiong Long & Ewen Tu\n\n3. The Hospital of Trade-Business of Hunan Province, Changsha, 410006, Hunan, China\n\n    Chenxiao Yao\n\n4. Hunan society of traditional Chinese medicine and integrated traditional Chinese and Western Medicine, Changsha, 410005, Hunan, China\n\n    Bo Zhang\n\n5. Brain Hospital of Hunan Province, Brain Hospital of Hunan Province(The Second Hospital of Hunan Province), Changsha, 410007, Hunan, China\n\n    Xuanqi Dong\n\nAuthors\n\n1. Yinhua Yan\n\n    You can also search for this author in [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Yinhua%20Yan) [Google Scholar](http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Yinhua%20Yan%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\n\n2. Chenxiao Yao\n\n    You can also search for this author in [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Chenxiao%20Yao) [Google Scholar](http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Chenxiao%20Yao%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\n\n3. Bo Zhang\n\n    You can also search for this author in [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Bo%20Zhang) [Google Scholar](http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Bo%20Zhang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\n\n4. Zhenyu Yang\n\n    You can also search for this author in [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Zhenyu%20Yang) [Google Scholar](http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Zhenyu%20Yang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\n\n5. Jiahui Xie\n\n    You can also search for this author in [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jiahui%20Xie) [Google Scholar](http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jiahui%20Xie%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\n\n6. Miao Tang\n\n    You can also search for this author in [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Miao%20Tang) [Google Scholar](http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Miao%20Tang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\n\n7. Qiong Long\n\n    You can also search for this author in [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Qiong%20Long) [Google Scholar](http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Qiong%20Long%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\n\n8. Ewen Tu\n\n    You can also search for this author in [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ewen%20Tu) [Google Scholar](http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ewen%20Tu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\n\n9. Xuanqi Dong\n\n    You can also search for this author in [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Xuanqi%20Dong) [Google Scholar](http://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Xuanqi%20Dong%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en)\n\n### Contributions\n\nAll authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Y.H.Y., C.X.Y., B.Z, Z.Y.Y., M.T., Q.L., and J.H.X. The first draft of the manuscript was written by Y.H.Y. and C.X.Y. All authors commented on previous versions of the manuscript. All authors have read and agreed to the published version of the manuscript.\n\n### Corresponding authors\n\nCorrespondence to Ewen Tu or Xuanqi Dong.\n\nEthics declarations\n-------------------\n\n### Ethics approval and consent to participate\n\nI confirm that all methods were performed in accordance with the relevant guidelines. This work has been carried out in accordance with the Declaration of Helsinki (2000) of the World Medical Association. This study has been approved by the Medical Ethics Committee of Hunan Brain Hospital (approval #2018K065). The requirement for informed consent was waived by the committee because of the retrospective nature of the study. All data were anonymized after extraction and before analysis.\n\n### Consent for publication\n\nNot applicable.\n\n### Competing interests\n\nThe authors declare no competing interests.\n\nAdditional information\n----------------------\n\n### Publisher‚Äôs note\n\nSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.\n\nElectronic supplementary material\n---------------------------------\n\nRights and permissions\n----------------------\n\n**Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article‚Äôs Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article‚Äôs Creative Commons licence, and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/).\n\nAbout this article\n------------------\n\nCite this article\n\nYan, Y., Yao, C., Zhang, B. _et al._ Olanzapine vs. magnesium valproate vs. lamotrigine in anti-N-methyl-D-aspartic acid receptor encephalitis: a retrospective study. _BMC Neurol_ **24**, 331 (2024). https://doi.org/10.1186/s12883-024-03811-z\n\n*   Received: 18 February 2024\n\n*   Accepted: 20 August 2024\n\n*   Published: 09 September 2024\n\n*   DOI: https://doi.org/10.1186/s12883-024-03811-z\n\n### Keywords', 'gpt-4o-mini']
2024-09-11 08:15:36,906 - INFO - Logged data to databases/llm.csv with DocumentID: fEIcd8MvuEf5WfoyM32k.
2024-09-11 08:15:36,906 - INFO - 'generated_post' length: 9. Content: ['2024-09-11 07:39:00', '2024-09-11 08:14:45', 'Have you considered the potential role of diabetes medication in HIV treatment? ü§î \n\n- New research from the Universit√© de Montr√©al reveals that metformin, a drug primarily used for type 2 diabetes, may play a crucial role in managing HIV by targeting immune reservoirs. \n- After three months of metformin usage, patients exhibited reduced chronic inflammation and improved immunity, thanks to inhibition of HIV replication via the mTOR pathway. \n- Surprisingly, metformin demonstrated a dual effect by both increasing HIV-infected cells and preventing the virus from escaping. This nuanced interaction highlights the complexity of viral reservoirs and immune response. \n- The study found metformin enhances the BST2 protein levels, which helps the immune system recognize and eliminate HIV-infected cells more effectively through neutralizing antibodies. \n- This encourages the application of a revised "shock-and-kill" strategy for HIV eradication, suggesting that metformin could reactivate viral reservoirs in conjunction with existing therapeutic antibodies. \n\nAs researchers embark on clinical trials to explore these findings further, how might this reshape our understanding of treatment strategies for patients with HIV?  \n\nFor more insights, read the full study here: https://medicalxpress.com/news/2024-09-diabetes-drug-immune-reservoirs-hiv.html', ['Research & Clinical Trials', 'ClinicalTrials', 'InfectiousDiseases', 'HealthTech', 'Hematology'], 'https://images.pexels.com/photos/7723389/pexels-photo-7723389.jpeg', 'https://medicalxpress.com/news/2024-09-diabetes-drug-immune-reservoirs-hiv.html', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'Diabetes drug helps the immune system recognize reservoirs of HIV, study discovers\n==================================================================================\n\nby Bruno Geoffroy, University of Montreal Hospital Research Centre\n\nMetformin, a drug used to treat type 2 diabetes, could help deplete the viral reservoir and eliminate it entirely in people living with HIV who receive antiretroviral therapy, Canadian researchers say in a new study.\n\nIn 2021, a team led by immunologist Petronela Ancuta of Universit√© de Montr√©al\'s affiliated hospital research center, the CRCHUM, showed that metformin, when taken for three months, improved patients\' immunity and reduced the chronic inflammation usually associated with complications such as cardiovascular disease.\n\nOne reason these benefits are so effective is that metformin inhibits the activity of the mTOR (mechanistic target of rapamycin) molecule, which in turn slows down HIV replication in the cells of patients infected with the virus.\n\nIn the journal _iScience_, Ancuta and her student Augustine Fert, the study\'s first author and a recent Ph.D. holder, go further. They studied the molecular mechanisms of action of metformin on HIV replication in CD4 T lymphocytes, which are immune system cells that provide shelter for the virus.\n\nIn these reservoirs, HIV keeps on replicating, which contributes to the chronic inflammation by constantly activating the immune system.\n\n"The results of our in vitro tests on cells from people living with HIV and treated with antiretroviral therapy caught us off guard at first," said Ancuta. "They were a bit surprising. We discovered that metformin had both a proviral and an antiviral effect. The drug helped boost the number of HIV-infected cells, while also stopping the virus from escaping the cell."\n\nAntibodies to the rescue\n------------------------\n\nAnother benefit of metformin is that it overexpresses the BST2 protein, which acts as a kind of glue to keep virions clinging to the surface of HIV-infected cells. The immune system then spots them and can target them with antibodies.\n\n"Together with my colleague Andr√©s Finzi, we tested the ability of several broad-spectrum neutralizing anti-HIV antibodies to recognize viral reservoir cells after metformin exposure in vitro," said Ancuta. "Some of them recognized the virus very well, suggesting their ability to attract and trigger the destruction of infected cells by NK cells through a process of cellular cytotoxicity."\n\nThese recent scientific advances mean that the "shock-and-kill" eradication strategy, often used in the fight against HIV, can be foreseen in a different way, she added.\n\n"In people living with HIV and treated with antiretroviral therapy, we could use metformin to reactivate the reservoir cells responsible for viral replication upon treatment interruption, in combination with antibodies that are already used clinically and well tolerated. These antibodies can then detect the rare infected cells and eliminate them."\n\nIn the next phase of her research, Ancuta plans to launch a clinical trial to validate her in vitro research results, in collaboration with Finzi and their CRCHUM colleague Nicolas Chomont, and Jean-Pierre Routy of the McGill University Health Center Research Institute.\n\nBefore she can move forward with this strategy, she will test it in preclinical models.\n\n**More information:** Augustine Fert et al, Metformin facilitates viral reservoir reactivation and their recognition by anti-HIV-1 envelope antibodies, _iScience_ (2024). DOI: 10.1016/j.isci.2024.110670\n\n**Journal information:** _iScience_\n\nProvided by University of Montreal Hospital Research Centre\n\n**Citation**: Diabetes drug helps the immune system recognize reservoirs of HIV, study discovers (2024, September 10) retrieved 11 September 2024 from https://medicalxpress.com/news/2024-09-diabetes-drug-immune-reservoirs-hiv.html\n\nThis document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.', 'gpt-4o-mini']
2024-09-11 08:15:36,907 - INFO - Logged data to databases/llm.csv with DocumentID: W4TMfs0JxyijACiukOeF.
2024-09-11 08:15:36,907 - INFO - 'generated_post' length: 9. Content: ['2024-09-11 07:23:00', '2024-09-11 08:15:08', 'üò∑ Have you ever considered the role of antidepressants in managing breathlessness for respiratory disease patients? Recent findings should give us pause.\n\n- A newly published phase 3 trial, BETTER B, has found that mirtazapine does not significantly reduce breathlessness in adults with COPD or interstitial lung disease. Despite its previous promise, this study urges healthcare professionals to rethink off-label prescribing of antidepressants for this purpose.\n\n- üòØ Participants were randomized into mirtazapine and placebo groups, and after 56 days of treatment, results showed no difference in the severity of breathlessness between the groups: adjusted mean score difference was 0.105 (P = 0.69). \n\n- With adverse events noted in 64% of participants on mirtazapine (most commonly dry mouth and sedation), the authors emphasized caution. They recommend rigorous trials for medications used in palliative care due to the lack of effective treatments for breathlessness.\n\nAs our understanding of symptom management evolves, how can we safely explore treatment options beyond our traditional boundaries? ü§î  \n\nFor further details, you can read the full study here: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(24)00187-5/fulltext\n\n#ClinicalTrials #RespiratoryHealth #PalliativeCare #MedicationSafety', ['Research & Clinical Trials', 'ClinicalTrials', 'PalliativeCare', 'Psychiatry', 'PatientSafety'], 'https://images.pexels.com/photos/5858850/pexels-photo-5858850.jpeg', 'https://www.hcplive.com/view/mirtazapine-fails-to-ease-breathlessness-in-new-study-despite-previous-hopes', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'Mirtazapine Fails to Ease Breathlessness in New Study Despite Previous Hopes\n===============================================================================\n\nSeptember 10, 2024\n\nBy Chelsie Derman\n\nNews\n\nArticle\n\nA phase 3 trial found mirtazapine ineffective in reducing breathlessness in respiratory disease patients, urging caution with off-label antidepressant use.\n\nMirtazapine may have previously shown promise in the modulation of respiratory sensation, but a new phase 3 study revealed this antidepressant does not improve breathlessness in patients with respiratory disease.\n\n‚ÄúDespite being a widespread issue, we still don‚Äôt have effective treatments available,‚Äù said first author Irene Higginson, FFPHM, from King‚Äôs College London, in a statement. ‚ÄúAs such, many doctors turn to off-label prescribing, trying to help their patients.‚Äù\n\nIt has been suggested antidepressants may modulate respiratory sensation even in the absence of a mood disorder by increasing serotonin levels in respiratory control and other centers such as the amygdala. After all, mirtazapine reduces panic, and it is known panic often comes with episodes of severe breathlessness.\n\nAlthough an earlier trial found sertraline did not affect chronic breathlessness, Higginson and colleagues conducted a study to evaluate whether another antidepressant‚Äîmirtazapine‚Äîwas effective at reducing breathlessness. Findings of BETTER B, an international, multicenter, phase 3, parallel-group, double-blind, randomized, placebo-controlled pragmatic trial, were presented at the ERS Congress in Vienna. The BETTER B trial was conducted in 16 centers in Australia, Germany, Ireland, Italy, New Zealand, Poland, and the UK and was informed by a feasibility trial published in 2020.\n\nThe primary outcome was the reduction of self-reported worst breathlessness over the past 24 hours, measured at day 56, compared with placebo. Secondary outcomes included the worst breathlessness at various times, average breathlessness, number and duration of breathlessness episodes, and physical and emotional aspects of breathlessness such as dyspnea, fatigue, emotional function, and quality life. Another secondary outcome was symptoms and concerns evaluated by the integrated palliative care outcome scale.\n\nThe sample, screened between February 4, 2021, and March 28, 2024, were aged ‚â• 18 years (mean age: 74 years); had either COPD, interstitial lung diseases, or both; and were grade 3 or 4 of the modified Medical Research Council breathlessness scale. All participants were stable for the previous 2 weeks before baseline and on optimal treatment for reversible causes of breathlessness, determined by the referring clinician and best clinical guidance. People were excluded from the study if they had existing use of antidepressants or serotonergic active substances, had known contraindications to mirtazapine, or received an Australia-modified Karnofsky Performance Scale score of ‚â§ 40 which indicates they are in bed ‚â• 50% of the time.\n\nParticipants (n = 225) were randomized 1:1 to receive either mirtazapine or placebo daily for 56 days. They had a dose of 15 mg orally for the first 14 days. After that, there were 2 assessments for dose escalations, at days 14 and 28. Participants had their dose increased to 30 mg at day 14 and to 45 mg at day 28 if they did not show improvement in their breathlessness, measured using the Numerical Rating Scale over the previous 24 hours. At the end of day 56, the dose was tapered and discontinued.\n\nInvestigators assessed participants at baseline and at days 7, 14, 28, 56, and 7 days after completing the trial to assess for safety and toxicity of the treatment. Participants were called 180 days from baseline by phone, video call, or mail to complete the last self-reported questionnaire. Caregivers completed questionnaires at days 28, 56, and 180.\n\nAt day 14, nearly half (48%) of participants on mirtazapine had escalation, compared with 53% on placebo. At day 28, 35% participants on mirtazapine had escalation, which was slightly less than those on placebo (36%).\n\nAt day 56, 3 participants on mirtazapine and 2 on placebo died. At day 180, the number of people who died was 6% in the mirtazapine arm and 10% in the placebo arm. In total, 5 participants were lost to follow-up, with 3% in the mirtazapine arm and 2% in the placebo arm.\n\nInvestigators did not observe a difference in worst breathlessness score day 56 between mirtazapine and placebo (difference in adjusted mean score [mirtazapine minus placebo], 0.105; 95% confidence interval [CI], -0.407 to 0.618; P = .69). The sensitivity analysis, to account for missing data, also found no evidence of a difference between treatment arms (difference in adjusted mean score; 0.232; 95% CI, -9.308 to 0.773; P = .40). Secondary outcomes also demonstrated no differences between the arms in terms of measures of breathlessness, overall palliative symptoms, average breathlessness score, chronic respiratory questionnaire subscales, anxiety and depression, number and duration of breathlessness, Australia-modified Karnofsky performance scale, and generalized-efficacy scale.\n\nThe study reported 215 adverse events in 64% participants on mirtazapine and 40% on placebo, with the most common ones in the mirtazapine arm being dry mouth, somnolence, fatigue, and sedation. Serious adverse events occurred in 5% of participants on mirtazapine and 6% on placebo.\n\n‚ÄúThis new trial concludes that mirtazapine is not recommended for the treatment of breathlessness, that the use of unlicensed medicines should be approached with caution and that it‚Äôs crucial to subject medicines in palliative care to rigorous trials,‚Äù Higginson said.\n\nReferences\n\n1. Higginson, I, Brown, S, Oluyase, A, et al. Mirtazapine to alleviate severe breathlessness in patients with COPD or interstitial lung diseases (BETTER-B): an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial. The Lancet Respiratory Medicine. 2024. [https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(24)00187-5/fulltext](https://www.thelancet.com/journals/lanres/article/PIIS2213-2600/(24/)00187-5/fulltext). Accessed September 10, 2024.\n2. Drugs prescribed off-label may do more harm than good. EurekAlert! September 9, 2024. [https://www.eurekalert.org/news-releases/1056889](https://www.eurekalert.org/news-releases/1056889). Accessed September 10, 2024.', 'gpt-4o-mini']
2024-09-11 08:15:36,908 - INFO - Logged data to databases/llm.csv with DocumentID: CqFgQAXBzh42vFImeW4o.
2024-09-11 08:15:36,908 - INFO - 'generated_post' length: 9. Content: ['2024-09-11 07:16:00', '2024-09-11 08:15:22', 'üéâ Exciting developments in the realm of neuroendocrine carcinoma treatments! \n\n- The FDA has granted orphan drug designation to ABD-147, a next-generation radiopharmaceutical specifically designed to target aggressive neuroendocrine tumors. This designation paves the way for Abdera Therapeutics to benefit from important incentives, such as tax credits for clinical trials and potential market exclusivity for up to 7 years.  \n\n- ‚öóÔ∏è ABD-147 employs a unique mechanism: it delivers actinium-225 to tumors expressing DLL3, a protein often found in high-grade neuroendocrine carcinomas like small cell lung cancer (SCLC). Dr. Philippe Bishop notes that current therapies lack effectiveness against these aggressive forms, underscoring the need for innovative solutions.  \n\n- This year marks the initiation of a Phase 1 trial evaluating the safety and efficacy of ABD-147 in patients with previously treated LCNEC and SCLC. The earlier fast track designation emphasizes its potential to address significant unmet medical needs effectively.  \n\nAs we await further progress on this promising treatment, how do you envision the future landscape of targeted therapies for high-grade neuroendocrine tumors? ü§î  \n\nFor further insights, check out the full article here: https://www.targetedonc.com/view/fda-grants-orphan-drug-designation-to-abd-147-in-neuroendocrine-carcinoma', ['Life Sciences & BioTech', 'Oncology', 'PrecisionMedicine', 'ClinicalTrials', 'Neurology', 'HealthTech'], 'https://images.pexels.com/photos/6724357/pexels-photo-6724357.jpeg', 'https://www.targetedonc.com/view/fda-grants-orphan-drug-designation-to-abd-147-in-neuroendocrine-carcinoma', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'FDA Grants Orphan Drug Designation to ABD-147 in Neuroendocrine Carcinoma\n=========================================================================\n\nSeptember 10, 2024\n\nBy [Sabrina Serani](https://www.targetedonc.com/authors/sabrina-serani)\n\nFact checked by [Jordyn Sava](https://www.targetedonc.com/authors/jordyn-sava)\n\n_News_\n\n_Article_\n\n[FDA Briefs|September 2024 Brief](https://www.targetedonc.com/fda-briefs/september-2024-brief)\n\nThe next-generation radiopharmaceutical ABD-147 was previously granted FDA fast track designation in extensive-stage small cell lung cancer.\n\nABD-147, a next-generation precision radiopharmaceutical, has been granted orphan drug designation by the FDA for the treatment of neuroendocrine carcinoma.\n\nWith this designation, Abdera Therapeutics, the sponsor, can be eligible for incentives like tax credits for clinical trials, exemption from user fees, and a potential 7 years of market exclusivity.\n\n‚ÄúNeuroendocrine carcinomas, including SCLC and LCNEC, are aggressive and challenging to treat effectively with current systemic therapies,‚Äù said Philippe Bishop, MD, chief medical officer of Abdera Therapeutics, in a press release. ‚ÄúBy delivering a potent radioisotope to neuroendocrine tumors expressing DLL3 with custom-engineered pharmacokinetic properties, we believe ABD-147 has the potential to become a best-in-class DLL3-targeting treatment for aggressive neuroendocrine tumors.‚Äù\n\nIn July 2024, the FDA also granted fast track designation to ABD-147 in extensive-stage SCLC. The fast track designation is intended to facilitate the development and review of drugs that treat serious conditions and fill unmet needs. The designation provides the sponsor with more frequent communication with the FDA as well as eligibility for accelerated approval and priority review.\n\nThis year, Abdera will begin a phase 1, first-in-human study evaluating ABD-147 in LCNEC and SCLC that has been previously treated with platinum-based therapy.\n\nABD-147 is designed to deliver actininum-225 to DLL3-expressing tumors. DLL3 is upregulated in some high-grade neuroendocrine carcinomas, including SCLC, while it is typically absent on the surface of nonmalignant cells, making it an attractive target for radiotherapy.\n\n###### REFERENCES:\n\n###### 1. Abdera Therapeutics announces FDA orphan drug designation for ABD-147 for the treatment of neuroendocrine carcinoma. News release. Abdera Therapeutics. September 5, 2024. Accessed September 10, 2024. [https://tinyurl.com/fccse5a7](https://tinyurl.com/fccse5a7)\n\n###### 2. Abdera Therapeutics announces FDA fast track designation for ABD-147, a next-generation precision radiopharmaceutical therapy, for the treatment of patients with extensive-stage small cell lung cancer. News release. Abdera Therapeutics. June 27, 2024. Accessed September 10, 2024. [https://tinyurl.com/3k2y8ece](https://tinyurl.com/3k2y8ece)', 'gpt-4o-mini']
2024-09-11 08:15:36,909 - INFO - Logged data to databases/llm.csv with DocumentID: nCVkmQNqfHfq6243bJkK.
2024-09-11 09:21:15,865 - INFO - Extracted 24 link records.
2024-09-11 09:21:15,870 - INFO - Extracted 24 image links.
2024-09-11 09:21:15,873 - INFO - Extracted 15 link records.
2024-09-11 09:21:15,875 - INFO - Extracted 5 link records.
2024-09-11 09:21:15,877 - INFO - Extracted 9 link records.
2024-09-11 09:21:15,877 - INFO - Unique links to process: 5
2024-09-11 09:21:15,877 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 09:21:17,512 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/, now generating post.
2024-09-11 09:21:17,973 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 09:21:17,975 - INFO - No article found for link https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/.
2024-09-11 09:21:17,976 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/. Skipping.
2024-09-11 09:21:17,976 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 09:21:17,976 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 09:21:20,074 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/, now generating post.
2024-09-11 09:21:20,574 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 09:21:20,575 - INFO - No article found for link https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/.
2024-09-11 09:21:20,575 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/. Skipping.
2024-09-11 09:21:20,575 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 09:21:20,575 - INFO - Starting to process link: http://r.jina.ai/https://www.prnewswire.com/news-releases/once-weekly-dose-of-insulin-efsitora-alfa-delivers-a1c-reduction-consistent-with-the-most-advanced-daily-insulin-in-people-with-type-2-diabetes-302243899.html
2024-09-11 09:21:22,049 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://www.prnewswire.com/news-releases/once-weekly-dose-of-insulin-efsitora-alfa-delivers-a1c-reduction-consistent-with-the-most-advanced-daily-insulin-in-people-with-type-2-diabetes-302243899.html, now generating post.
2024-09-11 09:21:49,754 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 09:21:54,177 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 09:21:54,504 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 09:21:54,505 - INFO - Image query: "diabetes management clinical trial"
2024-09-11 09:21:54,745 - INFO - Unique image link: https://images.pexels.com/photos/6823602/pexels-photo-6823602.jpeg
2024-09-11 09:21:54,746 - INFO - Post generated successfully for link: http://r.jina.ai/https://www.prnewswire.com/news-releases/once-weekly-dose-of-insulin-efsitora-alfa-delivers-a1c-reduction-consistent-with-the-most-advanced-daily-insulin-in-people-with-type-2-diabetes-302243899.html
2024-09-11 09:21:54,746 - INFO - Starting to process link: http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 09:21:57,410 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296, now generating post.
2024-09-11 09:21:57,846 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 09:21:57,846 - INFO - No article found for link https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296.
2024-09-11 09:21:57,846 - ERROR - No valid post generated for http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296. Skipping.
2024-09-11 09:21:57,846 - WARNING - Skipping entry due to missing or invalid log entry for link: https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 09:21:57,846 - INFO - Starting to process link: http://r.jina.ai/http://medscape.co.uk/viewarticle/top-tips-polycystic-ovary-syndrome-2024a1000fn8
2024-09-11 09:21:58,653 - INFO - Successfully fetched webpage content from http://r.jina.ai/http://medscape.co.uk/viewarticle/top-tips-polycystic-ovary-syndrome-2024a1000fn8, now generating post.
2024-09-11 09:23:35,699 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 09:23:42,483 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 09:23:42,860 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 09:23:42,861 - INFO - Image query: "polycystic ovary syndrome management"
2024-09-11 09:23:43,069 - INFO - Unique image link: https://images.pexels.com/photos/6837638/pexels-photo-6837638.jpeg
2024-09-11 09:23:43,069 - INFO - Post generated successfully for link: http://r.jina.ai/http://medscape.co.uk/viewarticle/top-tips-polycystic-ovary-syndrome-2024a1000fn8
2024-09-11 09:23:43,069 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/6823602/pexels-photo-6823602.jpeg'}
2024-09-11 09:23:43,069 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 09:23:43,069 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/6837638/pexels-photo-6837638.jpeg'}
2024-09-11 09:23:43,069 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 09:23:43,069 - INFO - Sending 2 log entries to Firebase.
2024-09-11 09:23:48,138 - INFO - Successfully sent batch data to Firebase: {'message': 'Batch processed successfully. 1 posts added.', 'documentIDs': ['YljJD5CZ6sQmpoIvKgys']}
2024-09-11 09:23:48,138 - ERROR - Mismatch in the number of document IDs and batch log entries. Got 1 document IDs for 2 entries.
2024-09-11 09:23:48,138 - ERROR - No document IDs returned from Firebase.
2024-09-11 09:23:48,138 - ERROR - No document IDs returned from Firebase, or mismatch in the number of entries. Skipping CSV logging.
2024-09-11 09:39:29,604 - INFO - Extracted 24 link records.
2024-09-11 09:39:29,609 - INFO - Extracted 24 image links.
2024-09-11 09:39:29,611 - INFO - Extracted 15 link records.
2024-09-11 09:39:29,613 - INFO - Extracted 5 link records.
2024-09-11 09:39:29,616 - INFO - Extracted 9 link records.
2024-09-11 09:39:29,616 - INFO - Unique links to process: 5
2024-09-11 09:39:29,616 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 09:39:30,028 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/, now generating post.
2024-09-11 09:39:30,405 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 09:39:30,407 - INFO - No article found for link https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/.
2024-09-11 09:39:30,407 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/. Skipping.
2024-09-11 09:39:30,407 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 09:39:30,407 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 09:39:30,803 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/, now generating post.
2024-09-11 09:39:31,220 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 09:39:31,221 - INFO - No article found for link https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/.
2024-09-11 09:39:31,221 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/. Skipping.
2024-09-11 09:39:31,221 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 09:39:31,221 - INFO - Starting to process link: http://r.jina.ai/https://www.prnewswire.com/news-releases/once-weekly-dose-of-insulin-efsitora-alfa-delivers-a1c-reduction-consistent-with-the-most-advanced-daily-insulin-in-people-with-type-2-diabetes-302243899.html
2024-09-11 09:39:32,164 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://www.prnewswire.com/news-releases/once-weekly-dose-of-insulin-efsitora-alfa-delivers-a1c-reduction-consistent-with-the-most-advanced-daily-insulin-in-people-with-type-2-diabetes-302243899.html, now generating post.
2024-09-11 09:40:02,434 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 09:40:06,816 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 09:40:07,102 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 09:40:07,105 - INFO - Image query: "diabetes care innovation"
2024-09-11 09:40:07,373 - INFO - Unique image link: https://images.pexels.com/photos/17072086/pexels-photo-17072086.jpeg
2024-09-11 09:40:07,373 - INFO - Post generated successfully for link: http://r.jina.ai/https://www.prnewswire.com/news-releases/once-weekly-dose-of-insulin-efsitora-alfa-delivers-a1c-reduction-consistent-with-the-most-advanced-daily-insulin-in-people-with-type-2-diabetes-302243899.html
2024-09-11 09:40:07,373 - INFO - Starting to process link: http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 09:40:08,013 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296, now generating post.
2024-09-11 09:40:08,861 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 09:40:08,862 - INFO - No article found for link https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296.
2024-09-11 09:40:08,862 - ERROR - No valid post generated for http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296. Skipping.
2024-09-11 09:40:08,862 - WARNING - Skipping entry due to missing or invalid log entry for link: https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 09:40:08,862 - INFO - Starting to process link: http://r.jina.ai/http://medscape.co.uk/viewarticle/top-tips-polycystic-ovary-syndrome-2024a1000fn8
2024-09-11 09:40:09,571 - INFO - Successfully fetched webpage content from http://r.jina.ai/http://medscape.co.uk/viewarticle/top-tips-polycystic-ovary-syndrome-2024a1000fn8, now generating post.
2024-09-11 09:41:38,967 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 09:41:44,884 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 09:41:45,224 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 09:41:45,225 - INFO - Image query: "PCOS awareness and management"
2024-09-11 09:41:45,363 - INFO - Unique image link: https://images.pexels.com/photos/8378750/pexels-photo-8378750.jpeg
2024-09-11 09:41:45,364 - INFO - Post generated successfully for link: http://r.jina.ai/http://medscape.co.uk/viewarticle/top-tips-polycystic-ovary-syndrome-2024a1000fn8
2024-09-11 09:41:45,364 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/17072086/pexels-photo-17072086.jpeg'}
2024-09-11 09:41:45,364 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 09:41:45,364 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/8378750/pexels-photo-8378750.jpeg'}
2024-09-11 09:41:45,364 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 09:41:45,364 - INFO - Sending 2 log entries to Firebase.
2024-09-11 09:41:50,804 - INFO - Successfully sent batch data to Firebase: {'message': 'Batch processed successfully. 2 posts added.', 'documentIDs': ['7l0VhTb9XPwjaQToapdm', 'm4TLJoxCYBP1g16HLycj']}
2024-09-11 09:41:50,804 - INFO - Received 2 document IDs from Firebase.
2024-09-11 09:41:50,804 - INFO - 'generated_post' length: 9. Content: ['2024-09-11 07:10:00', '2024-09-11 09:40:06', 'üåü Exciting news in diabetes care! Have you heard about the advances with insulin efsitora alfa?\n\n- In the recent QWINT-2 phase 3 trial, efsitora, a once-weekly insulin option, demonstrated comparable A1C reduction to the leading daily insulin, degludec. After 52 weeks, participants on efsitora achieved an impressive A1C of 6.87%, reducing A1C by 1.34% compared to 1.26% for degludec. \n- üìà Additionally, patients using efsitora enjoyed 45 more minutes in their target glucose range daily without increasing the risk of hypoglycemia.\n- Dr. Carol Wysham emphasizes the potential of efsitora to alleviate the complexities of daily insulin injections, which is a breakthrough for enhancing patient adherence and quality of life.\n- Noteworthy is the safety profile of efsitora, showing no severe hypoglycemic events during the trial, unlike its daily counterpart. \n\nAs we strive for improved diabetes management strategies, can a once-weekly option revolutionize how we treat type 2 diabetes? ü§î  \n\nTo dive deeper into the study findings, visit: https://www.prnewswire.com/news-releases/once-weekly-dose-of-insulin-efsitora-alfa-delivers-a1c-reduction-consistent-with-the-most-advanced-daily-insulin-in-people-with-type-2-diabetes-302243899.html', ['Research & Clinical Trials', 'DigitalHealth', 'Endocrinology', 'ClinicalTrials', 'DigitalHealth'], 'https://images.pexels.com/photos/17072086/pexels-photo-17072086.jpeg', 'https://www.prnewswire.com/news-releases/once-weekly-dose-of-insulin-efsitora-alfa-delivers-a1c-reduction-consistent-with-the-most-advanced-daily-insulin-in-people-with-type-2-diabetes-302243899.html', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes\n===============================================================================================================================================\n\nNews provided by\n\nEli Lilly and Company Sep 10, 2024, 11:18 ET\n\nShare this article\n\nIn QWINT-2, efsitora helped adults na√Øve to insulin therapy currently using and not using GLP-1 receptor agonists achieve an A1C below 7%\n\nDetailed results were published in The New England Journal of Medicine and simultaneously presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024\n\nINDIANAPOLIS, Sept. 10, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the QWINT-2 phase 3 trial evaluating once-weekly insulin efsitora alfa (efsitora) compared to once-daily insulin degludec in adults with type 2 diabetes using insulin for the first time (insulin na√Øve). The data were published in The New England Journal of Medicine (NEJM) and simultaneously presented today at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024.\n\nIn the trial, efsitora met the primary endpoint of non-inferior A1C reduction. For the efficacy estimand, efsitora reduced A1C by 1.34% compared to 1.26% for insulin degludec resulting in an A1C of 6.87% and 6.95% respectively at 52 weeks.\n\nAdditionally, participants taking efsitora achieved 45 minutes more time in range per day, a key secondary endpoint, without additional time in hypoglycemia (glucose <54 mg/dL) in comparison to insulin degludec for the efficacy estimand.\n\n"Traditionally, basal insulins are dosed once a day ‚Äî a treatment schedule that can make compliance difficult for a significant portion of people living with type 2 diabetes," said Carol Wysham, M.D., clinical professor of medicine at the University of Washington School of Medicine. "Efsitora has the potential to address treatment burden and improve adherence ‚Äî all while lowering A1C. These results can make a significant impact for people living with type 2 diabetes looking for a once-weekly option that provides similar outcomes as daily insulins."\n\n**Full Results**\n\n**QWINT-2 Study: Primary and Secondary Endpoints**\n\nEfficacy Estimand\n\nTreatment-Regimen Estimand\n\nPrimary Endpoint ‚Äì A1C Reduction (Resulting A1C) at Week 52\n\nEfsitora\n\n-1.34% (6.87%)\n\n-1.26% (6.97%)\n\nDegludec\n\n-1.26% (6.95%)\n\n-1.17% (7.05%)\n\nSecondary Endpoint ‚Äì A1C Reduction in Participants using GLP-1s (Resulting A1C) at Week 52\n\nEfsitora\n\n-1.30% (6.90%)\n\n-1.26% (6.96%)\n\nDegludec\n\n-1.28% (6.92%)\n\n-1.19% (7.02%)\n\nSecondary Endpoint ‚Äì A1C Reduction in Participants not using GLP-1s (Resulting A1C) at Week 52\n\nEfsitora\n\n-1.38% (6.85%)\n\n-1.26% (6.97%)\n\nDegludec\n\n-1.23% (6.99%)\n\n-1.15% (7.08%)\n\nSecondary Endpoint ‚Äì Percent Time in Range During the 4 Weeks Prior to Week 52\n\nEfsitora\n\n68.86%\n\n64.27%\n\nDegludec\n\n65.75%\n\n61.18%\n\n"For the past century, we\'ve been searching for the next scientific breakthrough that would alleviate the complexity that comes with starting insulin treatment," said Jeff Emmick, M.D., Ph.D., senior vice president, product development, Lilly. "With these results, we believe we\'re headed towards a future where people with type 2 diabetes who use basal insulin can achieve their desired results with a simple treatment option like efsitora."\n\nIn the trial, efsitora demonstrated a safety profile similar to daily insulins. There were no severe hypoglycemic events reported during treatment with efsitora compared to six reported with insulin degludec. Overall hypoglycemia rates in the study were low, with estimated combined rates of severe or clinically significant (blood glucose <54 mg/dL) hypoglycemic events per patient-year of exposure of 0.58 with efsitora vs. 0.45 with insulin degludec. Estimated combined rates of severe or clinically significant nocturnal hypoglycemic events per patient-year of exposure were 0.08 with both efsitora and insulin degludec. Additionally, rates of hypoglycemia were similar among people currently using GLP-1s and those not using GLP-1s. Adverse events were similar between treatment groups in the trial.\n\nDetailed results for QWINT-5 are also being presented at EASD and simultaneously published in The Lancet.\n\n**About the QWINT clinical trial program**  \nThe QWINT phase 3 global clinical development program for insulin efsitora alfa (efsitora) in diabetes began in 2022 and has enrolled more than 4,000 people living with type 1 or type 2 diabetes across five global registration studies.\n\nQWINT-2 (NCT05362058) was a parallel-design, open-label, treat-to-target, randomized controlled clinical trial comparing the efficacy and safety of efsitora as a once-weekly basal insulin to insulin degludec for 52 weeks in insulin-na√Øve adults with type 2 diabetes. The trial randomized 928 participants across the U.S., Brazil, Canada, China, Czechia (Czech Republic), Germany, Greece, Japan, Korea, Mexico and Puerto Rico to receive efsitora once weekly or insulin degludec once daily administered subcutaneously. The primary objective of the trial was to demonstrate non-inferiority in reducing A1C at week 52 with efsitora compared to insulin degludec. The trial was also designed to assess efficacy and safety for patients using and not using GLP-1 receptor agonists.\n\n**About insulin efsitora alfa**  \nInsulin efsitora alfa (efsitora) is a once-weekly basal insulin, a fusion protein that combines a novel single-chain variant of insulin with a human IgG2 Fc domain. It is specifically designed for once-weekly subcutaneous administration, and with its low peak-to-trough ratio, it has the potential to provide more stable glucose levels (less glucose variability) throughout the week. Efsitora is in phase 3 development for adults with type 1 and 2 diabetes.\n\n**About Lilly**  \nLilly is a medicine company turning science into healing to make life better for people around the world. We\'ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world\'s most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer\'s disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we\'re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram and LinkedIn. P-LLY\n\n**Cautionary Statement Regarding Forward-Looking Statements**  \nThis press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995), including statements about insulin efsitora alfa as a potential treatment for people with type 2 diabetes and the timeline for future readouts, presentations, and other milestones relating to insulin efsitora alfa and its clinical trials, and reflects Lilly\'s current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, that insulin efsitora alfa will prove to be a safe and effective treatment for type 2 diabetes, that insulin efsitora alfa will receive regulatory approval, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly\'s expectations, see Lilly\'s Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.\n\n1 The efficacy estimand represents the treatment effect had all participants adhered to the study drug without initiating rescue therapy for persistent severe hyperglycemia.  \n2 95% CI for treatment difference (-0.22% to 0.06%).  \n3 From a baseline A1C of 8.21% for efsitora and 8.23% for insulin degludec.  \n4 Blood glucose 70-180 mg/dL.  \n5 Treatment-regimen estimand represents the efficacy irrespective of adherence to the investigational medicine or introduction of rescue therapy for persistent severe hyperglycemia.  \n6 From a baseline A1C of 8.21% for efsitora and 8.24% for insulin degludec.  \n7 95% CI for treatment difference (-0.22% to 0.04%).\n\n**Refer to:**\n\nNiki Smithers; smithers_niki@lilly.com, 317-358-9074 (Media)\n\nJoe Fletcher; jfletcher@lilly.com, 317-296-2884 (Investors)\n\nSOURCE Eli Lilly and Company', 'gpt-4o-mini']
2024-09-11 09:41:50,806 - INFO - Logged data to databases/llm.csv with DocumentID: 7l0VhTb9XPwjaQToapdm.
2024-09-11 09:41:50,806 - INFO - 'generated_post' length: 9. Content: ['2024-09-11 02:59:00', '2024-09-11 09:41:44', "üö∫ Did you know that Polycystic Ovary Syndrome (PCOS) affects approximately 5-20% of women of reproductive age? As healthcare practitioners, it's crucial to stay informed about PCOS to effectively support our patients.\n\nHere are some practical insights from recent guidelines that can enhance your clinical practice:\n\n- UNDERSTANDING PCOS: This multifactorial condition is characterized by hyperandrogenism, ovulatory dysfunction, and the presence of polycystic ovaries. Recognition of these symptoms is essential for diagnosis. \n\n- DIAGNOSIS CRITERIA: Effective diagnosis now centers on the presence of two out of three criteria: clinical/biochemical hyperandrogenism, ovulatory dysfunction, and polycystic ovaries on ultrasound or elevated serum anti-M√ºllerian hormone (AMH) levels. \n\n- LONG-TERM RISKS: It's vital to inform patients of potential long-term health risks, including increased likelihood of type 2 diabetes, obesity, and cardiovascular issues. Regular screenings for these conditions should be part of management plans.  \n\n- WEIGHT MANAGEMENT: Encourage patients to engage in lifestyle modifications, including weight loss and exercise. These changes can significantly improve metabolic profiles and fertility outcomes, regardless of overall BMI.\n\n- TAILORED TREATMENTS: There is no one-size-fits-all treatment. Options range from hormonal contraceptives to anti-androgens based on individual symptoms, with tailored management yielding the best results. \n\n- METFORMIN USE: In primary care, consider metformin for patients with PCOS who have insulin resistance. This off-label use can aid metabolic outcomes, but ensure your patients are informed of its potential side effects.\n\nAs we strive to improve outcomes for women with PCOS, how can we better utilize these guidelines in our practices? Let's discuss! \n\nFor more in-depth insights, check out the article here: http://medscape.co.uk/viewarticle/top-tips-polycystic-ovary-syndrome-2024a1000fn8", ['Healthcare & Policy', 'GeneralResearch', 'Endocrinology', 'HealthEquity', 'PatientEducation'], 'https://images.pexels.com/photos/8378750/pexels-photo-8378750.jpeg', 'http://medscape.co.uk/viewarticle/top-tips-polycystic-ovary-syndrome-2024a1000fn8', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'Top Tips: Polycystic Ovary Syndrome\n===============\n\nThis site is intended for UK healthcare professionals\n\nWelcome to the new home of Guidelines in Practice\n\nBrowse our expert articles to support best practice for UK healthcare professionals.\n\nFor Primary Care | Top tips\n\nTop Tips: Polycystic Ovary Syndrome\n===================================\n\nDr Roger Henderson | Disclosures | 11 September 2024\n\n### Disclosures\n\nAuthor(s)\n\n**Dr Roger Henderson**\n\nGP, Dumfries and Galloway\n\n**Dr Roger Henderson Provides Seven Top Tips for Primary Care Practitioners on the Diagnosis and Management of Polycystic Ovary Syndrome**\n\nContinue Reading Below\n\nRead This Article to Learn More About:\n\n*   the causes of polycystic ovary syndrome (PCOS), and when to suspect it\n*   approaches to the diagnosis and management of PCOS\n*   the treatments available to reduce hyperandrogenism or to induce fertility.\n\nPolycystic ovary syndrome (PCOS) was first described in 1935 as Stein‚ÄìLeventhal syndrome by the American gynaecologists Irving Stein and Michael Leventhal, who associated the presence of ovarian cysts with anovulation. PCOS is the most common endocrinopathy in women of reproductive age, and is a well-known cause of infertility and complications in pregnancy. It is associated with a range of health issues, including insulin resistance, the metabolic syndrome, steatotic liver disease, and an increased risk of developing type 2 diabetes.\n\nIn the UK, up to one in three women have more than 10 follicles per ovary visible on ultrasound, a condition known as polycystic ovaries; in turn, one in three women with polycystic ovaries will have PCOS. In addition to polycystic ovaries, women with PCOS may have one or more of a group of characteristic features‚Äîincluding acne, male-pattern baldness, hirsutism, amenorrhoea, and oligomenorrhoea‚Äîand raised serum levels of testosterone and/or luteinising hormone (LH).\n\n### The Burden of PCOS\n\nThe burden of PCOS on women affected by it can be significant. At one time, it was considered to be mainly a reproductive condition, but it is now accepted that women with PCOS are at high risk of metabolic disorders, such as obesity and type 2 diabetes. Furthermore, women with PCOS have been shown to have an increased risk of psychological morbidity, asthma, and migraine.\n\n### Guidance on PCOS\n\nAlthough no NICE Guideline has been published specifically on PCOS, the condition is covered in NICE Clinical Guideline 156, _Fertility problems: assessment and treatment_, and further guidance on the symptoms, diagnosis, and management of PCOS is available from other sources, including:\n\n*   the _International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2023_\n    *   summary of recommendations\n    *   full guidance\n*   the European Society of Human Reproduction and Embryology (ESHRE)/American Society for Reproductive Medicine (ASRM) Workshop Group\n*   the Androgen Excess Society\n*   the Royal College of Obstetricians and Gynaecologists\n*   the _British National Formulary._\n\nThis article provides seven top tips for primary care practitioners on the causes of PCOS and when to suspect it, approaches to its diagnosis and management, and best practice regarding its treatment.\n\n1\\. Be Aware That the Causes of PCOS Remain Unclear\n---------------------------------------------------\n\nPCOS is reportedly present in around 5‚Äì15% of women of reproductive age. However, its prevalence rises to as much as 20% when the diagnostic criteria proposed by the ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (termed the ‚Äò2003 Rotterdam Criteria‚Äô) are used.\n\nThe causes of PCOS remain unclear, but the condition is multifactorial and appears to be inherited as a common, complex genetic disorder. Insulin resistance is found in approximately 65‚Äì80% of women with PCOS, independent of obesity, and is worsened by excess weight triggered by the condition. Levels of LH are increased in nearly 40% of women with PCOS because of increased production from the anterior pituitary gland. Theca cells in the ovaries produce excess androgens because of hyperinsulinaemia or increased serum levels of LH, and women with PCOS may also have increased serum oestrogen levels. As a result of continued exposure to oestrogen unopposed by progesterone, the endometrium may become hyperplastic, and testosterone is also converted to oestrogen in peripheral fat.\n\n2\\. Recognise That no Formal Classification System for PCOS Currently Exists\n----------------------------------------------------------------------------\n\nAlthough no formal classification system currently exists for PCOS, proposals have been made to establish one.\n\nBox 1: Phenotypes of PCOS\n\n*   **Mild PCOS (16% of women with PCOS)**‚Äîcharacterised by irregular periods, polycystic ovaries on ultrasound, mildly raised androgen concentrations, and normal insulin concentrations\n*   **Ovulatory PCOS (16% of women with PCOS)**‚Äîcharacterised by normal periods, polycystic ovaries on ultrasound, high androgen concentrations, and increased insulin concentrations\n*   **Hyperandrogenism and chronic anovulation (7% of women with PCOS)**‚Äîcharacterised by irregular periods, normal ovaries on ultrasound, high androgen concentrations, and increased insulin concentrations; this phenotype has potential long-term risks\n*   **Severe PCOS (61% of women with PCOS)**‚Äîcharacterised by irregular periods, polycystic ovaries on ultrasound, high androgen concentrations, and increased insulin concentrations; this phenotype also has potential long-term risks.\n\nCurrent guidance recommends that PCOS should be diagnosed using the international evidence-based guideline criteria, which build on the consensus-based 2003 Rotterdam criteria. These require the presence of two of the following to diagnose PCOS:\n\n*   clinical/biochemical hyperandrogenism\n*   ovulatory dysfunction\n*   polycystic ovaries on ultrasound.\n\nAlternatively, assessment of serum anti-M√ºllerian hormone (AMH) can now be used instead of ultrasound, provided that other aetiologies are also excluded. Importantly, when irregular menstrual cycles and hyperandrogenism are present, diagnosis is now simplified, and ultrasound or AMH are not required. In adolescents, both hyperandrogenism and ovulatory dysfunction are required, with ultrasound and AMH not recommended because of poor specificity. Note that, according to the 2003 Rotterdam criteria, a diagnosis of PCOS can only be made when other causes have been ruled out, such as congenital adrenal hyperplasia, androgen-secreting tumours, or Cushing‚Äôs syndrome.\n\nThe international evidence-based guideline criteria differ slightly from those issued in 2006 by the Androgen Excess Society, which require all of the following to be present for a diagnosis of PCOS to be made:\n\n*   hyperandrogenism‚Äîhirsutism and/or hyperandrogenaemia\n*   ovarian dysfunction‚Äîoligo-ovulation or anovulation and/or polycystic ovaries\n*   exclusion of other androgen excess or related disorders.\n\n3\\. Know That a Diagnosis of PCOS is One of Exclusion\n-----------------------------------------------------\n\nCommon features of PCOS include hirsutism (present in 60% of women), acne (present in 15‚Äì25%), scalp hair loss or male-pattern baldness (present in 5%), irregular and infrequent periods, weight gain or difficulty losing weight, and infertility. Acanthosis nigricans may also be present, especially in obese women with PCOS, and is thought to be linked to insulin resistance. Less commonly, there may be deepening of the voice, clitoromegaly, and increased muscle mass.\n\nSymptoms typically begin at the time of puberty and, in younger women, may be difficult to distinguish from the irregular menses that often occur in the first year after menarche. Although the diagnostic criteria for PCOS during adolescence are controversial, guidelines recommend that both ovulatory dysfunction and hyperandrogenism must be present to diagnose PCOS in adolescents.\n\nBody mass index (BMI) and waist-to-height ratio should be checked in all women with PCOS, as 40‚Äì80% of women with the syndrome are overweight or obese, with central obesity predominating (a waist-to-hip ratio of at least 0.85, or waist circumference of at least 88 cm). Blood pressure should also be monitored, as women with PCOS may have elevated blood pressure.\n\nDifferential diagnoses of PCOS are presented in Box 2.\n\nBox 2: Differential Diagnoses of PCOS\n\n*   Hypothyroidism\n*   Hyperprolactinaemia\n*   Acromegaly\n*   Cushing‚Äôs syndrome and androgen-secreting tumours\n*   Iatrogenic side effects from medication causing hirsutism such as danazol, high-dose corticosteroids, ciclosporin, and phenytoin.\n\n4\\. Understand That Investigations for PCOS Consist of Endocrine Tests and Ovarian Imaging\n------------------------------------------------------------------------------------------\n\nThe three main endocrine abnormalities in PCOS are:\n\n*   elevated serum LH levels, with normal serum follicle-stimulating hormone levels\n*   elevated free testosterone levels (a combination of increased testosterone production and reduced sex hormone-binding globulin), and\n*   insulin resistance with compensatory hyperinsulinaemia.\n\nWomen with PCOS typically have a serum testosterone level above 2.5 nmol/l and a serum LH level above 10 IU/l. If the total testosterone level is above 5 nmol/l, always check for other possible causes of androgen hypersecretion, such as androgen-secreting adrenal or ovarian tumours, or nonclassical congenital adrenal hyperplasia. Fasting plasma glucose and/or glycated haemoglobin are useful for assessing insulin resistance. Although these tests are less accurate than the oral glucose tolerance test (OGTT), they are acceptable alternatives if an OGTT cannot be performed. A lipid profile should also be obtained to evaluate cardiovascular risk. Prolactin testing is recommended to exclude hyperprolactinaemia, which may present with oligo-ovulation or anovulation. In addition, thyroid function tests are important because thyroid dysfunction may present with oligo-ovulation or anovulation, or irregular and heavy menstrual bleeding, and weight gain.\n\nUltrasound is used to assess for the presence of polycystic ovarian morphology, unless the diagnosis of PCOS is obvious on clinical and biochemical grounds. When appropriate, transvaginal ultrasound provides higher-resolution images of the ovaries compared with transabdominal ultrasound. Remember that the presence of polycystic ovaries alone does not confirm the diagnosis. Ultrasound should not be used to diagnose PCOS in adolescents and, in adults, it should ideally be done in the early follicular phase (days 3‚Äì5) after a spontaneous or progestin-withdrawal-induced menstruation. If menstrual bleeding is infrequent or reduced, ultrasound can be done at any time. If endometrial thickening is found on imaging, an endometrial biopsy is indicated to determine whether endometrial hyperplasia or cancer is present.\n\n5\\. Inform Women About Possible Long-term Risks and Lifestyle Interventions\n----------------------------------------------------------------------------\n\nHealthcare professionals should inform women with PCOS about the potential long-term health risks that are associated with the syndrome. Obesity, dyslipidaemia, and insulin resistance all increase cardiovascular risk, and screening should be offered for impaired glucose tolerance and diabetes.\n\nWomen diagnosed with PCOS should be advised about weight loss and exercise, as weight loss improves fertility and pregnancy outcomes, psychological symptoms, and metabolic risk‚Äîeven if BMI remains raised. A low-glycaemic-index diet may be helpful in managing PCOS. Hypertension should be treated in the usual way, although there is no rationale for the routine use of statins in women with PCOS outside normal guidelines.\n\n6\\. Consider the Range of Available Treatments\n----------------------------------------------\n\nNo single treatment can reverse the hormonal changes of PCOS or address all of its clinical features; therefore, medical management should be tailored to each individual‚Äôs specific symptoms. The combined oral contraceptive pill (COCP) is one of the treatments often considered, provided that there are no contraindications. It should be prescribed with the usual guidance about risks, side effects, and potential drug interactions. However, COCPs containing 35 mcg ethinyloestradiol and cyproterone acetate should not be used as a first-line treatment for PCOS because of their potential adverse effects, which include venous thromboembolism.\n\nIf acne is a significant issue, topical retinoids or antibiotics and/or oral antibiotics can be prescribed as appropriate. If hirsutism is present, hair removal methods, such as waxing or shaving, should be discussed. In general, the oral contraceptive pill is more effective for acne than for hirsutism in PCOS.\n\nIn women with prolonged amenorrhoea or abnormal vaginal bleeding, a cyclical progestogen should be prescribed to induce a withdrawal bleed, followed by a referral for a transvaginal ultrasound to assess endometrial thickness. If endometrial thickening is present, clinicians should refer women for endometrial sampling to exclude endometrial hyperplasia or cancer. If the endometrium is normal, women should be advised on treatment to prevent endometrial hyperplasia and its associated risks. These options include a low-dose COCP, a cyclical progestogen, or a levonorgestrel-releasing intrauterine device (LNG-IUD). If a woman is unwilling to take cyclical hormone treatment or use the LNG-IUD, specialist advice should be sought, as regular ultrasound is required to assess endometrial thickness.\n\nIf a woman with PCOS presents with infertility and wishes to conceive, NICE Clinical Guideline 156, _Fertility problems: assessment and treatment_, recommends that‚Äîafter weight loss (when indicated) and a full fertility work-up‚Äîtreatment should include clomifene citrate, metformin, or a combination of both. Clomifene citrate appears to be preferable to metformin for ovulation induction in women with obesity and PCOS.\n\n7\\. Keep in Mind That Metformin is Used Off Label to Treat PCOS\n---------------------------------------------------------------\n\nIn primary care, when considering starting metformin in women with PCOS but without diabetes, clinicians should consider seeking specialist advice, as metformin is not currently licensed for this indication. The _International evidence-based guideline for the assessment and management of PCOS 2023_, issued by the International PCOS Network, makes the following recommendations on the use of metformin for indications not relating to fertility:\n\n*   in addition to lifestyle interventions, metformin alone should be considered in women with a BMI greater than or equal to 25 kg/m2 for anthropometric and metabolic outcomes, including insulin resistance, glucose, and lipid profiles\n*   in combination with a COCP, metformin may be most beneficial in high metabolic risk groups, including women with a BMI greater than 30 kg/m¬≤, diabetes risk factors, and/or impaired glucose tolerance, and/or who have a high-risk ethnic background.\n\nIf metformin is initiated in primary care, off-label use should be explained alongside the fact that adverse effects may occur, such as gastrointestinal symptoms and reduced vitamin B12 levels.\n\nSummary\n-------\n\nPCOS is the most common endocrinopathy in women of reproductive age, as well as being a major cause of infertility and pregnancy complications. It gives rise to symptoms of hyperandrogenism, the presence of hyperandrogenaemia, oligo-ovulation or anovulation, and polycystic ovarian morphology on ultrasound. It is strongly associated with complications including insulin resistance, the metabolic syndrome, steatotic liver disease, and an increased risk of developing type 2 diabetes. The main aims of treatment are to reduce hyperandrogenism and to induce fertility. Primary care doctors are in an ideal position to identify women with symptoms and signs of PCOS early, and by doing so help to reduce the significant burden that PCOS can place on people with the condition.\n\nKey Points \n\n*   PCOS is the most common endocrinopathy in women of reproductive age, and a well-known cause of infertility and pregnancy complications\n*   In the UK, up to one in three women have more than 10 follicles per ovary visible on ultrasound (polycystic ovaries), and one in three women with polycystic ovaries will have PCOS\n*   PCOS is defined as the presence of polycystic ovaries together with one or more characteristic features, including acne, male-pattern baldness, hirsutism, amenorrhoea, and oligomenorrhoea, and raised serum levels of testosterone and/or LH\n*   The cause of PCOS is unclear, but it is multifactorial and inherited as a common, complex genetic disorder\n*   Insulin resistance is found in approximately 65‚Äì80% of women with PCOS, independent of obesity, and is exacerbated by excess weight triggered by the condition\n*   LH levels are increased in nearly 40% of women with PCOS because of increased production from the anterior pituitary gland\n*   Women with PCOS may also have increased serum oestrogen and testosterone levels\n*   Investigations for PCOS consist of endocrine tests and ovarian imaging\n*   Ultrasound is used to assess the presence of polycystic ovarian morphology, unless the diagnosis of PCOS is obvious on clinical and biochemical grounds\n*   No single treatment can reverse the hormonal changes of PCOS or address all of its clinical features, so medical management should be tailored to each individual‚Äôs symptoms\n*   Metformin, in combination with a combined oral contraceptive pill, may offer greater benefit in high metabolic risk groups, including women with a BMI >30 kg/m¬≤, diabetes risk factors, and/or impaired glucose tolerance, and/or from high-risk ethnic groups\n*   If metformin is initiated in primary care, off-label use should be explained alongside the fact that adverse effects may occur, such as gastrointestinal symptoms and reduced vitamin B12 levels.\n\nNote: At the time of publication (September 2024), some of the treatments discussed in this article did not have UK marketing authorisation for the indications discussed. Prescribers should refer to the individual summaries of product characteristics for further information and recommendations regarding the use of pharmacological therapies. For off-licence use of medicines, the prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council‚Äôs _Good practice in prescribing and managing medicines and devices_ for further information.\n\nNote: This issue only affects those of the female sex and so the terms woman/women and the pronouns she/her have been used throughout this article. Sensitivity should be used when your patient‚Äôs gender does not match their biological sex, including using the patient‚Äôs preferred pronouns.\n\n**Implementation Actions for ICSs**\n\n**written by Dr David Jenner, GP, Cullompton, Devon**\n\nThe following implementation actions are designed to support ICSs with the challenges involved in implementing new guidance at a system level. Our aim is to help you to consider how to deliver improvements to healthcare within the available resources.\n\n*   **Review** local care pathways for the investigation and management of PCOS to ensure that they include screening for comorbidities like type 2 diabetes\n*   **Update** local care pathways in line with the latest guidance, with triggers for referral to specialist care and required investigations\n*   **Consider** creating a specific ‚Äòsuspected PCOS‚Äô blood test request group in pathology request systems to ensure that the required set of biochemical tests are performed\n*   **Identify** on- and off-label therapies in formularies to assist in symptom management and endometrial protection\n*   **Make sure** that clear guidance is available to ensure endometrial protection because of the increased risk of endometrial hyperplasia and cancer\n*   **Signpost** to patient-centred resources to help patients understand PCOS and encourage weight loss and self-help.\n\nICS=integrated care system; PCOS=polycystic ovary syndrome\n\nContinue reading with a FREE Medscape UK account\n\nAccess the latest UK medical news, UK-specific clinical guideline summaries, UK vaccination schedule and more for free.\n\nRegister Today\n\nAlready a member? Log in\n\nReferences\n\n1.  Stein I. The Stein‚ÄìLeventhal syndrome; a curable form of sterility. _N Engl J Med_ 1958; **259** (9): 420‚Äì423. \n2.  Legro R. _Stein‚ÄìLeventhal syndrome._ [www.britannica.com/science/Stein-Leventhal-syndrome](http://www.britannica.com/science/Stein-Leventhal-syndrome) (accessed 28 August 2024).\n3.  Stein I, Leventhal M. Amenorrhea associated with bilateral polycystic ovaries. _Am J Obst Gynec_ 1935; **29** (2): 181‚Äì191. \n4.  BMJ Best Practice website. _Polycystic ovary syndrome._ [bestpractice.bmj.com/topics/en-gb/141](https://bestpractice.bmj.com/topics/en-gb/141) (accessed 28 August 2024).\n5.  GPnotebook website. _Polycystic ovary syndrome._ [gpnotebook.com/en-GB/pages/gynaecology/polycystic-ovary-syndrome](https://gpnotebook.com/en-GB/pages/gynaecology/polycystic-ovary-syndrome) (accessed 28 August 2024). \n6.  Lim S, Davies M, Norman R, Moran L. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. _Hum Reprod Update_ 2012; **18** (6): 618‚Äì637.\n7.  Ollila M, West S, Kein”ìnen-Kiukaaniemi S et al. Overweight and obese but not normal weight women with PCOS are at increased risk of type 2 diabetes mellitus‚Äîa prospective, population-based cohort study. _Hum Reprod_ 2017; **32** (2): 423‚Äì431.\n8.  Karjula S, Morin-Papunen L, Auvinen J et al. Psychological distress is more prevalent in fertile age and premenopausal women with PCOS symptoms: 15-year-follow-up. _J Clin Endocrinol Metab_ 2017; **102** (6): 1861‚Äì1869.\n9.  Htet T, Teede H, de Courten B et al. Asthma in reproductive-aged women with polycystic ovary syndrome and association with obesity. _Eur Respir J_ 2017; **49** (5): 1601334.\n10.  Glintbord D, Hass Rubin K, Nybo M et al. Morbidity and medicine prescriptions in a nationwide Danish population of patients diagnosed with polycystic ovary syndrome. _Eur J Endocrinol_ 2015; **172** (5): 627‚Äì638.\n11.  NICE. _Fertility problems: assessment and treatment_. Clinical Guideline 156. NICE, 2013 (last updated September 2017). Available at: [www.nice.org.uk/cg156](http://www.nice.org.uk/cg156)\n12.  Teede H, Tay C, Laven J et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. _J Clin Endocrinol Metab_ 2023; **108** (10): 2447‚Äì2469. \n13.  Teede H, Tay C, Laven J et al. _International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2023_. Melbourne, Australia: Monash University, 2023. Available at: [www.monash.edu/__data/assets/pdf_file/0003/3379521/Evidence-Based-Guidelines-2023.pdf](http://www.monash.edu/__data/assets/pdf_file/0003/3379521/Evidence-Based-Guidelines-2023.pdf)\n14.  Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). _Fertil Steril_ 2004; **81** (1): 19‚Äì25.\n15.  Azziz R, Carmina E, Dewailly D et al; Androgen Excess Society. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. _J Clin Endocrinol Metab_ 2006; **91** (11): 4237‚Äì4245.\n16.  Royal College of Obstetricians & Gynaecologists. _Long-term consequences of polycystic ovary syndrome._ Green-top Guideline 33. London: RCOG, 2014. Available at: [www.rcog.org.uk/media/qmtlp2b0/gtg_33.pdf](http://www.rcog.org.uk/media/qmtlp2b0/gtg_33.pdf)\n17.  NICE website. _Polycystic ovary syndrome._ British National Formulary. [bnf.nice.org.uk/treatment-summaries/polycystic-ovary-syndrome](https://bnf.nice.org.uk/treatment-summaries/polycystic-ovary-syndrome/) (accessed 28 August 2024).\n18.  Roos N, Kieler H, Sahlin L et al. Risk of adverse pregnancy outcomes in women with polycystic ovary syndrome: population based cohort study. _BMJ_ 2011; **343**: d6309. \n19.  Bozdag G, Mumusoglu S, Zengin D et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. _Hum Reprod_ 2016; **31** (12): 2841‚Äì2855. \n20.  Chiaffarino F, Cipriani S, Dalmartello M et al. Prevalence of polycystic ovary syndrome in European countries and USA: a systematic review and meta-analysis. _Eur J Obstet Gynecol Reprod Biol_ 2022; **279**: 159‚Äì170. \n21.  Goodarzi M. Looking for polycystic ovary syndrome genes: rational and best strategy. _Semin Reprod Med_ 2008; **26** (1): 5‚Äì13.\n22.  Norman R, Dewailly D, Legro R, Hickey T. Polycystic ovary syndrome. _Lancet_ 2007; **370** (9588): 685‚Äì697.\n23.  Balen A, Conway G, Kaltsas G et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. _Hum Reprod_ 1995; **10** (8): 2107‚Äì2111. \n24.  Baird D. Amenorrhoea. _Lancet_ 1997; **350** (9073): 275‚Äì279.\n25.  Carmina E, Gonzalez F, Vidali A et al. The contributions of oestrogen and growth factors to increased adrenal androgen secretion in polycystic ovary syndrome. _Hum Reprod_ 1999; **14** (2): 307-311. \n26.  Dumitrescu R, Mehedintu C, Briceag I et al. The polycystic ovary syndrome: an update on metabolic and hormonal mechanisms. _J Med Life_ 2015; **8** (2): 142‚Äì145.\n27.  Dewailly D, Catteau-Jonard S, Reyss A et al. Oligoanovulation with polycystic ovaries but not overt hyperandrogenism. _J Clin Endocrinol Metab_ 2006; **91** (10): 3922‚Äì3927.\n28.  Conway G, Jacobs H. Acanthosis nigricans in obese women with the polycystic ovary syndrome: disease spectrum not distinct entity. _Postgrad Med J_ 1990; **66**: 536‚Äì538.\n29.  Sheehan M. Polycystic ovarian syndrome: diagnosis and management. _Clin Med Res_ 2004; **2** (1): 13‚Äì27.\n30.  Rasquin L, Anastasopoulou C, Mayrin J. Polycystic ovarian disease. In: _StatPearls [Internet]_. Treasure Island, FL, USA: StatPearls Publishing Ltd, 2022. Available at: [www.ncbi.nlm.nih.gov/books/NBK459251](http://www.ncbi.nlm.nih.gov/books/NBK459251/)\n31.  Pe√±a A, Witchel S, Hoeger K et al. Adolescent polycystic ovary syndrome according to the international evidence-based guideline. _BMC Med_ 2020; **18**: 72. \n32.  Wild R, Carmina E, Diamanti-Kandarakis E et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. _J Clin Endocrinol Metab_ 2010; **95** (5): 2038‚Äì2049. \n33.  Sam S. Obesity and polycystic ovary syndrome. _Obes Manag_ 2007; **3** (2): 69‚Äì73.\n34.  Jurczewska J, Ostrowska J, Che≈Çchowska M et al. Abdominal obesity in women with polycystic ovary syndrome and its relationship with diet, physical activity and insulin resistance: a pilot study. _Nutrients_ 2023; **15** (16): 3652. \n35.  Lucidi R. _Polycystic ovarian syndrome differential diagnoses._ [emedicine.medscape.com/article/256806-differential](https://emedicine.medscape.com/article/256806-differential) (accessed 28 August 2024).\n36.  Hafsi W, Kaur J. Hirsutism. In: _StatPearls [Internet]_. Treasure Island, FL, USA. StatPearls Publishing Ltd, 2023. Available at: [www.ncbi.nlm.nih.gov/books/NBK470417/](http://www.ncbi.nlm.nih.gov/books/NBK470417/)\n37.  Lucidi R. _Polycystic ovarian syndrome workup._ [emedicine.medscape.com/article/256806-workup#c1](https://emedicine.medscape.com/article/256806-workup#c1) (accessed 28 August 2024).\n38.  GPnotebook website. _Ep 115‚Äîpolycystic ovary syndrome._ [gpnotebook.com/en-GB/podcasts/diabetes-and-endocrinology/ep-115-polycystic-ovary-syndrome](https://gpnotebook.com/en-GB/podcasts/diabetes-and-endocrinology/ep-115-polycystic-ovary-syndrome) (accessed 28 August 2024).\n39.  Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. _BMC Med_ 2010; **8**: 41. \n40.  Amreen S. Ultrasound in polycystic ovarian syndrome: what? when? how? why? who? _EMJ Radiol_ 2022; **3** (1): 44‚Äì48.\n41.  Marsh K, Steinbeck K, Atkinson F et al. Effect of a low glycemic index compared with a conventional healthy diet on polycystic ovary syndrome. _Am J Clin Nutr_ 2010; **92** (1): 83‚Äì92. \n42.  Raval A, Hunter T, Stuckey B, Hart R. Statins for women with polycystic ovary syndrome not actively trying to conceive. _Cochrane Database Syst Rev_ 2011; (**10**): CD008565. \n43.  Moghetti P, Toscano V. Treatment of hirsutism and acne in hyperandrogenism. _Best Pract Res Clin Endocrinol Metab_ 2006; **20** (2): 221‚Äì234.\n44.  Morley L, Tang T, Yasmin E et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. _Cochrane Database Syst Rev_ 2017; (**11**): CD003053.\n45.  NICE website. _Metformin hydrochloride_. British National Formulary. [bnf.nice.org.uk/drugs/metformin-hydrochloride/#unlicensed-use](https://bnf.nice.org.uk/drugs/metformin-hydrochloride/#unlicensed-use) (accessed 29 August 2024).', 'gpt-4o-mini']
2024-09-11 09:41:50,807 - INFO - Logged data to databases/llm.csv with DocumentID: m4TLJoxCYBP1g16HLycj.
2024-09-11 09:52:17,057 - INFO - Extracted 26 link records.
2024-09-11 09:52:17,063 - INFO - Extracted 26 image links.
2024-09-11 09:52:17,066 - INFO - Extracted 15 link records.
2024-09-11 09:52:17,068 - INFO - Extracted 5 link records.
2024-09-11 09:52:17,070 - INFO - Extracted 9 link records.
2024-09-11 09:52:17,070 - INFO - Unique links to process: 3
2024-09-11 09:52:17,070 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 09:52:17,415 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/, now generating post.
2024-09-11 09:52:17,781 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 09:52:17,784 - INFO - No article found for link https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/.
2024-09-11 09:52:17,784 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/. Skipping.
2024-09-11 09:52:17,784 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 09:52:17,784 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 09:52:18,119 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/, now generating post.
2024-09-11 09:52:18,549 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 09:52:18,550 - INFO - No article found for link https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/.
2024-09-11 09:52:18,550 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/. Skipping.
2024-09-11 09:52:18,550 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 09:52:18,550 - INFO - Starting to process link: http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 09:52:19,125 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296, now generating post.
2024-09-11 09:52:19,721 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 09:52:19,722 - INFO - No article found for link https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296.
2024-09-11 09:52:19,722 - ERROR - No valid post generated for http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296. Skipping.
2024-09-11 09:52:19,722 - WARNING - Skipping entry due to missing or invalid log entry for link: https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 10:19:26,893 - INFO - Extracted 26 link records.
2024-09-11 10:19:26,900 - INFO - Extracted 26 image links.
2024-09-11 10:19:26,902 - INFO - Extracted 15 link records.
2024-09-11 10:19:26,905 - INFO - Extracted 5 link records.
2024-09-11 10:19:26,907 - INFO - Extracted 9 link records.
2024-09-11 10:19:26,907 - INFO - Unique links to process: 3
2024-09-11 10:19:26,907 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 10:19:27,505 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/, now generating post.
2024-09-11 10:19:27,952 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 10:19:27,954 - INFO - No article found for link https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/.
2024-09-11 10:19:27,954 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/. Skipping.
2024-09-11 10:19:27,955 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 10:19:27,955 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 10:19:28,393 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/, now generating post.
2024-09-11 10:19:28,894 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 10:19:28,895 - INFO - No article found for link https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/.
2024-09-11 10:19:28,895 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/. Skipping.
2024-09-11 10:19:28,895 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 10:19:28,895 - INFO - Starting to process link: http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 10:19:29,570 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296, now generating post.
2024-09-11 10:19:30,316 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 10:19:30,317 - INFO - No article found for link https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296.
2024-09-11 10:19:30,317 - ERROR - No valid post generated for http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296. Skipping.
2024-09-11 10:19:30,317 - WARNING - Skipping entry due to missing or invalid log entry for link: https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 10:41:04,715 - INFO - Extracted 26 link records.
2024-09-11 10:41:04,721 - INFO - Extracted 26 image links.
2024-09-11 10:41:04,723 - INFO - Extracted 15 link records.
2024-09-11 10:41:04,725 - INFO - Extracted 5 link records.
2024-09-11 10:41:04,727 - INFO - Extracted 9 link records.
2024-09-11 10:41:04,727 - INFO - Unique links to process: 3
2024-09-11 10:41:04,727 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 10:41:06,997 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/, now generating post.
2024-09-11 10:41:07,513 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 10:41:07,515 - INFO - No article found for link https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/.
2024-09-11 10:41:07,515 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/. Skipping.
2024-09-11 10:41:07,515 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 10:41:07,515 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 10:41:09,419 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/, now generating post.
2024-09-11 10:41:09,915 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 10:41:09,916 - INFO - No article found for link https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/.
2024-09-11 10:41:09,916 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/. Skipping.
2024-09-11 10:41:09,916 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 10:41:09,916 - INFO - Starting to process link: http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 10:41:13,658 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296, now generating post.
2024-09-11 10:41:14,188 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 10:41:14,189 - INFO - No article found for link https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296.
2024-09-11 10:41:14,189 - ERROR - No valid post generated for http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296. Skipping.
2024-09-11 10:41:14,189 - WARNING - Skipping entry due to missing or invalid log entry for link: https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 10:52:37,882 - INFO - Extracted 26 link records.
2024-09-11 10:52:37,887 - INFO - Extracted 26 image links.
2024-09-11 10:52:37,890 - INFO - Extracted 15 link records.
2024-09-11 10:52:37,892 - INFO - Extracted 5 link records.
2024-09-11 10:52:37,894 - INFO - Extracted 9 link records.
2024-09-11 10:52:37,894 - INFO - Unique links to process: 3
2024-09-11 10:52:37,894 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 10:52:40,746 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/, now generating post.
2024-09-11 10:52:41,178 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 10:52:41,180 - INFO - No article found for link https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/.
2024-09-11 10:52:41,180 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/. Skipping.
2024-09-11 10:52:41,180 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 10:52:41,180 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 10:52:41,621 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/, now generating post.
2024-09-11 10:52:42,029 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 10:52:42,030 - INFO - No article found for link https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/.
2024-09-11 10:52:42,030 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/. Skipping.
2024-09-11 10:52:42,030 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 10:52:42,030 - INFO - Starting to process link: http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 10:52:42,353 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296, now generating post.
2024-09-11 10:52:43,226 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 10:52:43,226 - INFO - No article found for link https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296.
2024-09-11 10:52:43,226 - ERROR - No valid post generated for http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296. Skipping.
2024-09-11 10:52:43,226 - WARNING - Skipping entry due to missing or invalid log entry for link: https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 11:17:29,299 - INFO - Extracted 26 link records.
2024-09-11 11:17:29,305 - INFO - Extracted 26 image links.
2024-09-11 11:17:29,307 - INFO - Extracted 15 link records.
2024-09-11 11:17:29,309 - INFO - Extracted 5 link records.
2024-09-11 11:17:29,311 - INFO - Extracted 9 link records.
2024-09-11 11:17:29,311 - INFO - Unique links to process: 3
2024-09-11 11:17:29,311 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 11:17:31,868 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/, now generating post.
2024-09-11 11:17:32,409 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 11:17:32,412 - INFO - No article found for link https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/.
2024-09-11 11:17:32,412 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/. Skipping.
2024-09-11 11:17:32,412 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 11:17:32,412 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 11:17:32,808 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/, now generating post.
2024-09-11 11:17:33,329 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 11:17:33,330 - INFO - No article found for link https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/.
2024-09-11 11:17:33,330 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/. Skipping.
2024-09-11 11:17:33,330 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 11:17:33,330 - INFO - Starting to process link: http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 11:17:33,606 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296, now generating post.
2024-09-11 11:17:34,180 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 11:17:34,181 - INFO - No article found for link https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296.
2024-09-11 11:17:34,181 - ERROR - No valid post generated for http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296. Skipping.
2024-09-11 11:17:34,181 - WARNING - Skipping entry due to missing or invalid log entry for link: https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 11:39:08,732 - INFO - Extracted 26 link records.
2024-09-11 11:39:08,738 - INFO - Extracted 26 image links.
2024-09-11 11:39:08,740 - INFO - Extracted 15 link records.
2024-09-11 11:39:08,742 - INFO - Extracted 5 link records.
2024-09-11 11:39:08,745 - INFO - Extracted 9 link records.
2024-09-11 11:39:08,745 - INFO - Unique links to process: 3
2024-09-11 11:39:08,745 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 11:39:09,347 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/, now generating post.
2024-09-11 11:39:09,765 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 11:39:09,767 - INFO - No article found for link https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/.
2024-09-11 11:39:09,767 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/. Skipping.
2024-09-11 11:39:09,767 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 11:39:09,767 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 11:39:10,230 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/, now generating post.
2024-09-11 11:39:10,535 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 11:39:10,536 - INFO - No article found for link https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/.
2024-09-11 11:39:10,536 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/. Skipping.
2024-09-11 11:39:10,536 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 11:39:10,536 - INFO - Starting to process link: http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 11:39:10,847 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296, now generating post.
2024-09-11 11:39:11,119 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 11:39:11,120 - INFO - No article found for link https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296.
2024-09-11 11:39:11,120 - ERROR - No valid post generated for http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296. Skipping.
2024-09-11 11:39:11,120 - WARNING - Skipping entry due to missing or invalid log entry for link: https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 11:51:53,336 - INFO - Extracted 26 link records.
2024-09-11 11:51:53,342 - INFO - Extracted 26 image links.
2024-09-11 11:51:53,344 - INFO - Extracted 15 link records.
2024-09-11 11:51:53,346 - INFO - Extracted 5 link records.
2024-09-11 11:51:53,348 - INFO - Extracted 9 link records.
2024-09-11 11:51:53,348 - INFO - Unique links to process: 3
2024-09-11 11:51:53,348 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 11:51:53,752 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/, now generating post.
2024-09-11 11:51:54,187 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 11:51:54,189 - INFO - No article found for link https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/.
2024-09-11 11:51:54,189 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/. Skipping.
2024-09-11 11:51:54,189 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 11:51:54,189 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 11:53:37,050 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/, now generating post.
2024-09-11 11:53:37,358 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 11:53:37,359 - INFO - No article found for link https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/.
2024-09-11 11:53:37,359 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/. Skipping.
2024-09-11 11:53:37,359 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 11:53:37,359 - INFO - Starting to process link: http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 11:53:40,397 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296, now generating post.
2024-09-11 11:53:40,896 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 11:53:40,900 - INFO - No article found for link https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296.
2024-09-11 11:53:40,901 - ERROR - No valid post generated for http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296. Skipping.
2024-09-11 11:53:40,901 - WARNING - Skipping entry due to missing or invalid log entry for link: https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 12:37:12,205 - INFO - Extracted 26 link records.
2024-09-11 12:37:12,211 - INFO - Extracted 26 image links.
2024-09-11 12:37:12,214 - INFO - Extracted 15 link records.
2024-09-11 12:37:12,216 - INFO - Extracted 5 link records.
2024-09-11 12:37:12,218 - INFO - Extracted 10 link records.
2024-09-11 12:37:12,218 - INFO - Unique links to process: 4
2024-09-11 12:37:12,218 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 12:37:15,732 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/, now generating post.
2024-09-11 12:37:16,215 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 12:37:16,217 - INFO - No article found for link https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/.
2024-09-11 12:37:16,217 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/. Skipping.
2024-09-11 12:37:16,217 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 12:37:16,217 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 12:37:16,659 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/, now generating post.
2024-09-11 12:37:17,018 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 12:37:17,019 - INFO - No article found for link https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/.
2024-09-11 12:37:17,019 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/. Skipping.
2024-09-11 12:37:17,019 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 12:37:17,019 - INFO - Starting to process link: http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 12:37:21,153 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296, now generating post.
2024-09-11 12:37:21,585 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 12:37:21,586 - INFO - No article found for link https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296.
2024-09-11 12:37:21,586 - ERROR - No valid post generated for http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296. Skipping.
2024-09-11 12:37:21,586 - WARNING - Skipping entry due to missing or invalid log entry for link: https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 12:37:21,586 - INFO - Starting to process link: http://r.jina.ai/http://medscape.com/viewarticle/should-genetic-testing-be-routine-breast-cancer-2024a1000ggq
2024-09-11 12:37:23,257 - INFO - Successfully fetched webpage content from http://r.jina.ai/http://medscape.com/viewarticle/should-genetic-testing-be-routine-breast-cancer-2024a1000ggq, now generating post.
2024-09-11 12:37:32,722 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 12:37:36,292 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 12:37:36,868 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 12:37:36,869 - INFO - Image query: "genetic testing breast cancer"
2024-09-11 12:37:37,257 - INFO - Unique image link: https://images.pexels.com/photos/7723619/pexels-photo-7723619.jpeg
2024-09-11 12:37:37,257 - INFO - Post generated successfully for link: http://r.jina.ai/http://medscape.com/viewarticle/should-genetic-testing-be-routine-breast-cancer-2024a1000ggq
2024-09-11 12:37:37,257 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/7723619/pexels-photo-7723619.jpeg'}
2024-09-11 12:37:37,257 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 12:37:37,257 - INFO - Sending 1 log entries to Firebase.
2024-09-11 12:37:43,840 - INFO - Successfully sent batch data to Firebase: {'message': 'Batch processed successfully. 1 posts added.', 'documentIDs': ['vTN9WKCSgnLoj5M8lIYr']}
2024-09-11 12:37:43,840 - INFO - Received 1 document IDs from Firebase.
2024-09-11 12:37:43,840 - INFO - 'generated_post' length: 9. Content: ['2024-09-11 06:03:17', '2024-09-11 12:37:36', 'üîç Ever wondered if traditional risk criteria are enough for genetic testing in breast cancer? \n\n- A recent study highlighted that universal genetic testing found germline pathogenic variants in 7.3% of women diagnosed with breast cancer. üö® This suggests that relying solely on family history and ancestry may overlook a significant number of BRCA1, BRCA2, or PALB2 carriers, with more than 34% of those variants being missed under current guidelines.\n  \n- Involving 729 women, the research showed that younger patients (<40 years), those with a family history of ovarian cancer, as well as women with triple-negative or high-grade tumors, are particularly at risk for these variants. \n\n- The implication? Practitioners are encouraged to adopt MAINSTREAM, ONCOLOGY-LED GENETIC TESTING for all women diagnosed with invasive breast cancer under 50, those with triple-negative breast cancer, or bilateral cases, and even for affected men. \n\nAs we refine our screening processes, what changes are you considering in your approach to genetic testing for breast cancer? ü§î \n\nFor more information, read the full study here: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2823091', ['Research & Clinical Trials', 'Genomics', 'Oncology', 'ClinicalTrials', 'PatientSafety', 'HealthcareInnovation'], 'https://images.pexels.com/photos/7723619/pexels-photo-7723619.jpeg', 'http://medscape.com/viewarticle/should-genetic-testing-be-routine-breast-cancer-2024a1000ggq', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'Should Genetic Testing Be Routine for Breast Cancer?\n====================================================\n\nGargi Mukherjee\n\nSeptember 11, 2024\n\n0\n\n0\n\n**TOPLINE:**\n------------\n\nUniversal testing identified germline pathogenic variants in 7.3% of women with breast cancer, suggesting that traditional risk-based criteria may miss more than a third of _BRCA1_, _BRCA2_, or _PALB2_ carriers.\n\n**METHODOLOGY:**\n----------------\n\n*   Traditional risk-based criteria, including family history and ancestry, are used to guide genetic testing decisions in women with breast cancer. However, these criteria may overlook patients with actionable genetic variants, particularly those outside the typical risk profile.\n*   To assess the efficacy of universal genetic testing, researchers conducted a cross-sectional study that included 729 women (median age at diagnosis, 53 years; 65.4% White women) newly diagnosed with invasive breast cancer between September 2019 and April 2022 at three Canadian institutions.\n*   All patients received genetic counseling followed by testing for the presence of germline pathogenic variants in 17 breast cancer susceptibility genes. The primary gene panel included screening for _BRCA1_, _BRCA2_, and _PALB2_\xa0and the optional secondary panel included 14 additional breast cancer susceptibility genes.\n*   Of the participants, 659 (90.4%) were tested for both primary and secondary gene panels, whereas 70 (9.6%) underwent testing for only the primary panel. The majority of the cohort (66.8) were diagnosed with estrogen receptor (ER)‚Äìpositive breast cancer, while 15.4% had triple-negative breast cancer.\n\n**TAKEAWAY:**\n-------------\n\n*   The prevalence of germline pathogenic variants was 7.3% (53 patients) ‚Äî 5.3% for the\xa0primary gene panel and 2.1% for the secondary panel.\n*   Younger age (< 40 years; odds ratio \\[OR\\], 6.83), family history of ovarian cancer (OR, 9.75), high-grade disease (OR, 1.68), and triple-negative breast cancer (OR, 3.19) were independently associated with the presence of pathogenic genetic variants in _BRCA1_, _BRCA2_, or _PALB2_.\n*   Overall, 34.3% of patients with germline pathogenic variants in _BRCA1_, _BRCA2_, or _PALB2,_ and 85.7% of carriers of secondary panel variants would not have qualified for traditional genetic testing according to the current risk factors.\n*   A total of 13 patients with _BRCA1_, _BRCA2_, or _PALB2_\xa0variants had confirmed pathogenic mutations and were eligible for poly(adenosine diphosphate‚Äìribose) polymerase (PARP) inhibitors.\n\n**IN PRACTICE:**\n----------------\n\nThese findings have "informed our clinical practice, and we now offer mainstream, oncology-led genetic testing to all women diagnosed with incident invasive breast cancer younger than 50 years of age, those with triple-negative breast cancer and/or bilateral breast cancer, those potentially eligible for PARP inhibitors," as well as to men with breast cancer, the authors wrote.\n\n**SOURCE:**\n-----------\n\nThe study was led by Zoulikha Rezoug, MSc, Lady Davis Institute of the Jewish General Hospital, McGill University in Montreal, Quebec, Canada. It was [published online](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2823091) on September 3, 2024, in _JAMA Network Open_.\n\n**LIMITATIONS:**\n----------------\n\nThe COVID-19 pandemic resulted in a 6-month recruitment pause. Adjustments in recruitment criteria, focus on younger patients and those with triple-negative breast cancer could have overestimated prevalence of genetic pathogenic variants among women aged ‚â• 70 years.\n\n**DISCLOSURES:**\n----------------\n\nThe study was supported by grants from the Jewish General Hospital Foundation and the Quebec Breast Cancer Foundation, as well as an award from the Fonds de Recherche du Quebec Sant√©. Two authors reported receiving grants or personal fees from various sources.\n\n_This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication._\n\n0\n\nCredit  \n\nLead image: Katarzyna Bialasiewicz/Dreamstime\n\nMedscape Medical News ¬© 2024 WebMD, LLC  \nSend comments and news tips to [news@medscape.net](mailto:news@medscape.net).\n\nCite this: Should Genetic Testing Be Routine for Breast Cancer? - Medscape \\- September 11, 2024.', 'gpt-4o-mini']
2024-09-11 12:37:43,842 - INFO - Logged data to databases/llm.csv with DocumentID: vTN9WKCSgnLoj5M8lIYr.
2024-09-11 13:04:33,273 - INFO - Extracted 27 link records.
2024-09-11 13:04:33,279 - INFO - Extracted 27 image links.
2024-09-11 13:04:33,281 - INFO - Extracted 15 link records.
2024-09-11 13:04:33,283 - INFO - Extracted 5 link records.
2024-09-11 13:04:33,285 - INFO - Extracted 12 link records.
2024-09-11 13:04:33,285 - INFO - Unique links to process: 5
2024-09-11 13:04:33,285 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 13:04:33,833 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/, now generating post.
2024-09-11 13:04:34,307 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 13:04:34,309 - INFO - No article found for link https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/.
2024-09-11 13:04:34,309 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/. Skipping.
2024-09-11 13:04:34,309 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 13:04:34,309 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 13:04:36,191 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/, now generating post.
2024-09-11 13:04:36,703 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 13:04:36,704 - INFO - No article found for link https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/.
2024-09-11 13:04:36,704 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/. Skipping.
2024-09-11 13:04:36,704 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 13:04:36,704 - INFO - Starting to process link: http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 13:04:37,132 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296, now generating post.
2024-09-11 13:04:37,557 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 13:04:37,558 - INFO - No article found for link https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296.
2024-09-11 13:04:37,558 - ERROR - No valid post generated for http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296. Skipping.
2024-09-11 13:04:37,558 - WARNING - Skipping entry due to missing or invalid log entry for link: https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 13:04:37,558 - INFO - Starting to process link: http://r.jina.ai/https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older
2024-09-11 13:04:40,146 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older, now generating post.
2024-09-11 13:04:40,727 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 13:04:40,728 - INFO - No article found for link https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older.
2024-09-11 13:04:40,728 - ERROR - No valid post generated for http://r.jina.ai/https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older. Skipping.
2024-09-11 13:04:40,728 - WARNING - Skipping entry due to missing or invalid log entry for link: https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older
2024-09-11 13:04:40,728 - INFO - Starting to process link: http://r.jina.ai/http://medscape.co.uk/viewarticle/antibiotics-may-not-reduce-fever-duration-paediatric-strep-2024a1000g7k
2024-09-11 13:04:41,391 - INFO - Successfully fetched webpage content from http://r.jina.ai/http://medscape.co.uk/viewarticle/antibiotics-may-not-reduce-fever-duration-paediatric-strep-2024a1000g7k, now generating post.
2024-09-11 13:04:49,473 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 13:04:53,050 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 13:04:53,492 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 13:04:53,493 - INFO - Image query: ‚Äúpediatric strep throat treatment‚Äù
2024-09-11 13:04:53,895 - INFO - Unique image link: https://images.pexels.com/photos/9874622/pexels-photo-9874622.jpeg
2024-09-11 13:04:53,896 - INFO - Post generated successfully for link: http://r.jina.ai/http://medscape.co.uk/viewarticle/antibiotics-may-not-reduce-fever-duration-paediatric-strep-2024a1000g7k
2024-09-11 13:04:53,896 - WARNING - Invalid link found in link_info: {'Image': 'https://images.pexels.com/photos/9874622/pexels-photo-9874622.jpeg'}
2024-09-11 13:04:53,896 - WARNING - Skipping entry due to missing or invalid log entry for link: None
2024-09-11 13:04:53,896 - INFO - Sending 1 log entries to Firebase.
2024-09-11 13:04:57,371 - INFO - Successfully sent batch data to Firebase: {'message': 'Batch processed successfully. 1 posts added.', 'documentIDs': ['aKFUH8ZlT6GjKDlMQJR9']}
2024-09-11 13:04:57,371 - INFO - Received 1 document IDs from Firebase.
2024-09-11 13:04:57,371 - INFO - 'generated_post' length: 9. Content: ['2024-09-11 09:00:00', '2024-09-11 13:04:53', "ü§î Could our approach to treating pediatric strep throat be due for a shift?\n\n- A recent study involving 88 children aged 3-15 years with group A streptococcus (GAS) pharyngitis found that amoxicillin did not significantly shorten fever duration compared to placebo. In fact, both fever length and pain intensity showed no major differences between the two groups.\n\n- üìä Interestingly, the placebo group had a higher rate of positive throat cultures at day 30 (relative risk of 4.44), suggesting that antibiotics may not be as essential as previously thought in uncomplicated cases.\n\n- This leads to a crucial takeaway: In regions with good access to healthcare, a more cautious approach towards antibiotic prescribing might be warranted. Active follow-up combined with a stepwise prescription strategy could help mitigate unnecessary antibiotic use and its associated risks.\n\nAs healthcare professionals, how do we strike the right balance between treating our young patients and preventing antibiotic resistance? Let's discuss! \n\nFor further details, check out the study: http://medscape.co.uk/viewarticle/antibiotics-may-not-reduce-fever-duration-paediatric-strep-2024a1000g7k", ['Research & Clinical Trials', 'ClinicalTrials', 'Pediatrics', 'InfectiousDiseases', 'HealthPolicy'], 'https://images.pexels.com/photos/9874622/pexels-photo-9874622.jpeg', 'http://medscape.co.uk/viewarticle/antibiotics-may-not-reduce-fever-duration-paediatric-strep-2024a1000g7k', 'You are a social media content strategist tasked with creating ready-to-use social media posts aimed at healthcare professionals. Summarize key takeaways from a webpage scraping, ensuring the content is trustworthy and relevant. Present the information in a concise, bullet-point format, emphasizing actionable insights and recent updates relevant to clinical practice, while maintaining varied and engaging structures. The tone should be professional yet conversational to sustain interest, using reflective phrasing and deeper insight.\n\nKey Instructions:\n\n\t-\tDynamic Openings: Vary post introductions (e.g., posing questions, sharing surprising facts, or introducing patient scenarios). Avoid repetitive phrases like ‚ÄúNew Insights.‚Äù\n\t-\tProfessional but Engaging Tone: Use reflective language, nuanced phrasing, and sentence variety to keep the post fresh. Balance professionalism with conversational engagement.\n\t-\tEmojis for Emphasis: Use emojis sparingly to emphasize key points or statistics, ensuring they fit the professional tone. Avoid overuse.\n\t-\tActionable Focus: Highlight practical takeaways for clinical application.\n\t-\tEncouragement for Discussion: End with a thought-provoking question or reflective statement to encourage discussion or deeper consideration.\n\t-\tSource: Include a link to the source if provided.\n\nOutput only the post as plain text, not Markdown.\n\nExample Post:\n\nüë©\u200d‚öïÔ∏è Is an invasive approach always the best option for older NSTEMI patients?\n\n\t-\tA multicenter study followed patients aged 75+ years old with non-ST-segment elevation myocardial infarction (NSTEMI), comparing invasive treatment (angiography + revascularization) with medical therapy alone.\n\t-\tüìä Over 4.1 years, no significant differences were observed in cardiovascular death rates or nonfatal myocardial infarction between both groups.\n\t-\tInterestingly, while the invasive strategy resulted in fewer nonfatal myocardial infarctions (11.7% vs. 15.0%), it didn‚Äôt offer a clear survival advantage, prompting clinicians to reconsider routine invasive interventions for frail, elderly patients.\n\nAs treatment options evolve, should we be prioritizing patient quality of life over aggressive interventions? ü§î\n\nFor more details, read the full study here: https://www.nejm.org/doi/full/10.1056/NEJMoa2407791', 'Antibiotics May Not Abbreviate Fever in Paediatric Strep\n===============\n\nThis site is intended for UK healthcare professionals\n\nClinical Summary\n\nAntibiotics May Not Reduce Fever Duration in Paediatric Strep Throat\n====================================================================\n\nJenny Blair | 11 September 2024\n\nTOPLINE:\n--------\n\nFor children with group A streptococcus (GAS) pharyngitis, amoxicillin appears to be no more effective than placebo at reducing fever duration, pain intensity, and complication rates.\n\nMETHODOLOGY:\n------------\n\n*   A randomised, double-blind, non-inferiority clinical trial of 88 children aged 3-15 years with uncomplicated GAS pharyngitis.\n*   Participants were randomised to 6 days\' amoxicillin (weight-based dosing) vs placebo.\n*   The primary outcome was the fever duration.\n\nTAKEAWAY:\n---------\n\n*   Fever duration as well as pain did not differ significantly between groups.\n*   There were six treatment failures in the placebo group and two in the amoxicillin group, also a non-significant difference.\n*   However, in a subgroup analysis of culture-confirmed participants, the rate of positive throat cultures at day 30 was much higher in the placebo group (relative risk, 4.44; 95% CI, 1.48-13.26).\n\nIN PRACTICE:\xa0\n-------------\n\n"...An active follow-up with a stepwise approach to antibiotic prescription seems reasonable in countries \\[with\\] prompt access to healthcare and medication," the authors wrote. "Overall, our findings support a more restrictive attitude towards prescribing antibiotics."\n\nSOURCE:\n-------\n\nConducted by a Swiss team, the study appeared in _European Journal of Pediatrics_.\n\nLIMITATIONS:\n------------\n\nMany parents were reluctant to allow participation and recruitment stopped well short of goal. Small sample sizes resulted in wide confidence intervals.\n\nDISCLOSURES:\n------------\n\nThe study was funded by the University of Geneva, Gertrude Von Meissner Foundation, Geneva University Hospitals, and Soci√©t√© Acad√©mique de Gen√®ve. The authors declared they had no conflicts of interest.\n\nReferences\n\nGualtieri R, Verolet C, Mardegan C, et al. Amoxicillin vs. placebo to reduce symptoms in children with group A streptococcal pharyngitis: A randomized, multicenter, double-blind, non-inferiority trial. Eur J Pediatr. Published online August 31, 2024. doi:10.1007/s00431-024-05705-1', 'gpt-4o-mini']
2024-09-11 13:04:57,373 - INFO - Logged data to databases/llm.csv with DocumentID: aKFUH8ZlT6GjKDlMQJR9.
2024-09-11 13:31:35,419 - INFO - Extracted 28 link records.
2024-09-11 13:31:35,425 - INFO - Extracted 28 image links.
2024-09-11 13:31:35,427 - INFO - Extracted 15 link records.
2024-09-11 13:31:35,429 - INFO - Extracted 5 link records.
2024-09-11 13:31:35,431 - INFO - Extracted 12 link records.
2024-09-11 13:31:35,431 - INFO - Unique links to process: 4
2024-09-11 13:31:35,431 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 13:31:35,868 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/, now generating post.
2024-09-11 13:31:36,343 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 13:31:36,346 - INFO - No article found for link https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/.
2024-09-11 13:31:36,346 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/. Skipping.
2024-09-11 13:31:36,346 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 13:31:36,346 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 13:31:36,880 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/, now generating post.
2024-09-11 13:31:37,354 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 13:31:37,355 - INFO - No article found for link https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/.
2024-09-11 13:31:37,355 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/. Skipping.
2024-09-11 13:31:37,355 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 13:31:37,355 - INFO - Starting to process link: http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 13:31:37,682 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296, now generating post.
2024-09-11 13:31:37,901 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 13:31:37,902 - INFO - No article found for link https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296.
2024-09-11 13:31:37,902 - ERROR - No valid post generated for http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296. Skipping.
2024-09-11 13:31:37,902 - WARNING - Skipping entry due to missing or invalid log entry for link: https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 13:31:37,902 - INFO - Starting to process link: http://r.jina.ai/https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older
2024-09-11 13:31:38,692 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older, now generating post.
2024-09-11 13:31:39,088 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 13:31:39,089 - INFO - No article found for link https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older.
2024-09-11 13:31:39,089 - ERROR - No valid post generated for http://r.jina.ai/https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older. Skipping.
2024-09-11 13:31:39,089 - WARNING - Skipping entry due to missing or invalid log entry for link: https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older
2024-09-11 13:52:19,351 - INFO - Extracted 28 link records.
2024-09-11 13:52:19,357 - INFO - Extracted 28 image links.
2024-09-11 13:52:19,359 - INFO - Extracted 15 link records.
2024-09-11 13:52:19,361 - INFO - Extracted 5 link records.
2024-09-11 13:52:19,363 - INFO - Extracted 12 link records.
2024-09-11 13:52:19,363 - INFO - Unique links to process: 4
2024-09-11 13:52:19,363 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 13:52:21,640 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/, now generating post.
2024-09-11 13:52:22,270 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 13:52:22,273 - INFO - No article found for link https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/.
2024-09-11 13:52:22,273 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/. Skipping.
2024-09-11 13:52:22,273 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 13:52:22,273 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 13:52:22,911 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/, now generating post.
2024-09-11 13:52:23,339 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 13:52:23,340 - INFO - No article found for link https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/.
2024-09-11 13:52:23,340 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/. Skipping.
2024-09-11 13:52:23,340 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 13:52:23,340 - INFO - Starting to process link: http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 13:52:28,248 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296, now generating post.
2024-09-11 13:52:28,670 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 13:52:28,672 - INFO - No article found for link https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296.
2024-09-11 13:52:28,672 - ERROR - No valid post generated for http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296. Skipping.
2024-09-11 13:52:28,672 - WARNING - Skipping entry due to missing or invalid log entry for link: https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 13:52:28,672 - INFO - Starting to process link: http://r.jina.ai/https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older
2024-09-11 13:52:29,471 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older, now generating post.
2024-09-11 13:52:29,785 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 13:52:29,785 - INFO - No article found for link https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older.
2024-09-11 13:52:29,785 - ERROR - No valid post generated for http://r.jina.ai/https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older. Skipping.
2024-09-11 13:52:29,786 - WARNING - Skipping entry due to missing or invalid log entry for link: https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older
2024-09-11 14:17:26,643 - INFO - Extracted 28 link records.
2024-09-11 14:17:26,649 - INFO - Extracted 28 image links.
2024-09-11 14:17:26,651 - INFO - Extracted 15 link records.
2024-09-11 14:17:26,653 - INFO - Extracted 5 link records.
2024-09-11 14:17:26,656 - INFO - Extracted 12 link records.
2024-09-11 14:17:26,656 - INFO - Unique links to process: 4
2024-09-11 14:17:26,656 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 14:17:27,189 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/, now generating post.
2024-09-11 14:17:27,540 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 14:17:27,542 - INFO - No article found for link https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/.
2024-09-11 14:17:27,542 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/. Skipping.
2024-09-11 14:17:27,542 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 14:17:27,542 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 14:17:32,128 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/, now generating post.
2024-09-11 14:17:32,635 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 14:17:32,636 - INFO - No article found for link https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/.
2024-09-11 14:17:32,636 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/. Skipping.
2024-09-11 14:17:32,636 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 14:17:32,636 - INFO - Starting to process link: http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 14:17:36,972 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296, now generating post.
2024-09-11 14:17:37,379 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 14:17:37,380 - INFO - No article found for link https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296.
2024-09-11 14:17:37,380 - ERROR - No valid post generated for http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296. Skipping.
2024-09-11 14:17:37,380 - WARNING - Skipping entry due to missing or invalid log entry for link: https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 14:17:37,380 - INFO - Starting to process link: http://r.jina.ai/https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older
2024-09-11 14:17:40,503 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older, now generating post.
2024-09-11 14:17:41,103 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 14:17:41,103 - INFO - No article found for link https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older.
2024-09-11 14:17:41,103 - ERROR - No valid post generated for http://r.jina.ai/https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older. Skipping.
2024-09-11 14:17:41,103 - WARNING - Skipping entry due to missing or invalid log entry for link: https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older
2024-09-11 14:40:29,243 - INFO - Extracted 28 link records.
2024-09-11 14:40:29,250 - INFO - Extracted 28 image links.
2024-09-11 14:40:29,252 - INFO - Extracted 15 link records.
2024-09-11 14:40:29,254 - INFO - Extracted 5 link records.
2024-09-11 14:40:29,256 - INFO - Extracted 12 link records.
2024-09-11 14:40:29,256 - INFO - Unique links to process: 4
2024-09-11 14:40:29,256 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 14:40:29,651 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/, now generating post.
2024-09-11 14:40:30,077 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 14:40:30,079 - INFO - No article found for link https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/.
2024-09-11 14:40:30,079 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/. Skipping.
2024-09-11 14:40:30,079 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 14:40:30,079 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 14:40:30,720 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/, now generating post.
2024-09-11 14:40:31,295 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 14:40:31,295 - INFO - No article found for link https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/.
2024-09-11 14:40:31,296 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/. Skipping.
2024-09-11 14:40:31,296 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 14:40:31,296 - INFO - Starting to process link: http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 14:40:31,989 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296, now generating post.
2024-09-11 14:40:33,040 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 14:40:33,041 - INFO - No article found for link https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296.
2024-09-11 14:40:33,041 - ERROR - No valid post generated for http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296. Skipping.
2024-09-11 14:40:33,041 - WARNING - Skipping entry due to missing or invalid log entry for link: https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 14:40:33,041 - INFO - Starting to process link: http://r.jina.ai/https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older
2024-09-11 14:40:34,000 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older, now generating post.
2024-09-11 14:40:35,494 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 14:40:35,497 - INFO - No article found for link https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older.
2024-09-11 14:40:35,497 - ERROR - No valid post generated for http://r.jina.ai/https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older. Skipping.
2024-09-11 14:40:35,497 - WARNING - Skipping entry due to missing or invalid log entry for link: https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older
2024-09-11 14:51:58,875 - INFO - Extracted 28 link records.
2024-09-11 14:51:58,881 - INFO - Extracted 28 image links.
2024-09-11 14:51:58,883 - INFO - Extracted 15 link records.
2024-09-11 14:51:58,885 - INFO - Extracted 5 link records.
2024-09-11 14:51:58,887 - INFO - Extracted 12 link records.
2024-09-11 14:51:58,887 - INFO - Unique links to process: 4
2024-09-11 14:51:58,888 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 14:51:59,318 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/, now generating post.
2024-09-11 14:51:59,657 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 14:51:59,659 - INFO - No article found for link https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/.
2024-09-11 14:51:59,659 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/. Skipping.
2024-09-11 14:51:59,659 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 14:51:59,659 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 14:52:00,105 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/, now generating post.
2024-09-11 14:52:00,535 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 14:52:00,535 - INFO - No article found for link https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/.
2024-09-11 14:52:00,535 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/. Skipping.
2024-09-11 14:52:00,535 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 14:52:00,535 - INFO - Starting to process link: http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 14:52:01,522 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296, now generating post.
2024-09-11 14:52:02,086 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 14:52:02,086 - INFO - No article found for link https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296.
2024-09-11 14:52:02,086 - ERROR - No valid post generated for http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296. Skipping.
2024-09-11 14:52:02,087 - WARNING - Skipping entry due to missing or invalid log entry for link: https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 14:52:02,087 - INFO - Starting to process link: http://r.jina.ai/https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older
2024-09-11 14:52:03,010 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older, now generating post.
2024-09-11 14:52:03,773 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 14:52:03,773 - INFO - No article found for link https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older.
2024-09-11 14:52:03,773 - ERROR - No valid post generated for http://r.jina.ai/https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older. Skipping.
2024-09-11 14:52:03,773 - WARNING - Skipping entry due to missing or invalid log entry for link: https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older
2024-09-11 15:20:27,786 - INFO - Extracted 28 link records.
2024-09-11 15:20:27,791 - INFO - Extracted 28 image links.
2024-09-11 15:20:27,793 - INFO - Extracted 15 link records.
2024-09-11 15:20:27,795 - INFO - Extracted 5 link records.
2024-09-11 15:20:27,798 - INFO - Extracted 12 link records.
2024-09-11 15:20:27,798 - INFO - Unique links to process: 4
2024-09-11 15:20:27,798 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 15:20:29,819 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/, now generating post.
2024-09-11 15:20:30,356 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 15:20:30,359 - INFO - No article found for link https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/.
2024-09-11 15:20:30,359 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/. Skipping.
2024-09-11 15:20:30,359 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 15:20:30,359 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 15:20:41,961 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/, now generating post.
2024-09-11 15:20:42,492 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 15:20:42,493 - INFO - No article found for link https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/.
2024-09-11 15:20:42,493 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/. Skipping.
2024-09-11 15:20:42,493 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 15:20:42,493 - INFO - Starting to process link: http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 15:20:48,537 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296, now generating post.
2024-09-11 15:20:49,344 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 15:20:49,346 - INFO - No article found for link https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296.
2024-09-11 15:20:49,346 - ERROR - No valid post generated for http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296. Skipping.
2024-09-11 15:20:49,346 - WARNING - Skipping entry due to missing or invalid log entry for link: https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 15:20:49,346 - INFO - Starting to process link: http://r.jina.ai/https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older
2024-09-11 15:20:52,440 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older, now generating post.
2024-09-11 15:20:53,045 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 15:20:53,046 - INFO - No article found for link https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older.
2024-09-11 15:20:53,046 - ERROR - No valid post generated for http://r.jina.ai/https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older. Skipping.
2024-09-11 15:20:53,046 - WARNING - Skipping entry due to missing or invalid log entry for link: https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older
2024-09-11 15:40:10,487 - INFO - Extracted 28 link records.
2024-09-11 15:40:10,493 - INFO - Extracted 28 image links.
2024-09-11 15:40:10,496 - INFO - Extracted 15 link records.
2024-09-11 15:40:10,498 - INFO - Extracted 5 link records.
2024-09-11 15:40:10,500 - INFO - Extracted 12 link records.
2024-09-11 15:40:10,500 - INFO - Unique links to process: 4
2024-09-11 15:40:10,500 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 15:40:12,579 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/, now generating post.
2024-09-11 15:40:13,165 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 15:40:13,167 - INFO - No article found for link https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/.
2024-09-11 15:40:13,167 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/. Skipping.
2024-09-11 15:40:13,167 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/astrazenecas-monoclonal-antibody-misses-primary-endpoint-in-mid-stage-trial-in-copd/
2024-09-11 15:40:13,167 - INFO - Starting to process link: http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 15:40:13,806 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/, now generating post.
2024-09-11 15:40:14,920 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 15:40:14,921 - INFO - No article found for link https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/.
2024-09-11 15:40:14,921 - ERROR - No valid post generated for http://r.jina.ai/https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/. Skipping.
2024-09-11 15:40:14,921 - WARNING - Skipping entry due to missing or invalid log entry for link: https://endpts.com/fda-grants-full-approval-to-traveres-filspari-for-igan/
2024-09-11 15:40:14,921 - INFO - Starting to process link: http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 15:40:20,158 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296, now generating post.
2024-09-11 15:40:20,975 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 15:40:20,975 - INFO - No article found for link https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296.
2024-09-11 15:40:20,975 - ERROR - No valid post generated for http://r.jina.ai/https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296. Skipping.
2024-09-11 15:40:20,975 - WARNING - Skipping entry due to missing or invalid log entry for link: https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae598/7743296
2024-09-11 15:40:20,975 - INFO - Starting to process link: http://r.jina.ai/https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older
2024-09-11 15:40:21,720 - INFO - Successfully fetched webpage content from http://r.jina.ai/https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older, now generating post.
2024-09-11 15:40:22,539 - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2024-09-11 15:40:22,540 - INFO - No article found for link https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older.
2024-09-11 15:40:22,540 - ERROR - No valid post generated for http://r.jina.ai/https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older. Skipping.
2024-09-11 15:40:22,540 - WARNING - Skipping entry due to missing or invalid log entry for link: https://diabetesjournals.org/care/article/doi/10.2337/dc24-1058/157153/Diabetes-Overtreatment-and-Hypoglycemia-in-Older
